Clinical trial NCT02515630
Conditions: Primary Myelofibrosis (PMF) Post-polycythemia Vera (Post-PV) Myelofibrosis Postessential Thrombocythemia (Post-ET) Myelofibrosis
Sponsor: Sierra Oncology LLC - a GSK company
Start date: 2016-01-29; Completion date: 2017-08-15
Enrollment: 41 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).

Detailed description:

Arms: arm 1: MMB for 24 weeks (± 7 days)
Interventions: intervention 1: MMB
Intervention descriptions: intervention 1: Momelotinib (MMB) tablet administered orally once daily

Protocol documents:
Prot_000.pdf: 
CLINICAL STUDY PROTOCOL
Study Title:
A Phase 2, Open-label, Translational Biology Study of 
Momelotinib in Transfusion-Dependent Subjects with Primary 
Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential 
Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Sponsor:
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 USA
IND Number:
EudraCT Number:
101155
Not Applicable
Indication:
Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-
essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Protocol ID:
GS-US-352-1672
Clinical Program 
Manager:
Name:
Ryan Athearn
Telephone:
(650) 378-3104
Gilead Medical Monitor:
Name:
Peter Lee, MD, PhD
Telephone:
(650) 522-5377
Protocol Version/Date:
Original:
18 May 2015
CONFIDENTIALITY STATEMENT
The information contained in this document, particularly unpublished data, is the property or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The information is only to be used by you in 
connection with authorized clinical studies of the investigational drug described in the protocol. 
You will not disclose any of the information to others without written authorization from 
Gilead Sciences, Inc., except to the extent necessary to obtain informed consent from those 
persons to whom the drug may be administered.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 2
18 May 2015
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................................................2
LIST OF IN-TEXT TABLES........................................................................................................................................5
PROTOCOL SYNOPSIS ..............................................................................................................................................6
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS....................................................................13
1.
INTRODUCTION ..............................................................................................................................................16
1.1.
Background ............................................................................................................................................16
1.2.
Momelotinib (MMB) .............................................................................................................................17
1.2.1.
General Information .............................................................................................................17
1.2.2.
Preclinical Pharmacology and Toxicology...........................................................................17
1.2.3.
Clinical Trials of Momelotinib.............................................................................................21
1.2.4.
Special Risk..........................................................................................................................21
1.3.
Rationale for This Study ........................................................................................................................21
1.4.
Compliance ............................................................................................................................................22
2.
OBJECTIVES.....................................................................................................................................................23
3.
STUDY DESIGN................................................................................................................................................24
3.1.
Endpoint.................................................................................................................................................24
3.2.
Study Design..........................................................................................................................................24
3.3.
Study Treatments ...................................................................................................................................24
3.4.
Duration of Treatment............................................................................................................................24
3.5.
Discontinuation Criteria.........................................................................................................................24
3.6.
Source Data............................................................................................................................................24
3.7.
Biomarker Testing..................................................................................................................................25
3.7.1.
Biomarker Samples to Address the Study Objectives:.........................................................25
3.7.2.
Storage of Samples for Future Research ..............................................................................27
3.7.3.
Biomarker Samples for Genomic Research..........................................................................27
4.
SUBJECT POPULATION..................................................................................................................................28
4.1.
Number of Subjects and Subject Selection ............................................................................................28
4.2.
Inclusion Criteria....................................................................................................................................28
4.3.
Exclusion Criteria...................................................................................................................................29
5.
INVESTIGATIONAL MEDICINAL PRODUCTS ...........................................................................................30
5.1.
Enrollment and Treatment Assignment..................................................................................................30
5.2.
Description and Handling of MMB........................................................................................................30
5.2.1.
Formulation..........................................................................................................................30
5.2.2.
Packaging and Labeling .......................................................................................................30
5.2.3.
Storage and Handling...........................................................................................................30
5.3.
Dosage and Administration of MMB.....................................................................................................30
5.3.1.
Starting Dose........................................................................................................................30
5.3.2.
Discontinuing or Interrupting MMB Treatment...................................................................31
5.3.3.
MMB Dose Adjustments and Dose Interruption..................................................................31
5.3.4.
Dose Adjustments for Thrombocytopenia............................................................................31
5.3.5.
Dose Adjustments for Neutropenia ......................................................................................32
5.3.6.
Dose Adjustments for Non-hematologic Toxicities .............................................................32
5.3.7.
Dose Adjustments Based on Response.................................................................................32
5.3.8.
Dose Adjustments for Other Toxicities................................................................................33
5.4.
Prior and Concomitant Medications.......................................................................................................33
5.4.1.
Restricted Medications.........................................................................................................33


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 3
18 May 2015
5.4.2.
Proscribed Medications........................................................................................................33
5.4.3.
Breast Cancer Resistance Protein (BCRP) Substrates..........................................................33
5.4.4.
Organic Anion-Transporting Polypeptide (OATP) Inhibitors..............................................33
5.5.
Accountability for MMB........................................................................................................................34
5.5.1.
MMB Return or Disposal.....................................................................................................34
6.
STUDY PROCEDURES ....................................................................................................................................35
6.1.
Subject Enrollment and Treatment Assignment.....................................................................................35
6.2.
Study Procedure Descriptions ................................................................................................................35
6.2.1.
Informed Consent.................................................................................................................35
6.2.2.
Medical History....................................................................................................................35
6.2.3.
Medication History...............................................................................................................35
6.2.4.
Physical Examination and Myelofibrosis Symptom Assessment.........................................35
6.2.5.
Vital Signs............................................................................................................................36
6.2.6.
Ophthalmic Examinations ....................................................................................................36
6.2.7.
Laboratory Assessments.......................................................................................................36
6.2.8.
Biomarker Samples ..............................................................................................................37
6.2.9.
Pharmacokinetics .................................................................................................................38
6.2.10.
Patient-reported Outcomes Assessments (PRO) ..................................................................39
6.2.11.
Disease Assessments............................................................................................................39
6.3.
Pretreatment Assessments......................................................................................................................40
6.3.1.
Screening Visit .....................................................................................................................40
6.3.2.
Baseline Assessments...........................................................................................................41
6.4.
Enrollment..............................................................................................................................................42
6.4.1.
Enrollment Assessments.......................................................................................................42
6.5.
Treatment Assessments..........................................................................................................................43
6.5.1.
Week 2 .................................................................................................................................43
6.5.2.
Week 4, 8, 12, 16 and Week 20............................................................................................44
6.5.3.
Week 24 ...............................................................................................................................45
6.6.
Unscheduled visits .................................................................................................................................46
6.7.
Post-treatment Assessments ...................................................................................................................46
6.7.1.
Early Study Drug Discontinuation .......................................................................................46
6.7.2.
30-Day Follow-up Assessments...........................................................................................47
6.8.
Criteria for Discontinuation of Study Treatment....................................................................................48
6.9.
End of Study...........................................................................................................................................48
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT...............................................................................49
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events.................................49
7.1.1.
Adverse Events.....................................................................................................................49
7.1.2.
Serious Adverse Events........................................................................................................49
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events .........................................................................50
7.2.
Assessment of Adverse Events and Serious Adverse Events.................................................................51
7.2.1.
Assessment of Causality for MMB and Procedures.............................................................51
7.2.2.
Assessment of Severity ........................................................................................................51
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead.......................................................................................................................52
7.3.1.
Adverse Events.....................................................................................................................52
7.3.2.
Serious Adverse Events........................................................................................................52
7.4.
Gilead Reporting Requirements.............................................................................................................54
7.5.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events..........................................................................................................................54
7.6.
Toxicity Management ............................................................................................................................54
7.7.
Special Situations Reports......................................................................................................................55


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 4
18 May 2015
7.7.1.
Definitions of Special Situations..........................................................................................55
7.7.2.
Instructions for Reporting Special Situations.......................................................................55
8.
STATISTICAL CONSIDERATIONS................................................................................................................57
8.1.
Analysis Objectives and Endpoints........................................................................................................57
8.1.1.
Analysis Objectives..............................................................................................................57
8.1.2.
Primary Endpoint .................................................................................................................57
8.1.3.
Secondary Endpoints............................................................................................................57
8.1.4.
Exploratory Endpoints..........................................................................................................58
8.2.
Analysis Conventions.............................................................................................................................58
8.2.1.
Analysis Sets ........................................................................................................................58
8.3.
Data Handling Conventions ...................................................................................................................58
8.4.
Demographic Data and Baseline Characteristics ...................................................................................59
8.5.
Efficacy Analysis ...................................................................................................................................59
8.6.
Safety Analysis.......................................................................................................................................59
8.6.1.
Extent of Exposure...............................................................................................................59
8.6.2.
Adverse Events.....................................................................................................................59
8.6.3.
Laboratory Evaluations ........................................................................................................60
8.7.
Pharmacokinetics Analysis ....................................................................................................................61
8.8.
Biomarker Analysis................................................................................................................................61
8.9.
Sample Size............................................................................................................................................61
9.
RESPONSIBILITIES..........................................................................................................................................63
9.1.
Investigator Responsibilities ..................................................................................................................63
9.1.1.
Good Clinical Practice..........................................................................................................63
9.1.2.
Institutional Review Board (IRB) Review and Approval.....................................................63
9.1.3.
Informed Consent.................................................................................................................63
9.1.4.
Confidentiality......................................................................................................................64
9.1.5.
Study Files and Retention of Records ..................................................................................64
9.1.6.
Case Report Forms...............................................................................................................65
9.1.7.
Investigational Product Accountability and Return..............................................................66
9.1.8.
Inspections............................................................................................................................66
9.1.9.
Protocol Compliance............................................................................................................66
9.2.
Sponsor Responsibilities ........................................................................................................................66
9.2.1.
Protocol Modifications.........................................................................................................66
9.2.2.
Study Report and Publications .............................................................................................67
9.3.
Joint Investigator/Sponsor Responsibilities ...........................................................................................67
9.3.1.
Payment Reporting...............................................................................................................67
9.3.2.
Access to Information for Monitoring..................................................................................67
9.3.3.
Access to Information for Auditing or Inspections ..............................................................68
9.3.4.
Study Discontinuation..........................................................................................................68
10.
REFERENCES ...................................................................................................................................................69
11.
APPENDICES ....................................................................................................................................................72
Appendix 1.
Investigator Signature Page....................................................................................................73
Appendix 2.
Study Procedures Table..........................................................................................................74
Appendix 3.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements...................................................................................................77
Appendix 4.
Dynamic International Prognostic Scoring System (DIPSS) for Primary 
Myelofibrosis..........................................................................................................................80


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 5
18 May 2015
LIST OF IN-TEXT TABLES
Table 3-1.
Biomarker Specimens and Tests to Address Study Objectives ..............................................26
Table 5-1.
MMB Dose Reductions for Subjects with Thrombocytopenia...............................................31
Table 5-2.
Doses for Restarting MMB after Withholding Treatment for Toxicity..................................32
Table 6-1.
Analytes..................................................................................................................................37
Table 7-1.
Grading of Adverse Event Severity........................................................................................52
Table 7-2.
Grading of Anemia (Hgb) Severity ........................................................................................54
Table 8-1.
Exact 90% CIs for various response rates ..............................................................................62


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 6
18 May 2015
PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Dr.
Foster City, CA 94404
Study Title: 
A Phase 2, Open-label, Translational Biology Study of Momelotinib in 
Transfusion-Dependent Subjects with Primary Myelofibrosis (PMF) or 
Post-polycythemia Vera or Post-essential Thrombocythemia 
Myelofibrosis (Post-PV/ET MF) 
IND Number:
EudraCT Number:
101155
Not Applicable
Study Centers 
Planned:
Approximately 20 centers in North America
Objectives:
The primary objective of this study is:

To determine the transfusion independence response rate for 
transfusion dependent myelofibrosis (MF) subjects treated with 
momelotinib (MMB)
The secondary objectives of this study are: 

To evaluate baseline levels and changes in markers of iron 
metabolism in transfusion dependent MF subjects treated with 
MMB

To assess inhibition of JAK1/2 in transfusion dependent MF 
subjects treated with MMB 

To evaluate MMB pharmacokinetics (PK) in transfusion dependent  
MF subjects

To evaluate changes in circulating cytokine and inflammatory 
markers in transfusion dependent MF subjects treated with MMB   
Study Design:
This is a single-arm, open-label study of MMB in transfusion-
dependent subjects with PMF or Post-PV/ET MF.  Subjects will receive 
MMB for 24 weeks (7 days) on study.
After completion of the 24 week (7 days) treatment phase visit 
procedures, subjects who respond to treatment, at the investigator’s 
discretion, will have the option of maintenance therapy with MMB on 
Study GS-US-352-1154 at the MMB dose they tolerated and/or derived 
clinical benefit from during the 24-week treatment period.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 7
18 May 2015
Number of 
Subjects Planned:
Approximately 40
Target Population:
Subjects with PMF or Post-PV/ET MF who are transfusion dependent
Duration of 
Treatment:
The planned duration of study treatment is 24 weeks (±7 days). 
Diagnosis and 
Main Eligibility 
Criteria:
Inclusion Criteria:
1) Age ≥ 18 years old
2) Diagnosis of PMF or Post PV/ET-MF
3) Requires myelofibrosis therapy, in the opinion of the investigator
4) High risk or intermediate-2 risk defined by the Dynamic 
International Prognostic Scoring System (DIPSS) or intermediate-1 
risk defined by DIPSS and associated with symptomatic 
splenomegaly and/or hepatomegaly
5) Transfusion dependent at baseline, defined as ≥ 4U RBC transfusion 
in the 8 weeks prior to first dose of MMB
6) Acceptable organ function as evidenced by the following:
a) Platelet Count ≥ 50 x 109/L 
b) AST/SGOT and ALT/SGPT ≤ 3 x upper limit of normal (ULN)
or  AST/SGOT or ALT/SGPT ≤ 5 x ULN if liver is involved by 
disease process as judged by the investigator 
c) Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance 
of ≥ 60mL/min 
d) Direct bilirubin ≤ 2.0 x ULN
7) Peripheral blood blast count < 20% 
8) Expected Life expectancy of > 24 weeks
9) A negative serum pregnancy test for female subjects (unless 
surgically sterile or greater than two years postmenopausal) 
10) Male subjects and female subjects of childbearing potential who 
engage in heterosexual intercourse must agree to use protocol 
specified method(s) of contraception as described in Appendix 3


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 8
18 May 2015
11) Lactating females must agree to discontinue nursing before MMB
administration
12) Able to understand and willing to sign the informed consent form
Exclusion Criteria:
1) Prior splenectomy
2) Splenic irradiation within 3 months prior to the first dose of MMB
3) Prior treatment with MMB
4) Known positive status of human immunodeficiency virus (HIV)
5) Chronic active or acute viral hepatitis A, B, or C infection (testing 
required for hepatitis B and C), or hepatitis B or C carrier
6) Use of strong CYP3A4 inducer within 2 weeks prior to the first dose 
of MMB
7) Uncontrolled intercurrent illness including, but not limited to, active 
uncontrolled infection, uncontrolled cardiac arrhythmia, or 
psychiatric illness/social situation that would limit compliance with 
study requirements as judged by treating physician
8) History of a prior diagnosis of any malignancy other than PMF or 
Post PV/ET-MF except for the following: adequately treated local 
basal cell or squamous cell carcinoma of the skin, cervical 
carcinoma in situ, superficial bladder cancer, asymptomatic prostate 
cancer without known metastatic disease and with no requirement 
for therapy or requiring only hormonal therapy and with normal 
prostate specific antigen for >1 year prior to enrollment, or any other 
cancer that has been in complete remission without treatment for 
≥5 years prior to enrollment.
9) Treatment with a JAK inhibitor within 21 days of the planned 
first dose of MMB
10) Documented myocardial infarction or unstable/uncontrolled cardiac 
disease (eg, unstable angina, congestive heart failure [New York 
Heart Association > Class III]) within 6 months of randomization
11) Presence of peripheral neuropathy ≥ CTCAE Grade 2
12) Unwilling or unable to undergo Magnetic Resonance Imaging
(MRI) per requirements in Section 6.2.11.2
13) Unwilling to consent to genomics sampling
14) Pregnant or breast-feeding
15) Known hypersensitivity to the study investigational medicinal 
products, the metabolites, or formulation excipients


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 9
18 May 2015
Study Procedures/
Frequency:
Subjects may participate in the study for up to 28 weeks. This consists 
of up to 4 weeks (28 days) of screening and 24 weeks of study 
treatment.  Study visits will be completed at 2 weeks and 4 weeks 
following initiation of MMB treatment, and thereafter every 4 weeks
until week 24. 
During the screening period, subjects will undergo an MRI to assess 
spleen volume and liver iron concentration (LIC), bone marrow biopsy, 
and blood sampling for clinical and pharmacodynamics tests.  Subjects 
will receive an electronic diary (eDiary) for daily completion of the 
modified Myeloproliferative Neoplasm Symptom Assessment Form 
Total Symptom Score (MPNSAF TSS).  Subjects will complete the 
modified MPNSAF TSS daily through screening and 24 weeks of study 
participation.  Patient-reported outcomes, clinical, laboratory, and 
disease assessments will be completed at regular study visits as defined 
in Appendix 2.
Subjects discontinuing MMB prior to the Week 24 visit will complete 
an Early Study Drug Discontinuation visit within 7 days of 
discontinuing MMB and a Follow-up visit 30 days after the subject’s 
last dose of MMB.  Subjects completing the Week 24 visit and entering 
maintenance treatment on study GS-US-352-1154 will not complete the 
30-Day Follow-Up visit.
Test Product, Dose, 
and Mode of 
Administration:
The starting dose of MMB for all subjects will be 200 mg in a single 
tablet. MMB will be orally self-administered once daily, in the morning, 
and thereafter at approximately the same time each day. The dose of 
MMB may be withheld or adjusted according to the criteria in the 
protocol.
Reference Therapy, 
Dose, and Mode of 
Administration:
None
Criteria for 
Evaluation:
Safety:
The overall safety profile of MMB will be characterized by the type, 
frequency, severity, timing of onset, duration, and relationship to MMB 
of any adverse events (AEs) or abnormalities of laboratory tests; serious 
adverse events (SAEs); or AEs leading to discontinuation of MMB.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 10
18 May 2015
Efficacy:
Primary Endpoints
The primary endpoint is transfusion independence response rate by 
Week 24, defined as becoming transfusion independent for ≥ 12 weeks 
at any time on study.  A subject is considered as transfusion independent 
on study if no RBC transfusion occurs in any 12 weeks during the 24-
week treatment period.
Secondary Endpoints
The secondary endpoints are:

Transfusion response rate by Week 24, defined as becoming not 
transfusion dependent for ≥ 8 weeks at any time on study

Baseline and change in markers of anemia (eg, hepcidin, ferritin)

Change in pharmacodynamics biomarker pSTAT3

Splenic response rate at Week 24, defined as ≥35% reduction in 
spleen volume from baseline as measured by MRI

Response rate in total symptom score (TSS) at Week 24, defined as 
achieving a ≥ 50% reduction from baseline in TSS as measured by 
the modified MPNSAF TSS diary

Pharmacokinetics parameters (Cmax, Clast, Ctau and AUClast, if 
available) for MMB 

Change in circulating cytokine and inflammatory markers (eg, IL-6, 
IL-8, IFN gamma, TNF alpha)
Exploratory Endpoints
The exploratory endpoints are:

Baseline and change in markers of orthogonal or parallel signaling 
pathways (eg, RAS/MAPK, PI3K/AKT)

Baseline and change in gene expression profiles in whole blood and 
somatic mutations in whole blood

Baseline and change in immune subsets in whole blood

Change in exploratory pharmacodynamics markers of signaling 
mediated by JAK1 and/or JAK2 (eg, pSTAT1, pSTAT5, and 
pSTAT6)
Pharmacokinetics:
Blood samples will be collected at the time points specified in the 
protocol. 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 11
18 May 2015
Statistical Methods:
The Safety Analysis Set includes all subjects who receive ≥ 1 dose of 
MMB. Since this study is a non-randomized study, the Safety Analysis 
Set will be used for subject’s characteristics, efficacy and safety 
endpoints, and study treatment administration.
The Biomarker Analysis Set consists of all subjects in the Safety 
Analysis Set who have the necessary baseline and on-study 
measurements to provide interpretable results for the specific 
parameters of interest. The Biomarker Analysis Set will be used for 
biomarkers and the correlation analyses between biomarkers and 
efficacy clinical endpoints.
The PK Analysis Set consists of all subjects in the Safety Analysis Set 
who have the necessary baseline and on-study measurements to provide 
interpretable results for the specific parameters of interest.
Subject demographic and baseline characteristics will be listed and 
summarized as appropriate. 
Transfusion independence response rate, transfusion response rate, 
splenic response rate and TSS response rate will be presented with 
corresponding 2-sided 90% exact CIs using the binomial distribution. 
The number and percentage of subjects in each response category 
(complete remission [CR] or partial remission [PR]) will also be 
summarized. Subjects who do not have sufficient baseline or on-study 
tumor assessment to characterize response will be counted as 
non-responders.
All safety data collected on or after the date that MMB was 
first dispensed up to the date of last dose of MMB plus 30 days will be 
summarized. Data for the pretreatment will be included in data listings.
The baseline levels, and changes in biomarker levels over time from 
baseline level, will be evaluated. Descriptive statistics will be provided 
at each sampling time, and by response category for each clinical 
endpoint being considered for association with biomarkers, as 
appropriate. Exploratory graphics, such as side-by-side boxplots will 
also be generated.
Univariate and multivariate statistical techniques may be explored to 
evaluate the association of baseline biomarkers and changes in 
biomarkers with clinical outcomes as appropriate. Due to the 
exploratory nature of the end points, no formal hypothesis testing will 
be conducted.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 12
18 May 2015
Sample Size Calculation
This study will enroll approximately 40 subjects. Due to the exploratory 
nature, the study is not designed to detect a specific effect size. A 
sample size of 40 subjects is considered adequate for this exploratory 
study.
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 13
18 May 2015
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C
degrees Celsius
F
degrees Fahrenheit
ADME
absorption, distribution, metabolism, and elimination
AE
adverse event
ALT
alanine aminotransferase 
ANC
absolute neutrophil counts 
AST
aspartate aminotransferase
AUC
area under the plasma/serum/peripheral blood mononuclear cell
concentration versus time curve
AUClast
AUC up to the last measurable concentration
BCRP
Breast cancer resistant protein
BUN
blood urea nitrogen 
CBC
complete blood count 
CI
confidence interval 
CLcr
creatinine clearance
Cmax
the maximum observed serum/plasma/PBMC concentration of drug
Clast
last observed quantifiable concentration
CML
Chronic mylogenous leukemia
CR
complete remission
CRF
case report form(s)
CRO
contract (or clinical) research organization
CRP
C-Reactive Protein
CSR
Clinical Study Report
CT
computed tomography/computed axial tomography scan 
CTCAE
Common Terminology Criteria for Adverse Events 
CYP450
cytochrome P450
Da
Dalton
DIPSS
Dynamic International Prognostic Scoring System
DSPH
Drug Safety and Public Health
ECG
electrocardiogram
eCRF
Electronic case report form(s)
EDC
Electronic data capture
eDiary
Electronic diary
EPO
Erythropoietin
ESDD
Early Study Drug Discontinuation
ET
Essential thrombocythemia
FDA
(United States) Food and Drug Administration
FSH
Follicle stimulating hormone


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 14
18 May 2015
GLOSSARY OF ABBREVIATIONS AND DEFINITIONS OF TERMS (CONTINUED)
GCP 
Good Clinical Practice (guidelines) 
GD
Gestational Days
Gilead
Gilead Sciences, Inc.
GLP
Good Laboratory Practice (guidelines)
hCG
human chorionic gonadotropin
HDPE
high-density polyethylene
Hgb
hemoglobin
HIV
human immunodeficiency virus
HSPC
hematopoietic stem/progenitor cells
IB
investigator’s brochure
ICH
International Conference on Harmonisation
IEC
independent ethics committee
IND
Investigational New Drug (Application)
IRB
institutional review board
IUD
intrauterine device
IWG-MRT
International Working Group for Myelofibrosis Research and Treatment
IWRS
interactive web response system
JAK
Janus kinase
LIC
Liver iron concentration
LLN
lower limit of the normal range 
m
meter
MCV
Mean cell volume
medDRA
Medical dictionary for regulatory activities
MF
myelofibrosis
mg
milligram
MMB
momelotinib
MPL
megakaryocyte proliferative ligand
MPN
myeloproliferative neoplasm
MPNSAF TSS
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom
Score
MRI
magnetic resonance image 
N
Number in population
n
Number in data
NOAEL
no observed adverse effect level
NOEL
No observed effect level
PBMC
peripheral blood mononuclear  cell
PD
progressive disease
PGIC
Patient Global Impression of Change
PK
Pharmacokinetic


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 15
18 May 2015
GLOSSARY OF ABBREVIATIONS AND DEFINITIONS OF TERMS (CONTINUED)
PMF
primary myelofibrosis
PR
partial remission
PRO
patient-reported outcome
PV
polycythemia vera
QD
once daily
RBC
Red blood cell
SADR
Serious adverse drug reactions
SAE
serious adverse event
SAP
Statistical Analysis Plan
SOP
standard operating procedure
STAT
Signal Transducer and Activator of Transcription
SUSAR
Suspected Unexpected Serious Adverse Reaction 
tmax
The time (observed time point) of Cmax
t½
An estimate of the terminal elimination half-life of the drug
TYK
Tyrosine kinase
U
Units
ULN
upper limit of the normal range 
WHO
World Health Organization


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 16
18 May 2015
1.
INTRODUCTION
1.1.
Background
Myeloproliferative neoplasm (MPN) is classified by the World Health Organization (WHO) into 
eight categories that include polycythemia vera (PV), essential thrombocythemia (ET), primary 
myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, 
chronic eosinophilic leukemia, mast cell disease, and MPN unclassifiable {25836}. Clonal 
hematopoiesis is a shared feature of the MPNs, with CML characterized by the presence of the 
Philadelphia chromosome, the product of a reciprocal translocation between the long arms of 
chromosomes 9 and 22. This translocation results in the formation of the BCR-ABL1 oncogene, 
the molecular pathogenetic event of CML {25841}. Subsequently, a single acquired point 
mutation in the Janus kinase (JAK) 2 gene at codon 617, resulting in the substitution of valine for 
phenylalanine (JAK2V617F), was identified in patients with PV (~96%), ET (~50%), and 
myelofibrosis (~50%) {23864},{24753},{23911},{23913}. Positivity for the JAK2V617F mutation 
results in constitutive activation of the downstream Signal Transducer and Activator of 
Transcription (STAT), cytokine hypersensitivity, and formation of erythropoietin-independent 
erythroid colonies {25845}.  
Since the discovery of the JAK2V617F mutation in patients with MPN, additional mutations 
have been identified including signaling mutations that activate the thrombopoietin receptor 
(MPL).  Somatic mutations of CALR, the gene encoding calreticulin, have also been identified in 
patients with wild type JAK2, as well as mutations in epigenetic regulators of DNA methylation 
and chromatin structure {27663}.
Myelofibrosis is associated with a characteristic marrow stroma pattern, leukoerythroblastosis, 
and elevated levels of inflammatory cytokines. Patients may experience anemia, leukopenia or 
leukocytosis, thrombocytopenia or thrombocytosis, constitutional symptoms, and extramedullary 
hematopoiesis resulting in hepatosplenomegaly{27076}. In a proportion of patients, 
myelofibrosis may transform into acute leukemia {27070}. Treatment for PMF, and the 
phenotypically similar Post-PV/ET MF, are principally focused on symptom palliation, with 
allogeneic stem cell transplantation offering a potential cure for select patients {27077}.
Momelotinib (MMB) is a small molecule JAK1 and JAK2 inhibitor, with good selectivity over 
other JAK family kinases (JAK3, TYK2) and excellent selectivity over other tyrosine and 
serine/threonine kinases. In the phase 1/2 study of MMB which enrolled 166 subjects with PMF 
or Post-PV/ET MF (Study CCL09101), the rate of spleen response, defined as ≥ 50% reduction 
in palpable splenomegaly lasting ≥8 weeks for baseline splenomegaly ≥ 10 cm plus resolution of 
palpable splenomegaly lasting ≥ 8 weeks for baseline splenomegaly > 5 to < 10 cm, was 33%.  
Anemia response, defined as a transfusion-free interval of ≥ 12 weeks for baseline transfusion 
dependence, plus ≥ 2 g/dL rise in hemoglobin (Hgb) for baseline transfusion independence and 
Hgb < 10 g/dL, was 41%.  Baseline transfusion dependence for Study CCL09101 was defined as 
≥ 2 units (U) red blood cell (RBC) transfusion in the 30 days prior to first dose of MMB or 
identified as transfusion dependent in the medical history.  In general, over the course of the 
study, the mean total symptom scores decreased from baseline.  Most common Grade 3 or 4 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 17
18 May 2015
treatment-related events reported by ≥ 2 subjects on study were thrombocytopenia (24%), lipase 
increased (4%), neutropenia (3%), and anemia (2%).  Treatment-emergent peripheral neuropathy 
or sensory neuropathy adverse events were reported by 55 subjects (33%), with the neuropathy 
events categorized in 45 subjects (27%) as probably or possibly related to MMB. 
1.2.
Momelotinib (MMB)
1.2.1.
General Information
MMB dihydrochloride (N (cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-
yl)benzamide, CYT387, GS-0387) is a novel, weakly basic, disubstituted pyrimidine compound 
with a molecular weight of 487.38 daltons (Da). The free base is poorly soluble in water. MMB 
is presented for clinical administration as a dihydrochloride monohydrate salt. The 
dihydrochloride monohydrate salt shows kinetic solubility in water at concentrations up to 
60 mg/mL. MMB dihydrochloride is manufactured from a pyrimidine scaffold in a five-step 
process. 
In cellular assays and in vitro, MMB was shown to be a potent and selective ATP-competitive 
small-molecule inhibitor of JAK1 and JAK2, and is active at low nanomolar concentrations. 
MMB demonstrates marked disease-modifying properties in ex vivo assays of human erythroid 
cells from PV patients and in a transgenic mouse model of myeloproliferative neoplasm. Kinase 
profiling of MMB indicates the compound is broadly selective for JAK1 and JAK2 over other 
kinase enzymes, including the closely related JAK3 and tyrosine kinase (TYK) 2. MMB displays 
potent in vitro inhibitory activity against cells dependent on JAK.
For further information on MMB, refer to the investigator’s brochure (IB) for MMB. 
1.2.2.
Preclinical Pharmacology and Toxicology
1.2.2.1.
Absorption, Distribution, Metabolism, and Elimination (ADME)
Equivalent mean maximal plasma concentrations of MMB (~700 ng/mL) and comparable 
elimination half-lives (~1h) were observed in both fed and fasted animals, consistent with 
previous data. There was however a notable prolongation in absorption in fed dogs with a 
delayed Tmax (3h fed vs. 1h fasted). Furthermore, the AUC following dosing to feed dogs was 
approximately double that seen in fasted animal studies suggesting that MMB systemic 
availability is markedly improved when the compound is administered postprandially.
Consistent with the moderate to high bioavailability seen in nonclinical species, MMB shows 
high permeability in vitro across human Caco-2 cell monolayers with low efflux potential. These 
results indicate that MMB is likely to have high permeability across the intestinal mucosa in 
humans and high oral absorption in vivo. 
Data from plasma protein binding studies using rat and human plasma indicate that MMB binds 
extensively to rat plasma proteins (~ 97%) and moderately to human plasma proteins (87% to 
92%). The mean human blood-to-plasma ratio was determined to be approximately 1.1, 
suggesting similar distribution between the cellular and plasma fractions of blood. The rat 
blood-to-plasma ratio ranged from 0.6 to 0.8 indicating a lesser partitioning into blood cells.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 18
18 May 2015
The systemic clearance of MMB was low in rats and significantly higher in dogs. The steady 
state volume of distribution in both species substantially exceeded total body water. Following 
oral administration as the dihydrochloride salt, MMB showed high bioavailability in the rat 
(50%) and moderate bioavailability in the dog (20%). The pharmacokinetic (PK) parameters in 
both the rat and dog indicated that MMB was well absorbed. In the rat, less than 10% of an 
administered dose of MMB was recovered in the urine as parent compound suggesting that 
urinary excretion is a minor clearance route for the parent compound.
The distribution of MMB into brain tissue was assessed in Swiss outbred mice following 
intravenous administration (5 mg/kg). The brain-to-plasma ratio for MMB was determined to be 
0.075 and 0.215 at 5 and 60 minutes following MMB administration, respectively, suggesting 
low permeability of MMB across the blood brain barrier.
Metabolite profiling has identified major putative metabolites from in vitro and in vivo studies. 
Metabolite M19 (GS-642112) was present in greater amounts in both rat (both dose levels) and 
dog plasma pools, than in the human plasma pool. Metabolites M15, M17, and M20 were present 
in greater amounts in the rat plasma pool (both dose levels), than in the human or dog plasma 
pools. Metabolite M21 (GS-644603) was present in human plasma at higher levels than that 
observed in rat plasma (20 mg/kg or 80 mg/kg doses, respectively). Metabolite M21 was not 
observed in the dog plasma. M8 was not observed in either the rat or dog plasma pools. 
The ability of the major drug-metabolizing cytochrome P40 (CYP450) enzymes (CYP1A2, 2A6, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5) to metabolize 
MMB was assessed with recombinant human CYP450 enzymes (Supersomes™) and human 
primary hepatocytes.  MMB is primarily metabolized by multiple CYP enzymes, including 
CYP3A, CYP2C8 and CYP2C19, with aldehyde oxidase also participating in metabolism to 
form the major, active metabolite M21.
The potential of MMB to impair the metabolism of other agents by inhibition of major drug 
metabolizing enzymes has also been investigated. The half-maximal inhibitory concentration 
(IC50) of MMB on the five CYP isoforms investigated (CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4) was greater than 25 μM. MMB is therefore unlikely to mediate 
significant metabolic drug-drug interactions through inhibition of these isoforms in vivo. MMB 
was determined to have the potential to be an inhibitor of UGT1A1, a major human uridine 
diphosphate glucuronosyltransferase enzyme responsible for the glucuronidation of bilirubin, 
with an IC50 of 0.3 μM but it is not clinically relevant as no clinically significant elevation of 
indirect (unconjugated) bilirubin has been reported in the Phase 1/2 CCL09101 study.
The potential of MMB to inhibit major drug transporters was studied in cells in which the 
individual transporters were over expressed and determining were possible the MMB IC50 for the 
transport of probe substrates. MMB did not significantly inhibit P-gp, OAT1, OAT3, OCT1, 
OCT2, OATP1B1, OATP1B3 or BSEP mediated transport of probe substrates at 15 μM. MMB 
was determined to be an inhibitor of BCRP with an IC50 of 2.9 μM.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 19
18 May 2015
1.2.2.2.
Nonclinical Toxicology
Nonclinical safety pharmacology and toxicology studies have characterized the safety of MMB 
and included both repeat dose toxicology studies and in vitro genotoxicity studies. All pivotal 
toxicology studies, including the genotoxicity studies, were conducted in full compliance with 
good laboratory practice (GLP) regulations (21 CFR 58). The scope of the nonclinical safety 
evaluation is consistent with guidance issued by the International Conference on Harmonisation 
(ICH).
The potential for MMB to induce hemodynamic or electrocardiogram (ECG) effects was 
evaluated in male beagle dogs following a single oral dose of 5, 30 or 100 mg/kg. A marked 
decrease in mean arterial pressure and increase in heart rate was observed after a single dose of 
100 mg/kg.
MMB was generally well-tolerated clinically when given to rats for 26 weeks at doses of 5 and 
15 mg/kg/day. There were three unscheduled deaths in the 50 mg/kg/day group potentially 
related to MMB administration. By Week 26, 50 mg/kg/day group mean body weight in males 
was 23.6% lower than control and in females was 13.1% lower than control. A reversible, mild 
slowing of caudal and digital nerve conduction velocity, consistent with a mild, minimally 
progressive and reversible deficit in distal sensory velocities, was observed at 50 mg/kg/day. At 
all dose levels, decreases in leukocytes, lymphocytes, eosinophils, and/or basophils were 
indicative of bone marrow and lymphoid suppression (in spleen, lymph node, thymus, and/or gut 
associated lymphoid tissue [GALT]). The myelosuppression was considered adverse at 
50 mg/kg/day. No histopathological correlate was observed. At 50 mg/kg/day, mild, reversible 
decreases in red cell mass (erythrocytes, hemoglobin, and hematocrit) in both sexes, with 
concurrent increases in reticulocytes and mean cell volume (MCV) indicating an appropriate 
regenerative response, were observed. These alterations were associated with reversible increases 
in total bilirubin and correlated microscopically with irreversible tissue pigment seen 
microscopically in the kidney, mesenteric lymph nodes, liver, and spleen, and with 
erythrocytosis/erythrophagocytosis in the mandibular and mesenteric lymph nodes. Dose related 
adverse findings due to GS-0387 administration included reversible minimal tubular 
degeneration/regeneration in the kidney at ≥ 15 mg/kg/day and mild decreased cellularity in bone 
marrow, and irreversible degeneration/atrophy in testes and oligospermia/germ cell debris in 
epididymides at 50 mg/kg/day. Due to the adverse changes in the kidneys at 15 mg/kg/day, the 
no observed adverse effect level was 5 mg/kg/day. Following 26 weeks at 5 mg/kg/day in male 
and female rats, the GS-0387 AUC(0-24) values were 33800 and 73100 ng*hr/mL, respectively, 
and the Cmax values were 4020 and 7590 ng/mL, respectively.
Momelotinib was well-tolerated when given orally to dogs once daily for 39 weeks at doses up to 
20 mg/kg/day. The majority of dogs at 50 mg/kg/day had periodic body weight loss, decreased 
food consumption, and/or excessive emesis/vomitus, and three males at this dose were given 
week-long dose holidays. One male at 50 mg/kg/day was euthanized in extremis on Day 175 
with findings suggesting inanition played a role in the moribundity. Cataracts were observed in 
dogs at 50 mg/kg/day at termination and persisted through the recovery period. MMB-related 
microscopic findings were limited to the 50 mg/kg/day group and included minimal or mild 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 20
18 May 2015
tubular epithelial cell vacuolation in the kidneys in both sexes and a minimal decrease in 
cellularity in the bone marrow, mild spermatid/spermatocyte degeneration in the testes, and a 
mild increase in germ cell debris in the epididymides in males. The no-observed adverse effect 
level was considered to be 20 mg/kg/day. Following 39 weeks at this dose, the GS-0387 
AUC(0-24) value was 4620 ng*hr/mL, and the Cmax value was 938 ng/mL.
The plasma AUCτ in patients from Study CCL09101 at 300 mg capsule was 4.3 μg•h/mL. 
Therefore, the margin of exposure for the no-observed-adverse-effect-level (NOAEL) in the 
90-day toxicity studies to the steady state AUC NOAEL is 22 in the rat and 0.8 in the dogs.
An in vitro bacterial reverse mutation assay (Ames test), an in vitro mammalian cell gene 
mutation assay (chromosomal aberration test), and an in vivo rat bone marrow micronucleus 
assay were conducted with MMB. No evidence of mutagenicity or clastogenicity was observed 
indicating a low potential for MMB to cause genotoxicity. 
MMB was administered to adult male rats at 5, 25, and 100/68 mg/kg/day for 4 weeks prior to 
mating and throughout mating (~10 weeks total). Mortality, adverse clinical signs, reduced body 
weight gain, reduced fecundity and fertility, reduced testis and seminal vesicle weights and 
reduced sperm concentration and motility occurred in the group administered 100/68 mg/kg/day. 
Reduced body weight gain, reduced seminal vesicle weight and reduced sperm concentration and 
motility occurred in the group administered 25 mg/kg/day. Reduced body weight gain occurred 
in the group administered 5 mg/kg/day. The NOAEL for male fertility was 5 mg/kg/day. MMB 
was administered to adult female rats at 5, 25 or 100 (reduced to 68) mg/kg/day for 14 days prior 
to mating, throughout mating and through gestation day (GD) 7.  Maternal toxicity occurred after 
oral administration of 100/68 mg/kg/day to adult female rats as evidenced by mortality and 
associated clinical signs, reduced mean body weight and food consumption, significantly 
reduced numbers of corpora lutea and mean number of estrous cycles, and reduced mean ovarian 
and vagina weight. Adverse effects on cesarean section parameters were observed at 25 and 
100/68 mg/kg/day and included an increase in early resorptions, increased post-implantation loss 
and decreased number of live fetuses. Therefore, the no-observed-effect level (NOEL) for 
maternal toxicity and fertility was 25 mg/kg/day and the NOEL for early embryonic 
development was 5 mg/kg/day.
MMB when administered orally to pregnant rats during organogenesis (from GD 6-17) showed 
evidence of embryo-fetal toxicity. Adverse fetal effects were observed at 12 mg/kg/day. The 
12 mg/kg/day group had increased early resorptions, percent post implantation loss, and reduced 
gravid uterus weight. The number of live fetuses and adjusted mean fetal weight were also 
reduced. Therefore, the NOAEL for maternal toxicity was 12 mg/kg/ day (GD 17 GS-0387 Cmax
and AUC0-t of 7.45 μg/mL and 75.8 μg•hr/mL, respectively). The NOAEL for embryo-fetal 
effects was 6 mg/kg/day (GD 17 GS-0387 Cmax and AUC0-t of 3.58 μg/mL and 25.5 μg•hr/mL, 
respectively).
MMB produced maternal toxicity at 60 mg/kg/day when administered by oral gavage to rabbits 
from GD 7-20. Maternal toxicity was based on reductions in food consumption as well as 
associated clinical signs. Embryo-fetal effects (reduced adjusted mean fetal weight, delayed bone 
ossification, and an abortion) were considered secondary to maternal toxicity and not 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 21
18 May 2015
GS-0387-01-related. Therefore, the NOAEL for maternal toxicity was 30 mg/kg/day which 
corresponded to GD 20 Cmax and AUC0-t values of 312 ng/mL and 543 ng•hr/mL and the NOAEL 
for embryo-fetal toxicity was 60 mg/kg/day which corresponded to GD 20 Cmax and AUC0-t
values of 994 ng/mL and 4100 ng•hr/mL, respectively.
A more detailed summary of findings from the studies in rats and dogs is available in the 
investigator brochure IB) for MMB. Investigators should refer to this document prior to initiating 
therapy with MMB.
1.2.3.
Clinical Trials of Momelotinib
Completed and Ongoing Clinical Trials
Please refer to the MMB IB for a listing of completed and ongoing MMB clinical trials.
1.2.4.
Special Risk
Clinical development of the JAK2 inhibitor fedratinib (SAR302503) in myelofibrosis (MF) was 
halted due to reported cases of Wernicke’s encephalopathy.  One case of suspected Wernicke’s 
encephalopathy has been reported with MMB.  Preliminary nonclinical data have suggested that 
some JAK inhibitors, eg, fedratinib and AZD-1480, have the potential to inhibit the 
transporter-mediated uptake of thiamine from the intestine while others, including MMB, show 
no effect (data on file).  In order to understand the thiamine status of subjects with MF, thiamine 
level will be collected from all subjects at regular intervals across all MMB studies, with 
supplementation of thiamine as clinically indicated in the medical judgment of the treating 
physician.
1.3.
Rationale for This Study
Targeted inhibitors of JAK2 including MMB and ruxolitinib have demonstrated significant 
clinical activity in MF. Both drugs have been shown to provide substantial improvement in 
symptomatic splenomegaly and constitutional symptoms. Ruxolitinib treatment does not 
typically lead to improvement in anemia, while patients on MMB were noted to experience 
improvement in anemia per International Working Group-Myelofibrosis Research and Treatment 
(IWG-MRT) criteria.  A mechanistic explanation for this differential anemia response has not 
been elucidated. A phase 3 study comparing the efficacy of MMB versus ruxolitinib is currently 
ongoing, but specific biomarker studies to explore predictors and mechanisms of response were 
not able to be feasibly incorporated in the study design.
Anemia is a well-established prognostic factor in MF: 38% of patients have a Hgb level of 
<10 g/dL and 24% required RBC transfusions at initial diagnosis {27673}. Additionally, the 
prevalence of anemia increases during the course of the disease. Erythropoietin, the hormone that 
regulates RBC production, signals through JAK2. Therefore, a JAK2 inhibitor should reduce 
erythropoiesis, and aggravated anemia was not unexpected for ruxolitinib. Patients treated with 
MMB, however, experienced an improvement in anemia, with 53% of patients having a positive 
anemia response. To investigate the mechanism of this anemia benefit, markers of iron 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 22
18 May 2015
metabolism will be evaluated in this study. Red blood cell transfusions, required by many MF
patients, relieve anemia symptoms, but exacerbate iron storage. Markers of iron storage 
(eg, ferritin), markers of available iron (eg, serum iron and transferrin saturation), Liver Iron 
Concentration MRI (LIC MRI), and markers of erythropoiesis will be evaluated throughout this 
study, along with standard markers of inflammation. Furthermore, levels of the hormone 
hepcidin will also be tested. Hepcidin is considered to be the master regulator of iron 
homeostasis in the body, and responds to iron availability, inflammatory signals and other inputs 
{34378}. Increased hepcidin is associated with reduced dietary iron absorption and reduced iron 
availability, and is a poor prognostic factor for MF {34379}.  It is expected that markers of iron 
metabolism will help elucidate the MMB mechanism of anemia benefit as patients traverse from 
requiring transfusion to becoming transfusion-independent. 
Several important issues regarding the use of MMB in MF remain unresolved. Momelotinib, like 
ruxolitinib, inhibits both JAK1 and JAK2, and thus the relative role of JAK1 versus JAK2 
inhibition in providing clinical benefit in MF is uncertain. Anti-inflammatory effects mediated 
by JAK1 inhibition may be critical. Furthermore, the degree to which MMB is able to “hit the 
target” in the cells that matter, the CD34+ hematopoietic stem/progenitor cells (HSPC) that are 
thought to initiate and drive the disease, remains uncertain. Though several investigators have 
examined the effects of ex vivo treatment of primary patient cells with JAK inhibitors, to date 
there have been no comprehensive studies examining the in vivo effects of JAK inhibitors on 
signaling in the HSPC compartment. This is largely related to the technical nuances of 
examining signaling in relatively rare cells (HSPC) within complex, heterogeneous mixtures of 
cells, eg, blood or bone marrow. Conventional biochemical techniques are inadequate to address 
this important question.
Mass cytometry is a novel technology that merges aspects of flow cytometry with mass 
spectrometry, thereby enabling the simultaneous measurement of > 30 parameters at the single 
cell level {34561}. Using such an approach, up to 15-20 intracellular markers can be evaluated in 
distinct cell subsets across the entire hematopoietic continuum, including HSPC as well as 
myeloid and lymphoid lineage subsets. This technology has been implemented in several recent 
studies {34603} {34562} {34563} {34638} {34604}.
In addition to querying the effect of MMB on signaling in CD34+ cells, this technique will also 
allow investigation of how signaling in this and other blood cell subsets changes in response to 
MMB treatment. Integrating mass cytometry data with expression profiling of blood cells before 
and during MMB treatment will enable better understanding of the biological basis of response 
to MMB.
1.4.
Compliance
This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory requirements.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 23
18 May 2015
2.
OBJECTIVES
The primary objective of this study is:

To determine the transfusion independence response rate for transfusion dependent  MF 
subjects treated with MMB
The secondary objectives of this study are:

To evaluate baseline levels and changes in markers of iron metabolism in transfusion 
dependent MF subjects treated with MMB

To assess inhibition of JAK1/2 in transfusion dependent MF subjects treated with MMB 

To evaluate MMB PK in transfusion dependent MF subjects

To evaluate changes in circulating cytokine and inflammatory markers in transfusion 
dependent MF subjects treated with MMB   


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 24
18 May 2015
3.
STUDY DESIGN
3.1.
Endpoint
The endpoints of this study are described in Section 8.
3.2.
Study Design
This is a single-arm, open-label study of MMB in subjects with PMF or Post-PV/ET MF who are 
transfusion dependent.  Subjects will receive MMB for 24 weeks (7 days) on study.
After completion of the 24 week (7 days) treatment phase visit procedures, subjects who 
respond to treatment, at the investigator’s discretion, will have the option of maintenance therapy 
with MMB on Study GS-US-352-1154 at the MMB dose they tolerated and/or derived clinical 
benefit from during the 24-week treatment period. 
3.3.
Study Treatments
The study drug in is MMB, supplied by Gilead. The formulation and packaging of MMB are 
further described in Section 5.
3.4.
Duration of Treatment
The duration of study treatment is 24 weeks (± 7 days). Subjects will continue study treatment 
until disease progression, unacceptable toxicity, consent withdrawal, or subject’s refusal of 
treatment.
3.5.
Discontinuation Criteria
The study may be discontinued at any time based on periodic reviews of safety and efficacy data 
by Gilead.
Subject discontinuation criteria are described in Section 6.8.
3.6.
Source Data
Patient reported outcomes data that are collected on paper will be considered source data.
Subject identification number captured by the interactive web response system (IWRS) is
considered source data. 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 25
18 May 2015
3.7.
Biomarker Testing
3.7.1.
Biomarker Samples to Address the Study Objectives:
The following biological specimens will be collected in this study and used to evaluate the 
association of exploratory systemic and/or tissue specific biomarkers with MMB response 
including efficacy and/or adverse events, to increase knowledge and understanding of the 
biology of MF and related diseases, and may support development of possible companion
diagnostics. The specific analyses will include, but will not be limited to, the biomarkers and 
assays listed in Table 3-1.
Because biomarker science is a rapidly evolving area of investigation, it is not possible to specify 
prospectively all tests that will be done on the specimens provided. The testing outlined below is 
based upon the current state of scientific knowledge. It may be modified during or after the end 
of the study to remove tests no longer indicated and/or to add new tests based upon the growing 
state of our knowledge. Specimens will be collected from all subjects. 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 26
18 May 2015
Table 3-1.
Biomarker Specimens and Tests to Address Study Objectives
Study Objective
Biomarker Test
Blood
To evaluate the mechanism of anemia response of 
MMB, the tests to be performed may include but are not 
limited to:
Iron studies, eg, serum iron level, total iron binding 
capacity, ferritin, non-transferrin bound iron, transferrin 
saturation, soluble transferrin receptor
Hepcidin, a peptide hormone that regulates iron 
metabolism and which demonstrates daily fluctuations 
in levels.  Testing for hepcidin requires strict adherence 
to time-of-day requirements as described in 
Section 5.3.1
Complete blood count, reticulocyte count
To evaluate pharmacodynamics response to MMB, the 
tests to be performed may include but are not limited to:
Flow cytometric analysis of phosphorylated STAT3
Exploratory  pharmacodynamics test
To evaluate the effect of MMB on inflammation, the 
tests to be performed include but are not limited to:
Circulating cytokines and inflammatory markers (eg,
interleukin-8 [IL-8], interleukin-2 receptor [IL-2R[, 
interleukin 6 [IL-6], interferon gamma [IFN-], etc)
To evaluate how MMB treatment influences survival 
and proliferative signaling in blood cells, including 
CD34+ cells,  tests may include, but are not limited to:
Mass cytometry to interrogate multiple signaling 
pathways, such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-B) and RAS/MAPK 
Standard flow cytometry immunophenotyping, to 
investigate how MMB treatment influences the relative 
percentages of the blood cell subsets 
Evaluation of gene expression patterns (RNA) and DNA 
mutations may be performed. 
To evaluate mutation status (eg, JAK2V617F, CALR), 
and whether allele burden changes with MMB 
treatment. Tests may include, but are not limited to:
Molecular determination of JAK2V617F mutation
Molecular determination of other mutations that may be 
associated with MF (eg, CALR, MPL, TET2).
Bone Marrow Biopsy
To evaluate fibrosis, RBC development, markers of 
MMB mechanism and stored iron, and whether MMB 
treatment influences these, the tests may include, but are 
not limited to:
Trichrome, silver, Prussion blue, glycophorin, CD71 
stains
Evaluation of gene expression patterns (RNA) and DNA 
mutations may be performed
Liver Iron Concentration MRI
To evaluate iron storage in the liver (performed in conjunction with spleen MRI)
Buccal Swab
To provide normal genomic baseline for molecular studies.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 27
18 May 2015
3.7.2.
Storage of Samples for Future Research
All biomarker specimens and samples collected during the study will be stored for future 
research. These unused subject samples are instrumental for continued research to increase the 
knowledge of the biology of MF and related diseases, and about the mechanism of MMB action. 
Most importantly, the stored unused samples will enable future experiments to build upon the 
strong scientific understanding that will be gained from the testing that is part of this study, 
providing significantly greater breadth and depth of knowledge. As new information about MF 
becomes available, tests such as investigation into newly identified immune cell subsets or 
determination of circulating levels of a newly identified cytokine correlated with MF may be 
undertaken. This new information will benefit from the deep characterization of the subject 
samples that will be performed in the current study.
The investigator or authorized designee will explain to each patient the objectives, methods, and 
potential hazards of sample storage for future research. In the event of a subject's death or loss of 
competence, the subject's specimens and data will continue to be used as part of the future 
research.
The specimens collected for future research, including body fluids, solid tissues, and derivatives 
thereof (eg, RNA, proteins, peptides), will be destroyed no later than 15 years after the end of 
study.   The specimen storage period will be in accordance with the internal review board 
(IRB)-approved Informed Consent Form and applicable laws (eg, health authority requirements).
3.7.3.
Biomarker Samples for Genomic Research
The genomic sample (buccal swab) will be used to provide a normal baseline for each subject. 
This is required to correctly identify and validate disease-related somatic mutations in the 
planned molecular studies. 
In addition to the study-specific Informed Consent Form to be signed by each subject 
participating in the study, a separate specific signature will be required to document a subject’s 
agreement to participate in genomic research.  The investigator or authorized designee will 
explain to each patient the objectives, methods, and potential hazards of participation in the 
genomic research. Subjects who decline to participate will not participate in the study. Subjects 
have the right to withdraw their consent for genomic research and study participation at any time 
and for any reason.  If a patient wishes to withdraw consent, the investigator must inform the 
Sponsor.
In the event of a subject's death or loss of competence, the subject's specimens and data will 
continue to be used as part of the genomic testing.
The specimens consented for genomic research, including body fluids, solid tissues, and 
derivatives thereof (eg, DNA, proteins, peptides), will be destroyed no later than 15 years after 
the end of the study.   The specimen storage period will be in accordance with the IRB -approved 
Informed Consent Form and applicable laws (eg, health authority requirements).


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 28
18 May 2015
4.
SUBJECT POPULATION
4.1.
Number of Subjects and Subject Selection
Approximately 40 subjects will participate in this study.
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1) Age ≥ 18 years old
2) Diagnosis of PMF or Post PV/ET-MF
3) Requires myelofibrosis therapy, in the opinion of the investigator
4) High risk OR intermediate-2 risk defined by dynamic international prognostic scoring system 
(DIPSS) OR intermediate-1 risk defined by DIPSS and associated with symptomatic 
splenomegaly and/or hepatomegaly
5) Transfusion dependent at baseline, defined as ≥ 4U RBC transfusion in the 8 weeks prior to 
first dose of MMB
6) Acceptable organ function as evidenced by the following:
a) Platelet Count ≥ 50 x 109/L 
b) Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT)
≤3 x upper limit of normal (ULN) or  AST or ALT ≤ 5 x ULN if liver is involved by 
disease process as judged by the investigator 
c) Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance of ≥ 60mL/min
d) Direct bilirubin ≤ 2.0 x ULN
7) Peripheral blood blast count < 20% 
8) Life expectancy of > 24 weeks
9) A negative serum pregnancy test for female subjects (unless surgically sterile or greater than 
two years postmenopausal) 
10) Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 3
11) Lactating females must agree to discontinue nursing before MMB administration
12) Able to understand and willing to sign the informed consent form


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 29
18 May 2015
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
1) Prior splenectomy
2) Splenic irradiation within 3 months prior to the first dose of MMB
3) Prior treatment with MMB
4) Known positive status of human immunodeficiency virus (HIV)
5) Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B 
and C), or hepatitis B or C carrier
6) Use of strong CYP3A4 inducer within 2 weeks prior to the first dose of MMB
7) Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection,  
uncontrolled cardiac arrhythmia, or psychiatric illness/social situation that would limit 
compliance with study requirements as judged by treating physician
8) History of a prior diagnosis of any malignancy other than PMF or Post PV/ET-MF except for 
the following: adequately treated local basal cell or squamous cell carcinoma of the skin, 
cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without 
known metastatic disease and with no requirement for therapy or requiring only hormonal 
therapy and with normal prostate specific antigen for >1 year prior to randomization, or any 
other cancer that has been in complete remission without treatment for ≥5 years prior to 
randomization
9) Treatment with a JAK inhibitor within 21 days of the planned first dose of MMB
10) Documented myocardial infarction or unstable/uncontrolled cardiac disease (eg, unstable 
angina, congestive heart failure [New York Heart Association > Class III]) within 6 months 
of randomization
11) Presence of peripheral neuropathy ≥ CTCAE Grade 2
12) Unwilling or unable to undergo a MRI per requirements in Section 6.2.11.2
13) Unwilling to consent to genomics sampling
14) Pregnant or breast-feeding
15) Known hypersensitivity to the study investigational medicinal products, the metabolites, or 
formulation excipients


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 30
18 May 2015
5.
INVESTIGATIONAL MEDICINAL PRODUCTS
5.1.
Enrollment and Treatment Assignment
Subjects will be enrolled via IWRS. All subjects will receive a starting dose of MMB 200 mg in 
a single tablet, taken orally once-daily.
5.2.
Description and Handling of MMB
5.2.1.
Formulation
MMB is supplied as GS-0387-01(dihydrochloride monohydrate) and is available as 100 mg, 
150 mg, and 200 mg strength (as free base equivalent) tablets. The tablets contain excipients, 
microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, silicon dioxide, 
magnesium stearate, propyl gallate, polyvinyl alcohol, polyethylene glycol, talc, titanium 
dioxide, yellow iron oxide and red iron oxide. MMB tablets, 100 mg, are round-shaped, 
film-coated, brown tablets. MMB tablets, 150 mg, are round or triangle-shaped, film-coated, 
brown tablets. MMB tablets 200 mg, are capsule-shaped, film-coated, brown tablets.
5.2.2.
Packaging and Labeling
MMB tablets are packaged in white, high-density polyethylene (HDPE) bottles. Each bottle 
contains 30 tablets, a silica gel desiccant, and polyester packing material. Each bottle is enclosed 
with a white, continuous thread, child resistant screw cap with an induction-sealed, aluminum 
faced liner. 
All MMB bottles will be labeled to meet all applicable requirements of the US Food and Drug 
Administration (FDA) and/or other local regulations as applicable.
5.2.3.
Storage and Handling
MMB should be stored at controlled room temperature of 25ºC (77ºF); excursions are permitted 
between 15ºC and 30ºC (59ºF and 86ºF). 
Until dispensed to the subjects, all MMB bottles should be stored in a securely locked area, 
accessible only to authorized site personnel. To ensure the stability and proper identification, the 
drug products should not be stored in a container other than the container in which they were 
supplied.
5.3.
Dosage and Administration of MMB
5.3.1.
Starting Dose
The starting dose of MMB for all subjects will be 200 mg in a single tablet.  MMB will be orally 
self-administered once daily in the morning, and thereafter at approximately the same time each 
day. Subjects will be observed for 4 hours after the first MMB dose.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 31
18 May 2015
On the day of study visits, dosing should occur at the site. On the day of study visits requiring 
hepcidin sampling, MMB dosing must occur between 8 am and 10 am to accommodate the 
diurnal variation of hepcidin level.
5.3.2.
Discontinuing or Interrupting MMB Treatment
When discontinuing treatment with MMB, dosing of MMB may be tapered at the investigator’s 
discretion. For subjects on the 200 mg or 150 mg once-daily dose, it is recommended that the 
MMB dose be reduced to 100 mg once daily for 1 week prior to stopping treatment. Treatment 
may be stopped immediately for subjects receiving the 100 mg once-daily dose.
5.3.3.
MMB Dose Adjustments and Dose Interruption
Treatment may be interrupted for up to 28 days, inclusive of taper, and restarted per the sections 
below. Platelet count must be ≥ 50 x 109/L prior to restarting treatment, regardless of the reason 
for treatment interruption. If toxicity persists beyond 28 days, treatment may be restarted upon 
sponsor approval.
5.3.4.
Dose Adjustments for Thrombocytopenia
Platelet counts will be monitored throughout the study and the dose of MMB adjusted based on 
the degree of thrombocytopenia as per Table 5-1.  
Table 5-1.
MMB Dose Reductions for Subjects with Thrombocytopenia
Dose prior to reduction
200 mg QD
150 mg QD
100 mg QD
Platelet count
Reduce to the dose below
50 x 109/L
No dose adjustment required
25 x 109/L to < 50 x 109/L
If platelet count 100 x 109/L at study entry
150 mg QD
100 mg QD
Interrupt treatment
25 x 109/L to < 50 x 109/L
If platelet count < 100 x 109/L at study entry
No dose adjustment required
< 25 x 109/L
Interrupt treatment
After dose interruption for thrombocytopenia, treatment may be restarted as per Table 5-2 if 
platelet count is ≥ 50 x 109/L in the absence of platelet transfusion for at least 5 days.  


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 32
18 May 2015
Table 5-2.
Doses for Restarting MMB after Withholding Treatment for Toxicity
Dose at time of toxicity
Restarting dose level
200 mg QD
150 mg QD
150 mg QD
100 mg QD
100 mg QD
100 mg QD
5.3.5.
Dose Adjustments for Neutropenia
If the absolute neutrophil count (ANC) is < 0.5 x 109/L, treatment will be interrupted. After 
recovery of the ANC to ≥0.75 x 109/L, MMB may be restarted per Table 5-2.
5.3.6.
Dose Adjustments for Non-hematologic Toxicities
In the event of a new or recurrent Grade 3 or 4 non-hematologic toxicity that the investigator 
considers related to MMB, dosing will be interrupted for a maximum of 28 days, inclusive of 
taper, until the toxicity resolves or returns to baseline.  Upon resolution of the new or recurrent 
Grade 3 or 4 non-hematologic toxicity MMB treatment may be restarted as per Table 5-2.  If the 
toxicity persists beyond 28 days, treatment may be restarted only upon sponsor approval.
If a Grade 3 or 4 non-hematologic toxicity that the investigator considers related to MMB and 
had led to treatment interruption at the 100 mg once-daily dose recurs after restarting MMB at 
100 mg once-daily, treatment will be permanently discontinued.
5.3.7.
Dose Adjustments Based on Response
If efficacy is insufficient, subjects may increase the dose of MMB after dose reduction, provided 
there is no new or recurrent:

Grade 3 or 4 non-hematologic toxicity related to MMB, and/or

Platelet count < 50 x 109/L, and/or 

ANC < 0.75 x 109/L
The dose may not be increased during the first 4 weeks of therapy or within 4 weeks of a dose 
reduction. Where a dose increase is permitted, the dose may not be increased more frequently 
than every 2 weeks. The MMB dose may be increased by 50 mg per dose adjustment to a 
maximum of 200 mg per day.
Insufficient efficacy is defined as:

Failure to achieve a reduction from pretreatment baseline in either palpable spleen length of 
≥ 50% or spleen volume of ≥ 35% as measured by MRI


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 33
18 May 2015
5.3.8.
Dose Adjustments for Other Toxicities
In the event of a toxicity not covered in Sections 5.3.4, 5.3.5 or 5.3.6 that the investigator 
considers related to MMB, the investigator may interrupt dosing at their discretion for a 
maximum of 28 days.  Following interruption, treatment may be restarted at the same dose level.  
If the investigator believes a dose reduction is warranted, treatment may be restarted at a reduced 
dose level per Table 5-2 with sponsor approval.  If treatment interruption persists beyond 
28 days, treatment may be restarted only upon sponsor approval.
5.4.
Prior and Concomitant Medications
5.4.1.
Restricted Medications

Anti-hypertensive therapy should not be taken on the day of the first MMB dose until 4 hours 
after MMB administration

Strong CYP3A4 inducers (eg, carbamazepine, phenytoin, St. John’s Wort) may decrease 
MMB exposure and should be excluded

Moderate inducers of CYP3A/2C8/2C19 may decrease MMB exposure and alternative 
medications should be considered if clinically appropriate when co-administered with MMB
5.4.2.
Proscribed Medications
The following medications are proscribed during the treatment phase:

Experimental therapy other than MMB administered in this trial

Myelofibrosis therapy other than MMB administered in this trial
5.4.3.
Breast Cancer Resistance Protein (BCRP) Substrates
In vitro, MMB was determined to be an inhibitor of BCRP. Results from a clinical drug-drug 
interaction study suggested that multiple doses of MMB at 200 mg increased the exposure 
(Cmax and AUC) of rosuvastatin (a BCRP substrate) by approximately 3 fold. Plasma exposures 
of BCRP substrates may increase when administered with MMB. As such, when appropriate, 
dose modification or alternative medications as clinically appropriate should be considered when 
co-administered with MMB.
5.4.4.
Organic Anion-Transporting Polypeptide (OATP) Inhibitors
MMB was determined to be a substrate of OATP1B1 and OATP1B3. A single dose of rifampin 
(potent inhibitor of OATP1B1 and OATP1B3) increased MMB Cmax by ~40% and AUCinf by 
~56%. Care should be exercised when MMB is co-administered with OATP inhibitors.
Refer to the IB of MMB for more details.  Refer to prescribing information of co-administered 
drugs prior to administration.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 34
18 May 2015
5.5.
Accountability for MMB
The investigator is responsible for ensuring adequate accountability of all used and unused 
MMB.  This includes acknowledgement of receipt of each shipment of MMB (quantity and 
condition). All used and unused MMB dispensed to subjects must be returned to the site.
MMB accountability records will be provided to each study site to:

Record the date received and quantity of MMB bottles

Record the date, subject number, subject initials, the MMB kit number dispensed

Record the date, quantity of used and unused MMB returned, along with the initials of the 
person recording the information.
5.5.1.
MMB Return or Disposal
The methods of MMB return and destruction are described in Section 9.1.7.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 35
18 May 2015
6.
STUDY PROCEDURES
The study procedures to be conducted for each subject enrolled in the study are presented in 
tabular form in Appendix 2 and described in the text that follows.
The investigator must document any deviation from protocol procedures and notify the sponsor 
or contract research organization (CRO).
6.1.
Subject Enrollment and Treatment Assignment
A subject will be considered enrolled once enrolled in IWRS. It is the responsibility of the 
investigator to ensure that each subject is eligible for the study before enrolling the subject.
Details regarding treatment assignment are in section 5.1.
6.2.
Study Procedure Descriptions
The sections below describe the individual study procedures outlined in subsequent sections and 
the schedule of assessments (Appendix 2).
6.2.1.
Informed Consent
All subjects must personally sign and date the IRB approved informed consent form before any 
study procedures are performed (Section 9.1.3). 
6.2.2.
Medical History
A complete medical and surgical history will be obtained prior to enrollment and recorded on the 
eCRF. The medical history will include 3 months of transfusion history (Section 6.2.11.3) prior 
to screening, and JAK2V617F mutation status, if documented.
6.2.3.
Medication History
A history of medications taken within the 3 months prior to screening and during the screening 
period will be obtained prior to enrollment and recorded on the eCRF.
6.2.4.
Physical Examination and Myelofibrosis Symptom Assessment
At screening, a complete physical examination will be performed including height, weight, 
clinical signs and symptoms, and palpable spleen length, measured with a ruler. The physical 
exam will include assessment of splenomegaly and hepatomegaly. Breast, genital, and rectal 
examinations are not required at any study visit unless warranted in the opinion of the 
investigator. Height and weight should be collected per standard practice. Physical examination 
findings during the screening period will either be reported as medical history or adverse events 
(AEs) based on the requirements in Section 7.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 36
18 May 2015
At subsequent study visits, the physical examination will be an interim examination to monitor 
for any changes and will also include weight and assessment of myelofibrosis symptoms.
6.2.5.
Vital Signs
Vital signs will include pulse, systolic and diastolic blood pressure, and body temperature. Vital 
signs should be collected per standard practice.
6.2.6.
Ophthalmic Examinations
Eye examinations will be performed to assess for cataract and visual acuity. All assessments will 
be performed in accordance with local standard practice.
6.2.7.
Laboratory Assessments
All samples for laboratory assessments will be sent to the central laboratory with the exception 
of urine pregnancy tests which will be completed at the site, if applicable. Local laboratory 
complete blood count (CBC) assessments may be collected as required for dose adjustments 
throughout the study. Local laboratory assessments resulting in a dose change will be reported on 
the eCRF.
The central laboratory will be responsible for chemistry, CBC with differential, urinalysis, 
hepatitis serology, and serum pregnancy testing per Table 6-1 and storage or shipping of other 
study samples. Other tests listed in Table 6-1 will be performed by Gilead or a designated 
laboratory. Any samples collected per the Schedule of Assessments (Appendix 2) may be 
analyzed for any tests necessary to ensure subject safety. Specific instructions for processing, 
labeling, and shipping samples will be provided in a central laboratory manual. The date and 
time of sample collection will be reported.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 37
18 May 2015
Table 6-1.
Analytes
Chemistry
Urinalysis
CBC and Coagulation
Other Analytes
Albumin
Alkaline phosphatase
ALT 
AST
Amylase
Bicarbonate 
BUN 
Calcium
Chloride
Creatinine
Direct bilirubin
GGT 
Glucose 
Iron
Iron binding capacity
Ferritin
LDH
Lipase
Magnesium
Non-transferrin bound iron
Phosphorus
Potassium 
Sodium
Total bilirubin 
Total protein 
Transferrin saturation
Soluble transferrin receptor
Uric acid
Color and appearance
Specific gravity
pH
Occult blood
Protein
Glucose
Bilirubin
Leukocyte esterase
Ketones
Nitrite
Urobilinogen
Microscopica
RBC
Hemoglobin
Hematocrit
Platelets
WBC
Differential
Reticulocyte Count
% Hgb-Reticulocytes
Neutrophils
Bands/stabs
Eosinophils
Basophils
Lymphocytes
Monocytes
% blasts
Absolute neutrophil count
PT (INR)b
PTTb
Serum beta hCG
Hepatitis B surface antigen 
Hepatitis B surface 
antibody
Hepatitis B core antibody 
Hepatitis C antibody
MMB PK
C-reactive protein
Erythropoietin
Hepcidin
Thiamine
Pharmacodynamics and
exploratory biomarkers
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; GGT = gamma glutamyl 
transpeptidase; LDH = lactate dehydrogenase; PT (INR)= Prothrombin time; PTT= partial thromboplastin time; RBC = red 
blood cell; WBC = white blood cell
a
If applicable
b
Baseline and Week 24 only
6.2.8.
Biomarker Samples
Biomarker analysis will be performed on subject samples including: blood, Liver Iron 
Concentration (LIC) MRI, bone marrow biopsy, and buccal swab as indicated below. Refer to 
sections 6.3-6.5 and Appendix 2 for details regarding the biomarker sampling schedules.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 38
18 May 2015
6.2.8.1.
Blood Samples for Biomarker Analysis
Blood samples will be collected and transferred to the central laboratory for analysis as whole 
blood, serum or plasma. 
6.2.8.2.
Liver Iron Concentration MRI (LIC MRI)
This anemia-related test will be performed in conjunction with spleen MRI to determine the 
amount of iron stored in the liver.
MRIs will be performed at local imaging centers and sent to a central imaging laboratory for 
assessment of liver iron concentration. The central imaging laboratory will provide instructions 
for collection and transfer of the LIC MRI. Repeat MRI scans may be required if the original 
scan is not accepted by the central imaging laboratory, which may occur if the scan is of poor 
quality. Computed tomography (CT) scans may not be performed.
The central imaging laboratory will assess liver iron concentration as described in the 
Independent Review Charter.
6.2.8.3.
Bone marrow biopsy
The bone marrow biopsy, and if possible, bone marrow aspirate, should be processed according 
to the laboratory manual and shipped to the central lab embedded in paraffin blocks unless a 
block or unstained tissue slides are already available within 90 days of the Screening visit. 
Bone marrow samples may also be assessed for cytogenetic abnormalities at Baseline
(not required if previously completed within 90 days of the Screening visit and the required data 
are available for reporting to the eCRF). Cytogenetic assessments may be repeated for subjects 
with abnormalities at Baseline for assessment of cytogenetic response.
6.2.8.4.
Buccal Swab
The buccal swab will be performed to provide a normal genome sample as a baseline to enable 
identification of somatic molecular changes related to disease. The sample should be collected at 
the Baseline visit, but may be collected at any time during the study.
6.2.9.
Pharmacokinetics
Pharmacokinetics blood samples will be collected predose and at 2, 4, and 6 hours postdose at 
specified visits as instructed in sections 6.3-6.5.  


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 39
18 May 2015
6.2.10.
Patient-reported Outcomes Assessments (PRO)
6.2.10.1.
Modified Myeloproliferative Neoplasm Symptom Assessment Form Total 
Symptom Score (MPNSAF TSS) version 2
The modified MPNSAF TSS version 2 is an 8 item questionnaire developed to assess symptom 
burden and quality of life in patients with MPN.  The total symptom score is assessed over time 
to evaluate changes in MPN-related symptoms.  The questionnaire is completed daily on an 
electronic diary (eDiary) device.
6.2.10.2.
Patient Global Impression of Change (PGIC)
The PGIC is a single question to assess the patient’s impression of change in myelofibrosis 
symptoms since the start of study treatment. The Patient Global Impression of Change (PGIC) 
scale assessed patients’ perceptions of change in their myelofibrosis symptoms over time. The 
PGIC has been widely used to evaluate a patient’s overall sense of whether a treatment has been 
beneficial. In this study, subjects complete the PGIC on paper at the Week 24 visit. 
6.2.11.
Disease Assessments
6.2.11.1.
Dynamic International Prognostic Scoring System (DIPSS)
The DIPSS for myelofibrosis will be assessed at screening to determine a subject’s study 
eligibility. The DIPSS score is assessed using a combination of the subject’s age, constitutional
symptoms, and hematologic parameters. The DIPSS score corresponds to a risk group: low, 
intermediate-1, intermediate-2, or high {24006} (Appendix 4).
6.2.11.2.
Spleen MRI
MRIs will be performed at local imaging centers and sent to a central imaging laboratory for 
assessment of spleen volume. The central imaging laboratory will provide instructions for 
collection and transfer of the spleen MRI. The spleen MRI will be performed in conjunction with 
the LIC MRI. Repeat MRI scans may be required if the original scan is not accepted by the 
central imaging laboratory, which may occur if the scan is of poor quality. CT scans may not be 
performed.
The central imaging laboratory will assess spleen volume as described in the Independent 
Review Charter.
6.2.11.3.
Transfusion Recording
Subjects will record transfusion events in a diary during the screening period and throughout the 
study. The diary will include instructions for the transfusion clinic to provide the date, type (eg, 
whole blood, platelets, packed cells), and number of units of the transfusion. Transfusion events 
will be reported on the eCRF. The hemoglobin or platelet value at the time of the transfusion will 
be reported on the eCRF as an observational component of the study.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 40
18 May 2015
6.3.
Pretreatment Assessments
6.3.1.
Screening Visit 
The Screening visit date will be defined as the date the subject signs the informed consent form. 
Subjects will complete screening and baseline assessments within 28 days after signing the 
informed consent form to determine eligibility for participation in the study. Subjects who do not 
enroll within the 28 day window will be screen failed. The following assessments will be 
performed and documented at the screening visit (-28 to -21 days prior to first dose of MMB):

Informed consent

Medical history (includes prior 3 months of transfusion history)

Medication history

Physical examination

Myelofibrosis symptoms assessment

Vital signs

Disease Status
DIPSS

Distribution of eDiary with instructions for collection of daily modified MPNSAF TSS. 
Subjects will be issued a hand-held device and will complete the MPNSAF TSS 
questionnaire each night during screening through to the Week 24 visit.

Laboratory assessments:
Chemistry
Complete blood count (CBC) with differential, reticulocyte count (including 
hemoglobin-containing reticulocytes)
Viral hepatitis B and C testing
Serum pregnancy test, if applicable
C-Reactive Protein (CRP)
Urinalysis


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 41
18 May 2015

Biomarker Sampling:
Iron studies
Cytokines/chemokines
CD34+ cell count
Gene expression
Immunophenotype (flow cytometry)
From the time of obtaining informed consent through the first administration of MMB, all 
serious adverse events (SAEs), as well as any non-serious AEs related to protocol-mandated 
procedures must be recorded on the AE eCRF. All other untoward medical occurrences observed 
during the screening period, including exacerbation or changes in medical history are to be 
captured on the medical history eCRF. See Section 7 for additional details.
Laboratory assessments may be repeated 1 time during the screening period for confirmation 
prior to registering the subject as a screen failure. Subjects failing to meet eligibility or complete 
the initial screening will be registered as a screen failure and permitted to rescreen 1 time. 
Rescreening requirements will be the same as the screening requirements. Assessments from the 
first screening attempt that fall within the specified timeframes (eg, bone marrow aspirate/biopsy 
within 90 days of screening visit) do not need to be repeated.
6.3.2.
Baseline Assessments
The following baseline assessments will be completed within 7 days (±2 days) prior to first dose
of MMB, except for the ophthalmic examination which may be completed at any time during the 
screening period prior to first dose of MMB.
Laboratory assessments and biomarker samplings must be completed ≥ 7 days after a RBC 
transfusion.

Physical exam

Myelofibrosis symptoms assessment

Vital signs

Transfusion recording

Ophthalmic examination

Laboratory assessments:
CBC with differential, reticulocyte count (including hemoglobin-containing 
reticulocytes)


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 42
18 May 2015
Thiamine status
Erythropoietin (EPO)
CRP
Urine pregnancy test

Biomarker Sampling:
Iron Studies
Hepcidin (between 8-10 am, and 6 hours later)
Exploratory signaling (mass cytometry)
JAK2V617F allele burden, and other mutation tests
Buccal swab
Bone marrow biopsy and if possible aspirate (not required if previously completed within 
90 [+14] days of the Screening visit, and formalin-fixed paraffin embedded [FFPE] block 
or tissue slides plus the data are available)

Spleen & LIC MRI (per Section 6.2.11)

AEs and concomitant medications
6.4.
Enrollment
Enrollment may be completed following confirmation of subject eligibility and completion of the 
above screening and baseline procedures. The IWRS will assign medication at the time of 
enrollment. The site will train the subject on the dosing schedule for MMB at the time of 
dispensing. The first dose of MMB may occur within 5 days following enrollment in IWRS.
6.4.1.
Enrollment Assessments
The following enrollment assessments will be completed on the day of first dose of MMB:

Modified MPNSAF TSS (completed daily)

Physical examination

Myelofibrosis symptoms assessment

Vital signs


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 43
18 May 2015

Transfusion recording

Biomarker sampling:
Pharmacodynamics (predose, 2, 4, 6 hours postdose)
Pharmcokinetics (predose, 2, 4, 6 hours postdose)
Exploratory pharmacodynamics sample (predose, 2 hours postdose)
Hepcidin (predose, 6 hours postdose) 
Cytokines/chemokines (predose, 6 hours postdose)
CD34+ cell count (predose)
Gene expression (predose)
Immunophenotype (predose)

AEs and concomitant medications

MMB dosing
6.5.
Treatment Assessments
Each on-study visit will be scheduled based on the date of enrollment in IWRS. Visits will 
follow the schedule of assessments in Appendix 2.
6.5.1.
Week 2
The Week 2 visit may be completed within a window of ± 3 days. The following procedures will 
be completed at the Week 2 visit, unless otherwise specified:

Modified MPNSAF TSS (completed daily)

Physical examination

Myelofibrosis symptoms assessment

Transfusion recording

Laboratory assessments (all predose):
CBC with differential, reticulocyte count (including hemoglobin-containing 
reticulocytes)
CRP


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 44
18 May 2015

Biomarker Sampling:
Hepcidin (predose, 6 hrs postdose) 
Iron Studies

AEs and concomitant medications
6.5.2.
Week 4, 8, 12, 16 and Week 20
On-study visits during this period may be completed within a window of 3 days. The following 
procedures will be completed at each visit, unless otherwise specified:

Modified MPNSAF TSS (completed daily)

Physical examination

Myelofibrosis symptoms assessment

Vital signs

Transfusion recording

Laboratory Assessments:
CBC with differential ,reticulocyte count (including hemoglobin-containing 
reticulocytes) (All visits, predose)
Chemistry (Week 12 only, predose)
Thiamine status (Week 12 only, predose)
Erythropoietin (Weeks 8, 20, predose)
CRP (Week 12 only, predose)
Urinalysis

Biomarker Sampling:
Hepcidin (All visits, predose, 6 hours postdose)
Iron Studies(all visits, predose)
Cytokines/chemokines (All visits, predose)


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 45
18 May 2015
CD34+ cell count (Week 12, 20 predose)
Immunophenotype (flow cytometry) (Weeks 12, 20, predose)
Gene expression (Weeks 12, 20, predose)
Exploratory signaling (mass cytometry) (Weeks 4, 12, predose)
Pharmacodynamics (Week 4 predose, 2, 4, 6 hours postdose)
Pharmacokinetics (Week 4 predose, 2, 4, 6 hours postdose)

Urine pregnancy test (all visits; if applicable)

AEs and concomitant medications

MMB accountability and dispensing
6.5.3.
Week 24
Subjects will complete the Week 24 visit within a window of 7 days. Subjects will continue 
MMB treatment until completion of this visit. The following procedures will be completed:

Modified MPNSAF TSS (completed daily; the eDiary will be collected at this visit)

PGIC Questionnaire

Physical examination

Myelofibrosis symptoms assessment

Vital signs

Transfusion recording

Laboratory assessments:
Chemistry (predose)
CBC with differential, reticulocyte count (including hemoglobin-containing 
reticulocytes) (predose)
Thiamine status (predose)
CRP (predose)
Urinalysis


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 46
18 May 2015

Biomarker Sampling:
Hepcidin (predose, 6 hours postdose)
Exploratory signaling (mass cytometry) (predose)
Iron Studies (predose)
Cytokines/chemokines (predose)
JAK2V617F allele burden, and other mutation tests
Pharmacodynamics (predose, 2, 4, 6 hours postdose)
Pharmacokinetics (predose, 2, 4, 6 hours postdose)
Bone marrow biopsy/aspirate

Urine pregnancy test (if applicable) 

Ophthalmic examinations

Spleen & LIC MRI (per Section 6.2.11)

AEs and concomitant medications

MMB accountability
6.6.
Unscheduled visits
Unscheduled visits may occur at any time during the study. Vital signs, laboratory assessments, 
physical examination and MMB dispensation may be conducted at these visits.
6.7.
Post-treatment Assessments
6.7.1.
Early Study Drug Discontinuation
Subjects discontinuing study MMB prior to the Week 24 visit will complete the Early Study 
Drug Discontinuation (ESDD) visit and will not be eligible to receive MMB maintenance 
treatment. The following procedures will be completed within 7 days of early MMB 
discontinuation:

Modified MPNSAF TSS (completed daily, the eDiary will be collected at this visit)

Physical examination

Myelofibrosis symptoms assessment

Vital signs


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 47
18 May 2015

Spleen and LIC MRI

Ophthalmic examinations (not required if completed within 12 weeks prior to ESDD)

Laboratory assessments:
Chemistry
CBC with differential, reticulocyte count (including hemoglobin-containing 
reticulocytes)
CRP
Urinalysis

Urine pregnancy test (if applicable)

Biomarker Sampling:
JAK2V617F allele burden, and other mutation tests

Transfusion recording

AEs and concomitant medications

MMB accountability (if required)
6.7.2.
30-Day Follow-up Assessments
The following procedures will be completed 30 days after the subject’s last dose of MMB, within 
a window of ±7 days. Subjects completing the Week 24 visit and entering maintenance treatment 
on study GS-US-352-1154 will not complete the 30-Day Follow Up visit:

Physical examination

Myelofibrosis symptoms assessment

Vital signs

Laboratory assessments:
Chemistry
CBC with differential, reticulocyte count (including hemoglobin-containing 
reticulocytes)
Urinalysis


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 48
18 May 2015

Transfusion recording

AEs and concomitant medications
6.8.
Criteria for Discontinuation of Study Treatment
Study medication may be discontinued in the following instances:

Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study dosing at the discretion of the investigator.

Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the 
ability to continue study-specific procedures or is considered to not be in the subject’s best 
interest

Disease progression

Subject request to discontinue for any reason

Subject noncompliance

Pregnancy during the study; refer to Appendix 3

Discontinuation of the study at the request of Gilead, a regulatory agency or an IRB
6.9.
End of Study
End of Study for a subject is defined as the date of the last study-related procedure or the date of 
death for an on-study subject. All treatment-emergent AEs and laboratory abnormalities present 
at the end of study are to be followed until resolution or the event is determined to be irreversible 
by the investigator.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 49
18 May 2015
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1.
Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical study subject 
administered a medicinal product, which does not necessarily have a causal relationship with the
treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease 
temporally associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may also include pre- or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severity or change in nature during or 
as a consequence of participation in the clinical study will also be considered AEs.
An AE does not include the following:

Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion.
The condition that led to the procedure may be an adverse event and must be reported.

Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the 
screening visit that do not worsen

Situations where an untoward medical occurrence has not occurred (eg, hospitalization for 
elective surgery, social and/or convenience admissions)

Overdose without clinical sequelae (see Section 7.7.1)

Any medical condition or clinically significant laboratory abnormality with an onset date 
before the consent form is signed and not related to a protocol-associated procedure is not an 
AE. It is considered to be pre-existing and should be documented on the medical history case 
report form (CRF).
7.1.2.
Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

Death

Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it were more severe.)

In-patient hospitalization or prolongation of existing hospitalization


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 50
18 May 2015

Persistent or significant disability/incapacity

A congenital anomaly/birth defect

A medically important event or reaction: such events may not be immediately life-
threatening or result in death or hospitalization but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes constituting SAEs. Medical and scientific 
judgment must be exercised to determine whether such an event is a reportable under 
expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medically important event and subject to expedited reporting 
requirements.
7.1.2.1.
Protocol-Specific Serious Adverse Event Instructions
To maintain the integrity of the study, the following events that are assessed as unrelated to 
MMB will not be considered as SAEs:

Progression of myelofibrosis

Death related to progression of myelofibrosis
However, events of progression of myelofibrosis and death due to progression of myelofibrosis 
that are assessed by the investigator to be related to MMB will be considered as SAE and will be 
reported to regulatory agencies by Gilead accordingly.
All events of progression of myelofibrosis and death related to progression of myelofibrosis, 
regardless of investigator assessment of relationship to MMB, will be reported in the eCRFs and, 
as appropriate, in the final clinical study report (CSR) and in any relevant aggregate safety 
reports.
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that 
require medical or surgical intervention or lead to MMB interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, 
laboratory or other abnormal assessments (eg, electrocardiogram, x-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the 
definition of an AE or SAE as described in Sections 7.1.1and 7.1.2. If the laboratory abnormality 
is part of a syndrome, record the syndrome or diagnosis (eg, anemia), not the laboratory result 
(eg, decreased hemoglobin).


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 51
18 May 2015
For specific information on handling of clinical laboratory abnormalities in this study, please 
refer to Section 7.5.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments.
7.2.1.
Assessment of Causality for MMB and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to 
MMB therapy using clinical judgment and the following considerations:

No: Evidence exists that the adverse event has an etiology other than MMB treatment. For 
SAEs, an alternative causality must be provided (eg, pre-existing condition, underlying 
disease, intercurrent illness, or concomitant medication).

Yes: There is reasonable possibility that the event may have been caused by the 
investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causally related in 
the context of adverse event reporting. 
The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) 
should be assessed using the following considerations:

No: Evidence exists that the adverse event has an etiology other than the study procedure.

Yes: The adverse event occurred as a result of protocol procedures (eg, venipuncture)
7.2.2.
Assessment of Severity
The severity of AEs will be graded using the Common Terminology Criteria for Adverse Events 
(CTCAE), Version 4.03. For each episode, the highest severity grade attained should be reported.
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: Grade 1 
(mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), or Grade 5 (fatal) to 
describe the maximum intensity of the AE. For purposes of consistency with the CTCAE, these 
intensity grades are defined in Table 7-1.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 52
18 May 2015
Table 7-1.
Grading of Adverse Event Severity
Grade
Adjective
Description
Grade 1 
Mild
Sign or symptom is present, but it is easily tolerated, is not expected to have a 
clinically significant effect on the subject’s overall health and well-being, does 
not interfere with the subject’s usual function, and is not likely to require 
medical attention.
Grade 2 
Moderate
Sign or symptom causes interference with usual activity or affect clinical status, 
and may require medical intervention.
Grade 3 
Severe
Sign or symptom is incapacitating or significantly affects clinical status and 
likely requires medical intervention and/or close follow-up.
Grade 4 
Life-threatening
Sign or symptom results in a potential threat to life.
Grade 5 
Fatal
Sign or symptom results in death.
The distinction between the seriousness and the severity of an AE should be noted. Severity is a 
measure of intensity; thus, a severe reaction is not necessarily a serious reaction.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead 
Requirements for collection prior to initiation of MMB:
After informed consent, but prior to initiation of study medication, the following types of events 
should be reported on the case report form eCRF: all SAEs and adverse events related to 
protocol-mandated procedures.
7.3.1.
Adverse Events
Following initiation of study medication, collect all AEs, regardless of cause or relationship, 
until 30 days after last administration of MMB must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up 
period.
7.3.2.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur after the subject first consents to 
participate in the study (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol-required post treatment follow-up period, must be reported to the 
eCRF database and Gilead Drug Safety and Public Health (DSPH) as instructed. This also 
includes any SAEs resulting from protocol-associated procedures performed after informed 
consent is signed.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 53
18 May 2015
Any SAEs and deaths that occur after the post treatment follow-up visit but within 30 days of the 
last dose of MMB, regardless of causality, should also be reported. 
Investigators are not obligated to actively seek SAEs after the protocol defined follow up period. 
However, if the investigator learns of any SAEs that occur after study participation has 
concluded and the event is deemed relevant to the use of MMB, he/she should promptly 
document and report the event to Gilead DSPH.

All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
7.3.2.1.
Electronic Serious Adverse Event (eSAE) Reporting Process

Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.

If for any reason it is not possible to record the SAE information electronically, ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours as described above to Gilead DSPH: email  
Safety_FC@gilead.com; or fax +1 (650) 522-5477.

As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.

If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.

All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.

For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other 
documents are also to be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.

Additional information may be requested to ensure the timely completion of accurate safety 
reports.

Any medications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 54
18 May 2015
7.4.
Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country-specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by Gilead using reference safety 
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safety letter notifying them of relevant SUSAR reports associated 
with MMB. The investigator should notify the IRB of SUSAR reports as soon as is practical, 
where this is required by local regulatory agencies, and in accordance with the local institutional 
policy. 
7.5.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities are usually not recorded as AEs or SAEs (Section 7.1.3). When 
laboratory abnormalities are recorded as AEs or SAEs, severity should be recorded and graded 
according to the CTCAE Version 4.03 except for anemia (hemoglobin, Hgb) which will be 
graded using the CTCAE Version 3.0 as defined in Table 7-2.
Table 7-2.
Grading of Anemia (Hgb) Severity
Grade (CTCAE 3.0)
1
2
3
4
5
<LLN – 10.0 g/dL
<LLN – 6.2 mmol/L
<LLN – 100 g/L
<10.0 – 8.0 g/dL
<6.2 – 4.9 mmol/L
<100 – 80 g/L
<8.0 – 6.5 g/dL
<4.9 – 4.0 mmol/L
<80 – 65 g/L
<6.5 g/dL
<4.0 mmol/L
<65 g/L
Death
7.6.
Toxicity Management 
Dosing requirements for certain toxicities are specified in Section 5.3 and 5.3.3. The investigator 
may contact the medical monitor to review toxicities that are not directly discussed in the 
protocol. Laboratory abnormalities (eg, below normal thiamine level) identified at 
Screening/Baseline and during study participation should be treated at the investigator’s 
discretion.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 55
18 May 2015
7.7.
Special Situations Reports
7.7.1.
Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy reports regardless of an 
associated AE.  
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a 
subject.
Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in 
question). In cases of a discrepancy in drug accountability, overdose will be established only 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
7.7.2.
Instructions for Reporting Special Situations
7.7.2.1.
Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study subjects that are identified after 
initiation of study medication and throughout the study, including the post MMB treatment
follow-up period, to Gilead DSPH using the pregnancy report form within 24 hours of becoming 
aware of the pregnancy.
Refer to section 7.3 and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.
Any premature termination of pregnancy (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underlying medical reason for this procedure should be recorded as the AE term.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 56
18 May 2015
A spontaneous abortion is always considered to be an SAE and will be reported as described in 
sections 7.3 and 7.4. Furthermore, any SAE occurring as an adverse pregnancy outcome post 
study must be reported to Gilead DSPH
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome should be reported to or Gilead DSPH using the pregnancy outcome 
report form. If the end of the pregnancy occurs after the study has been completed, the outcome 
should be reported directly to Gilead DSPH. Gilead DSPH contact information is as follows: 
Email: Safety_FC@gilead.com and Fax: +1 (650) 522-5477. 
Pregnancies of female partners of male study subjects exposed to Gilead or other study drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy and pregnancy outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study 
has been completed, the outcome should be reported directly to Gilead DSPH, email 
Safety_FC@gilead.com or fax +1 (650) 522-5477. 
Refer to Appendix 3 for Pregnancy Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.7.2.2.
Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve MMB and/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 
Special situations involving non-Gilead concomitant medications do not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a non-
Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may be more appropriately documented as a protocol deviation.
Refer to section 7.3 and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and 
signs, clinical management, and outcome will be reported, when available.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 57
18 May 2015
8.
STATISTICAL CONSIDERATIONS
8.1.
Analysis Objectives and Endpoints
8.1.1.
Analysis Objectives
The primary objective of this study is:

To determine the transfusion independence response rate for transfusion dependent MF
subjects treated with MMB
8.1.2.
Primary Endpoint
The primary endpoint is:

Transfusion independence response rate by Week 24, defined as becoming transfusion 
independent for ≥ 12 weeks at any time on study.  A subject is considered as transfusion 
independent on study if no RBC transfusion occurs in any 12 weeks during the 24-week 
treatment period.
8.1.3.
Secondary Endpoints
Secondary endpoints are:

Transfusion response rate by Week 24, defined as becoming not transfusion dependent 
for ≥ 8 weeks at any time on study  

Baseline and change in marker of anemia (eg, hepcidin, ferritin)

Change in pharmacodynamics biomarker pSTAT3

Splenic response rate at Week 24, defined as ≥ 35% reduction in spleen volume from 
baseline as measured by MRI

Response rate in TSS at Week 24, defined as achieving a ≥50% reduction from baseline 
in TSS as measured by the modified MPNSAF TSS diary

Pharmacokinetics parameters (Cmax, Clast, Ctau and AUClast, if available) for MMB 

Change in circulating cytokine and inflammatory markers (eg, IL-6, IL-8, IFN gamma, 
TNF alpha)


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 58
18 May 2015
8.1.4.
Exploratory Endpoints
The exploratory endpoints are:

Baseline and change in markers of orthogonal or parallel signaling pathways (eg,
RAS/MAPK, PI3K/AKT)

Baseline and change in gene expression profiles in whole blood and change in somatic 
mutations in whole blood, if applicable.

Baseline and change in immune subsets in whole blood 

Change in exploratory pharmacodynamics markers of signaling mediated by JAK1 and/or 
JAK2 (eg, pSTAT1, pSTAT5, and pSTAT6)
8.2.
Analysis Conventions
8.2.1.
Analysis Sets
8.2.1.1.
Safety Analysis Set
The Safety Analysis Set includes all subjects who receive ≥ 1 dose of MMB. Since this study is a 
non-randomized study, Safety Analysis Set will be used for subject’s characteristics, efficacy and 
safety endpoints, and study treatment administration.
8.2.1.2.
Biomarker Analysis Set
The Biomarker Analysis Set consists of all subjects in the Safety Analysis Set who have the 
necessary baseline and on-study measurements to provide interpretable results for the specific 
parameters of interest. The Biomarker Analysis Set will be used for biomarkers and the 
correlation analyses between biomarkers and efficacy clinical endpoints.
8.2.1.3.
Pharmacokinetics (PK) Analysis Set
The PK Analysis Set consists of all subjects in the Safety Analysis Set who have the necessary 
baseline and on-study measurements to provide interpretable results for the specific parameters 
of interest.
8.3.
Data Handling Conventions
By-subject listings will be created for important variables from each eCRF module. Summary 
tables for continuous variables will contain the following statistics: N (number in population), n 
(number with data), mean, standard deviation (StD), 90% confidence intervals (CIs) on the 
mean, median, minimum, and maximum. Summary tables for categorical variables will include: 
N, n, percentage, and 90% CIs on the percentage. Unless otherwise indicated, 90% CIs for binary 
variables will be calculated using the binomial distribution (exact method) and will be 2 sided. 
Data will be described and summarized by relevant dose level, analysis set, and time point. As 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 59
18 May 2015
appropriate, changes from baseline to each subsequent time point will be described and 
summarized by dose level. Similarly, as appropriate, the best change from baseline during the 
study will also be described and summarized by dose level. Graphical techniques (eg, waterfall 
plots, Kaplan-Meier curves, line plots) may be used when such methods are appropriate and 
informative.
The baseline value will be the last (most recent) pre-treatment value. Data from all sites will be 
pooled for all analyses. Analyses will be based upon the observed data unless methods for 
handling missing data are specified. If there is a significant degree of non-normality, analyses 
may be performed on log-transformed data or nonparametric tests may be applied, as 
appropriate. 
8.4.
Demographic Data and Baseline Characteristics
Subject demographic and baseline characteristics will be listed and summarized for the Safety 
Analysis Set. Imbalances in subject characteristics may be compared using the Wilcoxon rank-
sum test for continuous variables and the Fisher’s exact test for categorical variables.
8.5.
Efficacy Analysis
Transfusion independence response rate, transfusion response rate, splenic response rate and 
response rate in TSS will be presented with corresponding 2-sided 90% exact CIs using the 
binomial distribution. Subjects who do not have sufficient baseline or on-study assessment to 
characterize the response will be counted as non-responders.
8.6.
Safety Analysis
All safety data collected on or after the date that MMB was first dispensed up to the date of last 
dose of MMB plus 30 days will be summarized. Data for the pretreatment will be included in 
data listings.
8.6.1.
Extent of Exposure
Descriptive information will be provided by dose level regarding the number of doses of MMB
prescribed, the total number of doses taken, the percent of expected doses taken, the number of 
days of MMB treatment, and the number and timing of prescribed dose modification and 
interruptions.
Compliance will be described by dose level in terms of the proportion of MMB actually taken 
based on returned pill count relative to the amount that was dispensed (taking into account 
physician-prescribed modification and interruptions).
8.6.2.
Adverse Events
All AEs will be listed. The focus of AE summarization will be on treatment-emergent AEs. A 
treatment-emergent AE is defined as an AE that occurs or worsens in the period from the first 
dose of MMB to 30 days after the last dose of MMB.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 60
18 May 2015
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA 
http://www.meddramsso.com) with descriptions by System Organ Class (SOC), High Level 
Group Term, High-Level Term, Preferred Term, and Lower-Level Term.  The severity of AEs 
will be graded by the investigator according to the CTCAE, Version 4.03, whenever possible. If 
a CTCAE criterion does not exist for a specific type of AE, the grade corresponding to the 
appropriate adjective will be used by the investigator to describe the maximum intensity of the 
AE: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life threatening), or Grade 5 
(fatal). The relationship of the AE to MMB will be categorized as related or unrelated.
Treatment-emergent AEs will be summarized by dose level. Summary tables will be presented to 
show the number of subjects reporting treatment-emergent AEs by severity grade and 
corresponding percentages. A subject who reports multiple treatment-emergent AEs within the 
same Preferred Term (or System Organ Class) is counted only once for that Preferred Term 
(or System Organ Class) using the worst severity grade.  AE descriptions will be presented by 
decreasing frequency for a given System Organ Class and Preferred Term. Separate listings and 
summaries will be prepared for the following types of treatment emergent AEs:

Study-drug-related AEs

AEs that are Grade ≥ 3 in severity

AEs leading to MMB interruption and/or dose modification

AEs leading to MMB discontinuation

SAEs
8.6.3.
Laboratory Evaluations
All laboratory data will be listed. Summaries of laboratory data will be based on observed data. 
The focus of laboratory data summarization will be on treatment-emergent laboratory 
abnormalities. A treatment-emergent laboratory abnormality is defined as an abnormality that, 
compared to baseline, worsens by >1 grade in the period from the first dose of MMB to 30 days 
after the last dose of MMB. If baseline data are missing, then any graded abnormality (ie, an 
abnormality that is Grade >1 in severity) will be considered treatment emergent.
Hematological, serum biochemistry, and urine data will be programmatically graded according 
to CTCAE severity grade, when applicable. For parameters for which a CTCAE scale does not 
exist, reference ranges from the central laboratory will be used to determine programmatically if 
a laboratory parameter is below, within, or above the normal range for the subject’s age, sex, etc.
Hematological and serum biochemistry and their changes from baseline will be summarized by 
dose level, by visit. Summary tables will be presented for each relevant assay to show the 
number of subjects by CTCAE severity grade with corresponding percentages. For parameters 
for which a CTCAE scale does not exist, the frequency of subjects with values below, within, 
and above the normal ranges will be summarized. Subjects will be characterized only once for a 
given assay, based on their worst severity grade observed during a period of interest (eg, during 
the study or from baseline to a particular visit).


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 61
18 May 2015
Shift tables for hematology and serum biochemistry will also be presented by showing change in 
CTCAE severity grade from baseline to the worst grade post-baseline. For parameters for which 
a CTCAE scale does not exist, shift tables will be presented showing change in results from 
baseline to the worst grade post baseline. Separate listings and summaries will be prepared for 
laboratory abnormalities that are Grade ≥ 3 in severity.
8.7.
Pharmacokinetics Analysis
The concentration data of MMB and its major metabolite GS-644603 will be summarized by 
nominal sampling time using descriptive statistics. PK parameters (Cmax, Clast, Ctau, and AUClast, 
if available), will be listed and summarized using descriptive statistics (eg, sample size, 
arithmetic mean, geometric mean, coefficient of variation (%) standard deviation, median, 
minimum, and maximum). Plasma concentrations over time will be plotted in semi logarithmic 
and linear formats as mean ± standard deviation, and median (Q1, Q3) if applicable. Exposure-
response relationship may also be evaluated.
8.8.
Biomarker Analysis
The baseline levels, and changes in biomarker levels over time from baseline level, will be 
evaluated. Descriptive statistics will be provided at each sampling time, and by response 
category for each clinical endpoint being considered for association with biomarkers, as 
appropriate. Exploratory graphics, such as side-by-side boxplots will also be generated.
Univariate and multivariate statistical techniques may be explored to evaluate the association of 
baseline biomarkers and changes in biomarkers with clinical outcomes as appropriate. Due to the 
exploratory nature of the end points, no formal hypothesis testing will be conducted.
8.9.
Sample Size
This study will enroll approximately 40 subjects. Due to the exploratory nature, the study is not 
designed to detect a specific effect size. A sample size of 40 subjects is considered adequate for 
the exploratory study.  Given a sample size of 40 subjects in the study, Table 8-1 shows the exact 
90% CIs using the binomial distribution for a given transfusion independence response rates 
ranging from 0.10 to 0.5. 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 62
18 May 2015
Table 8-1.
Exact 90% CIs for various response rates
No. of Responders
Response Rate
Exact 90% CI (N=40)
4
0.10
(0.035, 0.214)
6
0.15
(0.067, 0.274)
8
0.20
(0.104, 0.332)
10
0.25
(0.142, 0.387)
12
0.3
(0.183, 0.440)
14
0.35
(0.226, 0.492)
16
0.4
(0.269, 0.542)
18
0.45
(0.315, 0.591)
20
0.5
(0.361, 0.639)


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 63
18 May 2015
9.
RESPONSIBILITIES
9.1.
Investigator Responsibilities
9.1.1.
Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study subject. 
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part 50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary 
interests in the investigational drug under study. This documentation must be provided prior to 
the investigator’s (and any subinvestigator’s) participation in the study. The investigator and 
subinvestigator agree to notify Gilead of any change in reportable interests during the study and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol-defined activities.
9.1.2.
Institutional Review Board (IRB) Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and any accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study used to obtain 
informed consent) to an IRB. The investigator will not begin any study subject activities until 
approval has been documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB any modifications made to the protocol or any accompanying material to be provided to 
the subject after initial IRB approval, with the exception of those necessary to reduce immediate 
risk to study subjects.
9.1.3.
Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study and before undertaking any study-related procedures. The 
investigator must use the most current IRB approved consent form for documenting written 
informed consent. Each informed consent (or assent as applicable) will be appropriately signed 
and dated by the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by an impartial witness if required by IRB or local 
requirements.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 64
18 May 2015
9.1.4.
Confidentiality
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed by local law) and an identification code will be recorded on any 
form or biological sample submitted to the Sponsor, or laboratory. Laboratory specimens must 
be labeled in such a way as to protect subject identity while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory instructions. NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations. 
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF, MMB, and any other study information, remain the 
sole and exclusive property of Gilead during the conduct of the study and thereafter. This
information is not to be disclosed to any third party (except employees or agents directly 
involved in the conduct of the study or as required by law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure by any employee or agent of the study site to any third party or otherwise into the 
public domain.
9.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study file, and 
(2) subject clinical source documents.
The investigator’s study file will contain the protocol/amendments, CRF and query forms, IRB
and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:

Subject identification (name, date of birth, gender);

Documentation that subject meets eligibility criteria, ie, history, physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);

Documentation of the reason(s) a consented subject is not enrolled

Participation in study (including study number);

Study discussed and date of informed consent;

Dates of all visits;


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 65
18 May 2015

Documentation that protocol specific procedures were performed;

Results of efficacy parameters, as required by the protocol;

Start and end date (including dose regimen) of MMB, including dates of dispensing and 
return;

Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity);

Concomitant medication (including start and end date, dose if relevant; dose changes);

Date of study completion and reason for early discontinuation, if it occurs.
All clinical study documents must be retained by the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an ICH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may be required to retain documents longer if 
specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The 
investigator must notify Gilead before destroying any clinical study records.
Should the investigator wish to assign the study records to another party or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securely away from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away from the site.
9.1.6.
Case Report Forms
For each subject consented, an eCRF will be completed by an authorized study staff member 
whose training for this function is documented according to study procedures. The eCRF should 
be completed on the day of the subject visit to enable the sponsor to perform central monitoring 
of safety data.  Subsequent to data entry, a study monitor will perform source data verification 
within the electronic data capture (EDC) system. Original entries as well as any changes to data 
fields will be stored in the audit trail of the system.  Prior to database lock (or any interim time 
points as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accurately reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System-generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by the monitor or internal Gilead staff, 
who routinely review the data for completeness, correctness, and consistency. The site 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 66
18 May 2015
coordinator is responsible for responding to the queries in a timely manner, within the system, 
either by confirming the data as correct or updating the original entry, and providing the reason 
for the update (eg, data entry error). At the conclusion of the trial, Gilead will provide the site 
with a read-only archive copy of the data entered by that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7.
Investigational Product Accountability and Return
Gilead recommends that used and unused MMB supplies be returned to the shipping facility 
from which it came for eventual destruction. The study monitor will provide instructions for 
return. If return is not possible, the study monitor will evaluate each study center’s disposal 
procedures and provide appropriate instruction for destruction of unused MMB supplies. If the 
site has an appropriate standard operating procedure (SOP) for drug destruction as determined by 
Gilead QA, the site may destroy used (empty or partially empty) and unused MMB supplies in 
accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained 
for central files. 
If MMB is destroyed on site, the investigator must maintain accurate records for all MMB
destroyed. Records must show the identification and quantity of each unit destroyed, the method 
of destruction, and the person who disposed of the MMB supplies. Upon study completion, 
copies of the accountability records must be filed at the site. Another copy will be returned to 
Gilead.
The study monitor will review MMB supplies and associated records at periodic intervals.
9.1.8.
Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed study monitors, to IRBs, or to regulatory authority or health authority 
inspectors.
9.1.9.
Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2.
Sponsor Responsibilities
9.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Gilead. The investigator must submit all protocol modifications to the IRB in 
accordance with local requirements and receive documented IRB approval before modifications 
can be implemented.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 67
18 May 2015
9.2.2.
Study Report and Publications
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in 
certain cases.
Investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after the following conditions have been met:

The results of the study in their entirety have been publicly disclosed by or with the consent 
of Gilead in an abstract, manuscript, or presentation form, OR

The study has been completed at all study sites for at least 2 years
The investigator will submit to Gilead any proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 days before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply with Gilead’s request to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary.
9.3.
Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study staff may be asked to provide services performed under this 
protocol, eg, attendance at Investigator's Meetings.  If required under the applicable statutory and 
regulatory requirements, Gilead will capture and disclose to Federal and State agencies any 
expenses paid or reimbursed for such services, including any clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any other transfer of value.
9.3.2.
Access to Information for Monitoring
In accordance with regulations and guidelines, the study monitor must have direct access to the 
investigator’s source documentation in order to verify the accuracy of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to any subject records needed to 
verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through any type of monitoring (eg, central, on site) are resolved.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 68
18 May 2015
9.3.3.
Access to Information for Auditing or Inspections
Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the 
clinical study. If the investigator is notified of an inspection by a regulatory authority the 
investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to 
provide to representatives of a regulatory agency or Gilead access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
9.3.4.
Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies), and IRBs. In terminating the study, Gilead and the investigator will 
assure that adequate consideration is given to the protection of the subjects’ interests.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 69
18 May 2015
10.
REFERENCES
23864
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. 
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative 
disorders. Lancet 2005;365 (9464):1054-61.
23911
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A 
unique clonal JAK2 mutation leading to constitutive signalling causes 
polycythaemia vera. Nature 2005;434 (7037):1144-8.
23913
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-
of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 
2005;352 (17):1779-90.
24006
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New 
prognostic scoring system for primary myelofibrosis based on a study of the 
International Working Group for Myelofibrosis Research and Treatment. Blood 
2009;113 (13):2895-901.
24753
Hasselbalch HC. Perspectives on chronic inflammation in essential 
thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation 
a trigger and driver of clonal evolution and development of accelerated 
atherosclerosis and second cancer? Blood 2012;119 (14):3219-25.
25836
Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization 
classification system for myeloproliferative neoplasms: order out of chaos. Cancer 
2009;115 (17):3842-7.
25841
Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic 
myeloid leukemia. Blood 2009;113 (8):1619-30.
25845
Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, et al. 
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively 
inhibit cells of myeloproliferative neoplasms. PLoS ONE 2013;8 (1):e54826.
26493
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A 
dynamic prognostic model to predict survival in primary myelofibrosis: a study 
by the IWG-MRT (International Working Group for Myeloproliferative 
Neoplasms Research and Treatment). Blood 2010;115 (9):1703-8.
27070
Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, et al. Genetic 
analysis of transforming events that convert chronic myeloproliferative neoplasms 
to leukemias. Cancer Res 2010;70 (2):447-52.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 70
18 May 2015
27076
Harrison C, Verstovsek S, McMullin MF, Mesa R. Janus kinase inhibition and its 
effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? 
Br J Haematol 2012;157 (4):426-37.
27077
Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, et al. 
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year 
experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 
Haematologica 2008;93 (10):1514-22.
27663
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. 
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated 
JAK2. N Engl J Med 2013;369 (25):2391-405.
27673
Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, et al. One 
thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo 
Clin Proc 2012;87 (1):25-33.
34378
Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 
2012;1823 (9):1434-43.
34379
Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and 
prognostic interactions between circulating levels of hepcidin, ferritin and 
inflammatory cytokines in primary myelofibrosis. Am J Hematol 2013;88 
(4):312-6.
34561
Bendall SC, Nolan GP. From single cells to deep phenotypes in cancer. Nat 
Biotechnol 2012;30 (7):639-47.
34562
Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-
cell mass cytometry of differential immune and drug responses across a human 
hematopoietic continuum. Science 2011;332 (6030):687-96.
34563
Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV, et al. 
Multiplexed mass cytometry profiling of cellular states perturbed by small-
molecule regulators. Nat Biotechnol 2012;30 (9):858-67.
34603
Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. 
viSNE enables visualization of high dimensional single-cell data and reveals 
phenotypic heterogeneity of leukemia. Nat Biotechnol 2013;31 (6):545-52.
34604
Gibbs KD, Jr., Jager A, Crespo O, Goltsev Y, Trejo A, Richard CE, et al. 
Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-
Meis1-driven AML. Cell stem cell 2012;10 (2):210-7.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 71
18 May 2015
34638
Fisher DAC, Malkova O, Fulbright MC, Behbehani GK, Nolan GP, Oh ST. 
Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in 
Myeloproliferative Neoplasms [Abstract]. Blood 2014;124 (21).


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 72
18 May 2015
11.
APPENDICES
Appendix 1.
Investigator Signature Page
Appendix 2.
Study Procedures Table
Appendix 3.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 4.
Dynamic International Prognostic Scoring System (DIPSS) for Primary 
Myelofibrosis




Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 74
18 May 2015
Appendix 2.
Study Procedures Table
Assessment
Screening 
(-28 to -
21 Days)
Baseline  
(-7 +/- 2 
Days)
Enrollment
Week 
2 
(+/- 3 
days)
Week 4 
(+/- 3 
days)
Week 8 
(+/- 3 
days)
Week 12 
(+/- 3 
days)
Week 16 
(+/- 3 
days)
Week 20 
(+/- 3 
days)
Week 24 
(+/- 7 
days)
Early Study 
Drug 
Discontinuation
30 Day 
Follow-
Up
Informed consent
X
Medication and 
medical history
X
Transfusion 
Recording
X
X
X
X
X
X
X
X
X
X
X
X
Physical exam and 
myelofibrosis 
symptoms assessment
X
X
X
X
X
X
X
X
X
X
X
X
DIPSS Assessment
X
Vital Signs
X
X
X
X
X
X
X
X
X
X
X
AEs, Concomitant 
Medications
X
X
X
X
X
X
X
X
X
X
X
Ophthalmic 
examination
X
X
X
MMB accountability 
and dispensingg
X
X
X
X
X
X
X
X
MMB dosing at site
X
X
X
X
X
X
X
X
Patient Reported Outcomes
Modified MPNSAF 
TSS
----------------------------------------------------------------- Daily ---------------------------------------------------------------
X
PGIC
X
X


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 75
18 May 2015
Assessment
Screening 
(-28 to -
21 Days)
Baseline  
(-7 +/- 2 
Days)
Enrollment
Week 
2 
(+/- 3 
days)
Week 4 
(+/- 3 
days)
Week 8 
(+/- 3 
days)
Week 12 
(+/- 3 
days)
Week 16 
(+/- 3 
days)
Week 20 
(+/- 3 
days)
Week 24 
(+/- 7 
days)
Early Study 
Drug 
Discontinuation
30 Day 
Follow-
Up
Laboratory Assessments
Viral Hepatitis B and 
C
X
Chemistry
X
X
X
X
X
CBC with differential, 
reticulocyte count
X
X
X
X
X
X
X
X
X
X
X
Thiamine status
X
X
X
Erythropoietin
X
X
X
C-Reactive Protein 
(CRP)
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
X
X
X
X
Serum pregnancy testa
X
Urine pregnancy test
X
X
X
X
X
X
X
X
Biomarker Samples
Bone marrow biopsy 
& aspirate
X
X
Buccal Swab
X
Spleen & LIC MRI
X
X
X
Iron Studies
X
X
X
X
X
X
X
X
X
Hepcidin
X
X
X
X
X
X
X
X
X


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 76
18 May 2015
Assessment
Screening 
(-28 to -
21 Days)
Baseline  
(-7 +/- 2 
Days)
Enrollment
Week 
2 
(+/- 3 
days)
Week 4 
(+/- 3 
days)
Week 8 
(+/- 3 
days)
Week 12 
(+/- 3 
days)
Week 16 
(+/- 3 
days)
Week 20 
(+/- 3 
days)
Week 24 
(+/- 7 
days)
Early Study 
Drug 
Discontinuation
30 Day 
Follow-
Up
JAK2V617F allele
burden and other 
mutation tests
X
X
X
Pharmacodynamicsc,d
Xd
X
X
Pharmacokineticse
X
X
X
Cytokines/chemokines
X
Xf
X
X
X
X
X
X
Exploratory signaling 
(mass cytometry)
X
X
X
X
CD34+ Cell Count
X
X
X
X
Gene expression
X
X
X
X
Immunophenotype 
(flow cytometry)
X
X
X
X
a
For female subject post-menopausal for less than two years, if FSH 40 mIU/ mL a serum pregnancy test will be required
b
Hepcidin sample collection will occur at the following times: Baseline Visit:, between 8 am-and 10 am, 6 hours later; Enrollment, Weeks 4, 8, 12, 16, 20, and 24 predose
(between 8 am and 10 am) and 6 hours postdose
c
Pharmacodynamics biomarker sample collection will occur at the following times: predose, 2, 4, and 6 hours postdose at Enrollment, then Weeks 4 and 24. 
d
Additional exploratory pharmacodynamics sample collection will occur at the following times: predose, and 2 hours postdose at Enrollment only. 
e
PK sample collection at the following times: predose, 2, 4, and 6 hours postdose at Enrollment, then Weeks 4 and 24.
f
Cytokine sample collection times at enrollment: predose, 6 hours postdose. All other time points: predose only.
g
MMB accountability ONLY at Week 24 and ESDD visits


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 77
18 May 2015
Appendix 3.
Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1. Pregnancy and Contraception Requirements for Males and Females of Childbearing 
Potential 
The risks of treatment with momelotinib (MMB) during pregnancy have not been evaluated. 
Data available at this time suggest that this drug does not have a drug-drug interaction (DDI) 
with hormones used for contraception. Please refer to the latest version of the investigator’s 
brochure for additional information.
2.
Definition of Female of Childbearing Potential
For the purposes of this study, a female subject of childbearing potential is a nonmenopausal 
female who has not had a hysterectomy, bilateral oophorectomy, or medically documented 
ovarian failure. This definition includes a pubertal female who has not yet started menstruating. 
A woman who has had a tubal sterilization is considered to be of childbearing potential.
A female subject may be considered menopausal in either of the following conditions:

Surgical menopause: Appropriate medical documentation of prior complete bilateral 
oophorectomy (ie, surgical removal of the ovaries and occurring at the age at which the 
procedure was performed)

Spontaneous menopause: Permanent cessation of previously occurring menses as a result of 
ovarian failure with documentation of hormonal deficiency by a certified health care 
provider. The worldwide mean age of spontaneous menopause is 49.24 (SD 1.73) years

A hormonal deficiency should be properly documented in the case of suspected spontaneous 
menopause as follows:

If age 54 years and with the absence of normal menses: serum follicle stimulating hormone 
(FSH) level elevated to within the postmenopausal range based on the laboratory reference 
range where the hormonal assay is performed

If age <54 years and with the absence of normal menses: negative serum or urine human 
chorionic gonadotropin (hCG) with concurrently elevated serum FSH level in the 
postmenopausal range, depressed estradiol (E2) level in the postmenopausal range, and 
absent serum progesterone level, based on the laboratory reference ranges where the 
hormonal assays are performed
3. Contraceptive Requirements 
Male subjects and female subjects of childbearing potential who engage in intercourse must 
agree to utilize protocol specified methods of contraception from the screening/enrollment visit 
throughout the study period and, for male subjects for 90 days following the last dose of MMB, 
and for female subjects of childbearing potential, for 30 days following the last dose of MMB. 


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 78
18 May 2015
Female study subjects who are not heterosexually active must provide periodic confirmation of 
continued abstinence from heterosexual intercourse and regular pregnancy testing while taking 
MMB. The investigator will counsel subjects on the protocol specified method(s) for avoiding 
pregnancy in case the subject chooses to engage in heterosexual intercourse. See 
Appendix Table 1 for the protocol specified contraceptive methods.
If tubal sterilization is via the Essure procedure, verification of tubal blockage by 
hysterosalpingogram (HSP) must be performed approximately 3 months after microinsertion. 
Prior to verification, Essure is not considered a reliable form of contraception and the 
contraception methods described below must be used.
Female subjects who utilize hormonal contraceptives as one of their birth control methods must 
have used the same method for at least 3 months before study dosing.
Female subjects of childbearing potential must have a negative serum pregnancy test at screening 
and a negative urine pregnancy test prior to receiving the first dose of MMB. Lactating females 
must discontinue nursing before MMB administration.
Appendix Table 1.
Protocol Specified Contraceptive Methods
Methods to Use by Themselves
Combination Methods
Hormone Methods
(choose one and use with a barrier 
method)
Barrier Methods
(choose one and use with a hormone 
method)
Intrauterine Devices (IUDs)

Copper T 380A IUD

LNg 20 IUD
Tubal Sterilization
Estrogen and Progesterone

Oral contraceptives

Transdermal patch

Vaginal ring
Progesterone

Injection

Implant

Diaphragm with spermicide
OR
Cervical cap with spermicide

Male condom (with or without 
spermicide)
Partner’s vasectomy must be used with a hormone or barrier method.
The investigator will counsel all subjects on the most effective method(s) for avoiding pregnancy 
during the study.
4. Additional Requirements for Male Subjects
Male subjects must agree to use condoms during heterosexual intercourse and avoid sperm 
donation while enrolled in the study and for at least 90 days after administration of the last dose 
of MMB.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 79
18 May 2015
5. Procedures to be Followed in the Event of Pregnancy
Subjects should be instructed to notify the investigator if they become pregnant at any time 
during the study, or if they become pregnant within 30 days of last MMB dose. Subjects who 
become pregnant or who suspect that they are pregnant during the study must report the 
information to the investigator and discontinue MMB immediately. The investigator should 
report all pregnancies to the CRO Safety Department using the pregnancy report form within 24 
hours of becoming aware of the pregnancy. The investigator should counsel the subject 
regarding the possible effects of prior MMB exposure on the fetus and the need to inform the 
study site of the outcome of the pregnancy. Subjects whose partner has become pregnant or 
suspects she is pregnant during the study must report the information to the investigator.
Instructions for reporting pregnancy, partner pregnancy, and pregnancy outcome are outlined in 
Section 7.7.


Momelotinib (MMB)
Protocol GS-US-352-1672
Final
Gilead Sciences, Inc. 
Original
CONFIDENTIAL
Page 80
18 May 2015
Appendix 4.
Dynamic International Prognostic Scoring System (DIPSS) for 
Primary Myelofibrosis
Prognostic variable
Value
0
1
2
Age
≤ 65
> 65
WBC
≤25
> 25
Hgb
≥10
< 10
Peripheral blast
< 1
≥1
Constitutional symptoms
No
Yes
The risk category is obtained by adding up the values of each prognostic variable.
Risk categories are defined as:
Low: 0
Intermediate-1: 1 or 2
Intermediate-2: 3 or 4
High: > 4
{26493}

SAP_001.pdf: 
STATISTICAL ANALYSIS PLAN
Study Title:
A Phase 2, Open-label, Translational Biology Study of
Momelotinib in Transfusion-Dependent Subjects with Primary 
Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential 
Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Name of Test Drug:
Momelotinib (MMB)
Study Number:
GS-US-352-1672
Protocol Version (Date):
18 May 2015
Analysis Type:
Final Analysis
Analysis Plan Version:
Version 1.0
Analysis Plan Date:
16 October 2017
Analysis Plan Author:
Yafeng Zhang
CONFIDENTIAL AND PROPRIETARY INFORMATION


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 2
16 October 2017
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................................................2
LIST OF TABLES.........................................................................................................................................................4
LIST OF ABBREVIATIONS........................................................................................................................................5
1.
INTRODUCTION ................................................................................................................................................8
1.1.
Study Objectives ......................................................................................................................................8
1.2.
Study Design............................................................................................................................................8
1.2.1.
Design Configuration and Subject Population .......................................................................8
1.2.2.
Number of Subjects Planned ..................................................................................................9
1.2.3.
Inclusion Criteria....................................................................................................................9
1.2.4.
Exclusion Criteria.................................................................................................................10
1.2.5.
Efficacy Endpoints ...............................................................................................................11
1.2.6.
Safety....................................................................................................................................12
1.3.
Sample Size and Power..........................................................................................................................12
2.
TYPE OF PLANNED ANALYSIS ....................................................................................................................13
2.1.
Data Monitoring Committee ..................................................................................................................13
2.2.
Interim Analysis.....................................................................................................................................13
2.3.
Final Analysis ........................................................................................................................................13
2.4.
Follow-up Analysis ................................................................................................................................13
3.
GENERAL CONSIDERATIONS FOR DATA ANALYSES............................................................................14
3.1.
Analysis Sets..........................................................................................................................................14
3.1.1.
Safety Analysis Set...............................................................................................................14
3.1.2.
Biomarker Analysis Set........................................................................................................14
3.1.3.
Pharmacokinetic Analysis Set..............................................................................................14
3.2.
Strata and Covariates..............................................................................................................................14
3.3.
Examination of Subject Subsets.............................................................................................................15
3.4.
Multiple Comparisons............................................................................................................................15
3.5.
Missing Data and Outliers......................................................................................................................16
3.5.1.
Missing Data ........................................................................................................................16
3.5.2.
Outliers.................................................................................................................................16
3.6.
Data Handling Conventions and Transformations .................................................................................16
3.6.1.
Data Handling for Non-PK Laboratory Data .......................................................................16
3.6.2.
Data Handling for PK Data ..................................................................................................17
3.6.3.
Data Handling for Efficacy Endpoints .................................................................................17
3.7.
Visit Windows........................................................................................................................................18
3.7.1.
Definition of Study Day .......................................................................................................18
3.7.2.
Analysis Windows................................................................................................................18
3.7.3.
Selection of Data in the Event of Multiple Records in an Analysis 
Window................................................................................................................................21
4.
SUBJECT DISPOSITION ..................................................................................................................................23
4.1.
Subject Enrollment and Disposition.......................................................................................................23
4.2.
Extent of Exposure.................................................................................................................................23
4.2.1.
Duration of Exposure to MMB ............................................................................................24
4.2.2.
Adherence to MMB..............................................................................................................24
4.3.
Protocol Deviations................................................................................................................................25
5.
BASELINE CHARACTERISTICS....................................................................................................................27
5.1.
Demographics ........................................................................................................................................27


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 3
16 October 2017
5.2.
Other Baseline Characteristics ...............................................................................................................27
5.3.
Medical History......................................................................................................................................27
5.3.1.
General Medical History ......................................................................................................27
5.3.2.
Myelofibrosis Disease History .............................................................................................27
5.4.
Myelofibrosis Disease-Specific Prior Therapy ......................................................................................28
6.
EFFICACY ANALYSES ...................................................................................................................................29
6.1.
Primary Efficacy Endpoint.....................................................................................................................29
6.1.1.
Definition of the Primary Efficacy Endpoint .......................................................................29
6.1.2.
Statistical Hypothesis for the Primary Efficacy Endpoint....................................................30
6.1.3.
Analysis of the Primary Efficacy Endpoint..........................................................................30
6.1.4.
Exploratory Analysis............................................................................................................30
6.2.
Secondary Efficacy Endpoints ...............................................................................................................31
6.2.1.
Definition of Secondary Efficacy Endpoints........................................................................31
6.2.2.
Analysis Methods for Secondary Efficacy Endpoints..........................................................36
6.3.
Exploratory Efficacy Endpoint...............................................................................................................38
6.3.1.
Definition of Exploratory Efficacy Endpoints......................................................................38
6.3.2.
Analysis Methods for Exploratory Efficacy Endpoints........................................................39
6.4.
Changes From Protocol-Specified Efficacy Analyses............................................................................39
7.
SAFETY ANALYSES........................................................................................................................................40
7.1.
Adverse Events and Deaths....................................................................................................................40
7.1.1.
Adverse Event Dictionary ....................................................................................................40
7.1.2.
Adverse Event Severity........................................................................................................40
7.1.3.
Relationship of Adverse Events to MMB.............................................................................40
7.1.4.
Serious Adverse Events........................................................................................................40
7.1.5.
Treatment-Emergent Adverse Events...................................................................................40
7.1.6.
Summaries of Adverse Events and Deaths...........................................................................41
7.1.7.
Additional Analysis of Adverse Events ...............................................................................43
7.2.
Laboratory Evaluations ..........................................................................................................................44
7.2.1.
Graded Laboratory Values ...................................................................................................44
7.2.2.
Shifts Relative to the Baseline Value ...................................................................................45
7.3.
Body Weight ..........................................................................................................................................45
7.4.
Prior and Concomitant Medications.......................................................................................................46
7.4.1.
Prior Medications and Concomitant Medications ................................................................47
7.5.
Electrocardiogram Results .....................................................................................................................47
7.6.
Other Safety Measures ...........................................................................................................................47
7.6.1.
Overall Survival (OS)...........................................................................................................47
8.
PHARMACOKINETIC ANALYSES ................................................................................................................48
9.
REFERENCES ...................................................................................................................................................49
10.
SOFTWARE.......................................................................................................................................................50
11.
SAP REVISION..................................................................................................................................................51
12.
APPENDICES ....................................................................................................................................................52
Appendix 1.
Table of Contents for Statistical Tables, Figures, and Listings ..............................................53
Appendix 2.
Study Procedures Table..........................................................................................................60
Appendix 3.
Peripheral Neuropathy SMQ AEs ..........................................................................................63
Appendix 4.
Cataract MST AEs..................................................................................................................65
Appendix 5.
Leukemic Transformation MST AEs .....................................................................................66
Appendix 6.
Validation document of hepcidin testing from Radboud University......................................68
Appendix 7.
Validation document of pSTAT testing from Covance ..........................................................69


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 4
16 October 2017
LIST OF TABLES
Table 3-1.
Analysis Windows for Efficacy Endpoints MRI Spleen Volume Response 
Assessment and MRI Liver Iron Content ...............................................................................19
Table 3-2.
Analysis Windows for Efficacy Analyses of TSS Response Rate at Week 24 ......................19
Table 3-3.
Analysis Windows for Hepcidin.............................................................................................20
Table 3-4.
Analysis Windows for Anemia Related Biomarkersa.............................................................20
Table 3-5.
Analysis Windows for Erythropoietin....................................................................................20
Table 3-6.
Analysis Windows for C-reactive Protein..............................................................................21
Table 3-7.
Analysis Windows for Pharmacodynamics Biomarker pSTAT3 ...........................................21
Table 7-1.
Grading of Hemoglobin Severity ...........................................................................................44


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 5
16 October 2017
LIST OF ABBREVIATIONS
AE
adverse event
ADME
absorption, distribution, metabolism and elimination
ALT
alanine aminotransferase
ANC
absolute neutrophil count
AST
aspartate aminotransferase
ATC
Anatomical-Therapeutic-Chemical (drug coding system)
BCRP
breast cancer resistant protein
BLQ
below the limit of quantitation
BMI
body mass index
BUN
blood urea nitrogen
CBC
complete blood count
CFR
Code of Federal Regulations
CI
confidence interval
CLcr
creatinine clearance
CML
chronic myelogenous leukemia
CR
complete remission
CK
creatine kinase
CRF
case report form
CRO
contract (or clinical) research organization
CRP
C-reaction protein
CSR
clinical study report
CT
computed tomography/computed axial tomography scan
CTCAE
Common Terminology Criteria for Adverse Events
CYP450
cytochrome P450
Da
dalton
DIPSS
Dynamic International Prognostic Scoring System
DMC
data monitoring committee
DSPH
Drug Safety and Public Health
ECG
electrocardiogram
eCRF
electronic case report form(s)
EDC
electronic data capture
eDiary
electronic diary
EOT
end of treatment
EPO
erythropoietin
ESDD
Early Study Drug Discontinuation
ET
essential thrombocythemia
FAS
Full Analysis Set
FDA
(United States) Food and Drug Administration


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 6
16 October 2017
FSH
follicle stimulating hormone
GCP
Good Clinical Practice(guidelines)
Gilead
Gilead Sciences
GLP
Good Laboratory Practice(guidelines)
hCG
human chorionic gonadotropin
Hgb
hemoglobin
HLGT
high-level group term
HLT
high-level term
HIV
human immunodeficiency virus
IB
investigator’s brochure
ICH
International Conference on Harmonisation (of Technical Requirements for Registration of 
Pharmaceuticals for Human Use)
ID
subject identification
IP
investigational product
IPSS
International Prognostic Scoring System
ITT
intent to treat
IWG
International Working Group
LIC
liver iron concentration
LLOQ
lower limit of quantitation
MedDRA
Medical Dictionary for Regulatory Activities
MF
myelofibrosis
MMB
momelotinib
MPN
myeloproliferative neoplasm
MPN-SAF TSS
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
MRI
magnetic resonance imaging
MST
MedDRA Search Term
ORR
overall response rate
PGIC
Patient Global Impression of Change
PK
pharmacokinetic
PMF
primary myelofibrosis
PP
per protocol
PRO
patient-reported outcome
PT
preferred term
PV
polycythemia vera
Q1, Q3
first quartile, third quartile
RBC
red blood cell
SAP
statistical analysis plan
SE
standard error
SI (units)
international system of units
SOC
system organ class


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 7
16 October 2017
SRR24
splenic response rate at Week 24
StD
standard deviation
TD
transfusion-dependent/ dependence
TEAE
treatment-emergent adverse event
TFLs
tables, figures, and listings
TI
transfusion-independent/independence
TSAT
transferrin saturation 
TSS
total symptom score
U
units
ULN
upper limit of normal
WHO
World Health Organization


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 8
16 October 2017
1.
INTRODUCTION
This statistical analysis plan (SAP) describes the statistical analysis methods and data 
presentations to be used in tables, figures, and listings (TFLs) in the clinical study report (CSR) 
for Study GS-US-352-1672. This SAP is based on the study protocol dated 18 May 2015 and the 
electronic case report form (eCRF). The SAP will be finalized before database finalization. Any 
changes made after the finalization of the SAP will be documented in the CSR.
1.1.
Study Objectives
The primary objective of this study is as follows:

To determine the transfusion independence response rate for transfusion dependent 
myelofibrosis (MF) subjects treated with momelotinib (MMB) 
The secondary objectives of this study are as follows:

To evaluate baseline levels and changes in markers of iron metabolism in transfusion 
dependent MF subjects treated with MMB

To assess inhibition of JAK1/2 in transfusion dependent MF subjects treated with MMB

To evaluate MMB pharmacokinetics (PK) in transfusion dependent MF subjects

To evaluate changes in circulating cytokine and inflammatory markers in transfusion 
dependent MF subjects treated with MMB
1.2.
Study Design
1.2.1.
Design Configuration and Subject Population
This is a Phase 2, single-arm, open-label study of MMB to determine the transfusion independent 
response rate for transfusion-dependent subjects with primary myelofibrosis (PMF) or 
post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/MF). Study 
candidates will be adult males or females who are transfusion dependent with PMF or 
Post-PV/MF. 
Eligible subjects will receive MMB tablet once daily for 24 weeks (7 days) on study. The 
starting dose of MMB for all subjects will be 200 mg tablet.  The dose of MMB may be withheld 
or adjusted according to the criteria in the protocol. 
Study visits will be completed at 2 weeks and 4 weeks following the initiation of MMB 
treatment, and every 4 weeks thereafter until Week 24.  Following the screening, subjects will 
receive an electronic diary (eDiary) for daily completion of the modified Myeloproliferative 
Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS).  Subjects will 


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU
FRPSOHWH WKHPRGLILHG0316$)766GDLO\VWDUWLQJIURP VFUHHQLQJDQGWKURXJKZHHNVRI
VWXG\SDUWLFLSDWLRQ/DERUDWRU\DQDO\VHVVHUXPFKHPLVWU\OLYHUWHVWVKHPDWRORJ\ XULQDO\VLV
SUHJQDQF\WHVWLQJIRUIHPDOHV RI FKLOGEHDULQJSRWHQWLDOYLWDOVLJQV DGYHUVHHYHQWV$(V
FRQFRPLWDQWPHGLFDWLRQV DQG GLVHDVHDVVHVVPHQWVZLOOEHFRPSOHWHGDWUHJXODUVWXG\YLVLWVDV
GHILQHGLQ $SSHQGL[
$IWHUFRPSOHWLRQRIWKHZHHN± GD\VWUHDWPHQWSKDVHYLVLWSURFHGXUHVVXEMHFWVZKR
UHVSRQGWRWUHDWPHQWDWWKHLQYHVWLJDWRU¶VGLVFUHWLRQZLOOKDYHWKHRSWLRQRIFRQWLQXLQJRQ
PDLQWHQDQFHWKHUDS\ZLWK00%RQ6WXG\*686DWWKH00%GRVHOHYHOWKH\
WROHUDWHGDQGRUGHULYHGFOLQLFDOEHQHILWIURPGXULQJWKHZHHNWUHDWPHQWSHULRG

1XPEHURI 6XEMHFWV3ODQQHG
$SSUR[LPDWHO\

,QFOXVLRQ &ULWHULD
6XEMHFWVPXVWPHHWDOORIWKHIROORZLQJLQFOXVLRQFULWHULDWREHHOLJLEOHIRUSDUWLFLSDWLRQLQWKLV
VWXG\
 $JH\HDUVROG
 'LDJQRVLVRI30)RU3RVW39(70)
 5HTXLUHVP\HORILEURVLVWKHUDS\LQWKHRSLQLRQRIWKHLQYHVWLJDWRU
 +LJKULVNRULQWHUPHGLDWHULVNGHILQHGE\WKH'\QDPLF ,QWHUQDWLRQDO3URJQRVWLF6FRULQJ
6\VWHP',366RULQWHUPHGLDWH ULVNGHILQHGE\',366DQGDVVRFLDWHGZLWKV\PSWRPDWLF
VSOHQRPHJDO\DQGRUKHSDWRPHJDO\
 7UDQVIXVLRQGHSHQGHQWDWEDVHOLQHGHILQHGDV8UHGEORRGFHOO5%& WUDQVIXVLRQ LQWKH
ZHHNVSULRUWRILUVWGRVHRI00%
 $FFHSWDEOHRUJDQIXQFWLRQDVHYLGHQFHGE\WKHIROORZLQJ
D 3ODWHOHW&RXQW൒50 ൈ10ଽ/
E $676*27DQG$/76*37[XSSHUOLPLWRIQRUPDO8/1 RU$676*27RU
$/76*37[8/1LIOLYHULVLQYROYHGE\ GLVHDVHSURFHVVDVMXGJHGE\WKH
LQYHVWLJDWRU
F 6HUXPFUHDWLQLQHPJG/RUFDOFXODWHGFUHDWLQLQHFOHDUDQFH RIP/PLQ
G 'LUHFWELOLUXELQ[8/1
 3HULSKHUDOEORRGEODVWFRXQW
 /LIHH[SHFWDQF\RI!ZHHNV


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 10
16 October 2017
9) A negative serum pregnancy test for female subjects (unless surgically sterile or greater than 
two years postmenopausal)
10) Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 3 in the protocol
11) Lactating females must agree to discontinue nursing before MMB administration
12) Able to understand and willing to sign the informed consent form
1.2.4.
Exclusion Criteria
Subject who meet any of the following exclusion criteria are not to be enrolled in this study:
1) Prior splenectomy
2) Splenic irradiation within 3 months prior to the first dose of MMB
3) Prior treatment with MMB
4) Known positive status of human immunodeficiency virus (HIV)
5) Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B 
and C), or hepatitis B or C carrier
6) Use of strong CYP3A4 inducer within 2 weeks prior to the first dose of MMB
7) Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection, 
uncontrolled cardiac arrhythmia, or psychiatric illness/social situation that would limit 
compliance with study requirements as judged by treating physician
8) History of a prior diagnosis of any malignancy other than PMF or Post PV/ET-MF except for 
the following: adequately treated local basal cell or squamous cell carcinoma of the skin, 
cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without 
known metastatic disease and with no requirement for therapy or requiring only hormonal 
therapy and with normal prostate specific antigen for >1 year prior to enrollment, or any 
other cancer that has been in complete remission without treatment for ≥ 5 years prior to 
enrollment.
9) Treatment with a JAK inhibitor within 21 days of the planned first dose of MMB
10) Documented myocardial infarction or unstable/uncontrolled cardiac disease (eg, unstable 
angina, congestive heart failure [New York Heart Association > Class III]) within 6 months 
of randomization
11) Presence of peripheral neuropathy ≥ CTCAE Grade 2


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 11
16 October 2017
12) Unwilling or unable to undergo Magnetic Resonance Imaging (MRI) per requirements 
(Please see the Section 6.2.11.2 in the protocol)
13) Unwilling to consent to genomics sampling
14) Pregnant or breast-feeding
15) Known hypersensitivity to the study investigational medicinal products, the metabolites, or 
formulation excipients
1.2.5.
Efficacy Endpoints
Primary Endpoint
The primary endpoint is transfusion independence response rate by Week 24, defined as 
becoming transfusion independent for ≥ 12 weeks at any time on study. A subject is considered 
as transfusion independent on study if no RBC transfusion occurs in any 12 weeks during the 
24-week treatment period.
Secondary Endpoints
The secondary endpoints are:

Transfusion response rate by Week 24, defined as becoming not transfusion dependent for 
≥8 weeks at any time on study

Baseline and change in markers of anemia (eg, hepcidin, ferritin)

Change in pharmacodynamic biomarker pSTAT3

Splenic response rate at Week 24, defined as ≥ 35% reduction in spleen volume from 
baseline as measured by MRI/CT

Response rate in total symptom score (TSS) at Week 24, defined as achieving a ≥ 50% 
reduction from baseline in TSS as measured by the modified MPNSAF TSS diary

Pharmacokinetics parameters (Cmax, Clast, Ctau, and AUClast, if available) for MMB

Change in circulating cytokine and inflammatory markers (eg, IL-6, IL-8, IFN-gamma, 
TNF-alpha)
Exploratory Endpoints
The exploratory endpoints are:

Baseline and change in markers of orthogonal or parallel signaling pathways 
(eg, RAS/MAPK, PI3K/AKT)


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 12
16 October 2017

Baseline and change in gene expression profiles in whole blood and somatic mutations in 
whole blood, if applicable.

Baseline and change in immune subsets in whole blood

Change in exploratory pharmacodynamics markers of signaling mediated by JAK1 and/or 
JAK2 (eg, pSTAT1, pSTAT5, and pSTAT6)
Pharmacokinetics
Blood samples will be collected at the time points specified in the protocol.
1.2.6.
Safety
The overall safety profile of MMB will be characterized by the type, frequency, severity, timing 
of onset, duration, and relationship to MMB of any adverse events (AEs) or abnormalities of 
laboratory tests; serious adverse events (SAEs); or AEs leading to discontinuation of MMB.
1.3.
Sample Size and Power
This study will enroll approximately 40 subjects. Due to the exploratory nature, the study is not 
designed to detect a specific effect size. A sample size of 40 subjects is considered adequate for 
this exploratory study.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 13
16 October 2017
2.
TYPE OF PLANNED ANALYSIS
2.1.
Data Monitoring Committee
This study does not have a data monitoring committee (DMC).
2.2.
Interim Analysis
No formal interim efficacy analysis is planned.
2.3.
Final Analysis
After all subjects have completed the study, outstanding data queries have been resolved, and the 
database has been cleaned and finalized, the final analysis of the data will be performed.
2.4.
Follow-up Analysis
After the final analysis, additional supplemental analyses of efficacy and safety may be 
performed to satisfy regulatory requirements and to perform long-term efficacy, safety, and 
overall survival follow-up.


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU

*(1(5$/&216,'(5$7,216)25'$7$$1$/<6(6
$QDO\VLVUHVXOWVZLOOEHSUHVHQWHGXVLQJGHVFULSWLYHVWDWLVWLFV)RUFDWHJRULFDOYDULDEOHVWKH
QXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFKFDWHJRU\ZLOOEHSUHVHQWHGIRUFRQWLQXRXVYDULDEOHV
WKHQXPEHURIVXEMHFWV>Q@PHDQVWDQGDUGGHYLDWLRQ >6W'@ RUVWDQGDUGHUURU>6(@PHGLDQ
ILUVW TXDUWLOH>4@WKLUGTXDUWLOH>4@PLQLPXP DQGPD[LPXP ZLOOEHSUHVHQWHG
$OOVWDWLVWLFDOWHVWVZLOOEHVLGHGDQGSHUIRUPHGDWWKHVLJQLILFDQFHOHYHOXQOHVVRWKHUZLVH
VSHFLILHG
'DWDFROOHFWHGLQWKHVWXG\ZLOOEHSUHVHQWHGLQE\VXEMHFWOLVWLQJVIRUDOOHQUROOHG VXEMHFWV
UHJDUGOHVVRIZKHWKHURUQRWWKH\UHFHLYHG00%$OOE\VXEMHFWOLVWLQJVZLOOEHSUHVHQWHGE\
VXEMHFWLGHQWLILFDWLRQ,'QXPEHULQDVFHQGLQJRUGHU XQOHVVRWKHUZLVHVSHFLILHG

$QDO\VLV6HWV
$QDO\VLVVHWVGHILQHWKHVXEMHFWVWREHLQFOXGHGLQDQDQDO\VLV$QDO\VLVVHWVDQGWKHLUGHILQLWLRQV
DUHSURYLGHGLQWKLVVHFWLRQ )RUHDFKDQDO\VLVVHWWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVHOLJLEOH
IRULQFOXVLRQDVZHOODVWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZKRZHUHH[FOXGHGDQGWKH
UHDVRQVIRUWKHLUH[FOXVLRQZLOOEHSURYLGHG$ OLVWLQJRIUHDVRQVIRUH[FOXVLRQIURPDQDO\VLVVHWV
ZLOOEHSURYLGHGE\VXEMHFW

6DIHW\$QDO\VLV6HW
7KH6DIHW\ $QDO\VLV6HW LQFOXGHVDOOVXEMHFWVZKRUHFHLYH൒GRVHRI00%6LQFHWKLVVWXG\LV
DQRQUDQGRPL]HGVWXG\WKH6DIHW\ $QDO\VLV6HW ZLOOEHXVHGIRUVXEMHFW¶VFKDUDFWHULVWLFV
HIILFDF\DQGVDIHW\HQGSRLQWVDQGVWXG\WUHDWPHQWDGPLQLVWUDWLRQ7KLVLVWKHSULPDU\DQDO\VLV
VHWIRUVDIHW\DQDO\VHV

%LRPDUNHU$QDO\VLV6HW
7KH%LRPDUNHU $QDO\VLV6HWFRQVLVWVRIDOOVXEMHFWVLQWKH6DIHW\$QDO\VLV6HWZKRKDYH WKH
QHFHVVDU\EDVHOLQHDQGRQVWXG\PHDVXUHPHQWVWRSURYLGHLQWHUSUHWDEOHUHVXOWVIRUWKHVSHFLILF
SDUDPHWHUVRILQWHUHVW7KH%LRPDUNHU$QDO\VLV6HWZLOOEHXVHGIRUELRPDUNHUVDQGWKH
FRUUHODWLRQDQDO\VHVEHWZHHQELRPDUNHUVDQGHIILFDF\FOLQLFDOHQGSRLQWV

3KDUPDFRNLQHWLF$QDO\VLV6HW
7KH3KDUPDFRNLQHWLF3. $QDO\VLV6HWLQFOXGHVDOOVXEMHFWVZKRKDYH EHHQDGPLQLVWHUHGDW
OHDVW GRVHRILQYHVWLJDWLRQDOGUXJDQGKDYHDWOHDVWQRQPLVVLQJSRVWGRVHFRQFHQWUDWLRQYDOXH
IRUWKHFRUUHVSRQGLQJDQDO\VLV LQVHUXPRUSODVPD

6WUDWDDQG&RYDULDWHV
7KLVVWXG\GRHVQRWXVHDVWUDWLILHGUDQGRPL]DWLRQVFKHGXOHLQHQUROOLQJVXEMHFWV


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU

([DPLQDWLRQRI6XEMHFW6XEVHWV
7KHSULPDU\HIILFDF\HQGSRLQWVZLOOEHH[DPLQHGXVLQJ WKHIROORZLQJVXEVHWV
•
$JH \HDUV DQG ≥\HDUV
•
*HQGHU PDOHDQGIHPDOH
•
5DFHZKLWHDQGDOORWKHUUDFHV
•
',366DVVHVVPHQW,QWHUPHGLDWHDQGKLJKULVN
•
7\SHRI0)30)3RVW390) DQG3RVW(70)
•
-$.9)PXWDWLRQVWDWXV DWEDVHOLQH SRVLWLYH DQGQHJDWLYH
•
+HPRJORELQOHYHODWEDVHOLQHJG/DQG൒JG/
•
766DWEDVHOLQHPHGLDQDQG൒PHGLDQ
•
6SOHHQYROXPHDWEDVHOLQHPHGLDQDQG൒PHGLDQ
•
+HSFLGLQDWEDVHOLQHPRUQLQJWLPHSRLQWPHGLDQDQG൒PHGLDQ
•
/LYHULURQFRQWHQWDWEDVHOLQHPHGLDQDQG൒PHGLDQ
•
7UDQVIHUULQVDWXUDWLRQDWEDVHOLQHDQG൒
3KDUPDFRNLQHWLFVHQGSRLQWV$(VDQGODEDEQRUPDOLWLHVPD\ EHH[DPLQHGLQWKHIROORZLQJ
VXEJURXSV
⎯$JH \HDUV DQG≥\HDUV
⎯*HQGHU PDOHDQGIHPDOH
⎯5DFHZKLWHDQGDOORWKHUUDFHV

0XOWLSOH&RPSDULVRQV
$OOHQGSRLQWWHVWVZLOOEHGRQHDWWKHVLJQLILFDQFHOHYHORI XQOHVVRWKHUZLVHVSHFLILHG1R
PXOWLSOLFLW\DGMXVWPHQWZLOOEHPDGHIRUWHVWLQJ EHFDXVH WKH HQGSRLQWV DUHFRQVLGHUHG
H[SORUDWRU\LQQDWXUH


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 16
16 October 2017
3.5.
Missing Data and Outliers
3.5.1.
Missing Data
In general, missing data will not be imputed unless methods for handling missing data are 
specified. 
For missing last dosing date of MMB, imputation rules are described in Section 4.2.1. The 
handling of missing or incomplete dates for disease diagnosis is described in Section 5.3.2.1, for 
AE onset is described in Section 7.1.5.2, and for prior and concomitant medications in 
Section 7.4.1.
3.5.2.
Outliers
Outliers will be identified during the data management and data analysis process, but no 
sensitivity analyses will be conducted. All data will be included in the data analysis.
3.6.
Data Handling Conventions and Transformations
By-subject listings will be presented for all subjects in the primary analysis set that these listings 
are supporting and sorted by subject ID number, visit date, and time (if applicable). Data 
collected on log forms, such as AEs, will be presented in chronological order within subject. 
Age (in years) on the date of the first dose of MMB will be used for analyses and presentation in 
listings.
If a subject was not dosed with MMB at all, the date the informed consent was signed will be 
used instead of the first dose date of MMB. For some countries, only birth year is collected on 
the CRF. In those cases, “01 January” will be used for the unknown birth day and month for the 
purpose of age calculation, unless age is captured on the CRF. 
3.6.1.
Data Handling for Non-PK Laboratory Data
Non-PK data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed as follows:

A value that is one unit less than the limit of quantitation will be used for calculation of 
descriptive statistics if the datum is reported in the form of “x” (where x is considered the 
limit of quantitation). For example, if the values are reported as < 50 and < 5.0, values of 
49 and 4.9, respectively, will be used for calculation of summary statistics.  An exception to 
this rule is any value reported as < 1. For values reported as < 1 or < 0.1, a value of 0.9 or 
0.09, respectively, will be used for calculation of summary statistics.

A value that is one unit above the limit of quantitation will be used for calculation of 
descriptive statistics if the datum is reported in the form of “> x” (where x is considered the 
limit of quantitation). Values with decimal points will follow the same logic as above.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 17
16 October 2017

The limit of quantitation will be used for calculation of descriptive statistics if the datum is 
reported in the form of “≤ x” or “≥ x” (where x is considered the limit of quantitation).
If methods based on the assumption that the data are normally distributed are not adequate, 
analyses may be performed on transformed or nonparametric analysis methods may be used, as 
appropriate.
3.6.2.
Data Handling for PK Data
Natural logarithm transformation will be used for plasma/blood concentrations. Plasma 
concentration values that are below the limit of quantitation (BLQ) will be presented as “BLQ” 
in the concentration data listing. Values that are BLQ will be treated as 0 at predose time points, 
and one-half the value of the lower limit of quantitation (LLOQ) at post-baseline time points, 
where LLOQ is corrected for the dilution factor (i.e., reported LLOQ/dilution factor) for 
determination of summary and order statistics. 
The following conventions will be used for the presentation of summary and order statistics:

If at least 1 subject has a concentration value of BLQ for the time point, the minimum value 
will be displayed as “BLQ.”

If more than 25% of the subjects have a concentration data value of BLQ for a given time 
point, the minimum and Q1 values will be displayed as “BLQ.” 

If more than 50% of the subjects have a concentration data value of BLQ for a given time 
point, the minimum, Q1, and median values will be displayed as “BLQ.” 

If more than 75% of the subjects have a concentration data value of BLQ for a given time 
point, the minimum, Q1, median, and Q3 values will be displayed as “BLQ.” 

If all subjects have concentration data values of BLQ for a given time point, all order 
statistics (minimum, Q1, median, Q3, and maximum) will be displayed as “BLQ.”
3.6.3.
Data Handling for Efficacy Endpoints
If there is a significant degree of non-normality for a continuous endpoint, analysis may be
performed on log-transformed data or using nonparametric methods, as appropriate.
For MRI spleen response, TSS response, and transfusion-independence (TI) response subjects 
will be considered as non-responder and as transfusion-dependent (TD) for TD response status in 
the primary analysis, if subjects early discontinued in the MMB treatment phase prior to the visit 
or with missing assessments at the corresponding visit.  


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 18
16 October 2017
3.7.
Visit Windows
3.7.1.
Definition of Study Day
Study Day 1 will be defined as the day of first dose of MMB administration in the study.
Study day will be calculated from the date of first dose of MMB administration and derived as 
follows:

For post dose study days: Assessment Date – First Dosing Date + 1

For days prior to the first dose: Assessment Date – First Dosing Date
The last participation date is defined as:

If subject did not roll over to the GS-US-352-1154 study: the last date from the datasets 
including  BM_MF2 (bone marrow biopsy),COVLAB (Covance lab), 
ECG_EG(Electrocardiogram), EPRO_ERT (patient-reported outcomes), 
QS_PGIC(patient-reported outcomes), EX (MMB administration), IWG (IWG-MRT/ELN
response assessment),  LVSPQL_MF (Length of palpable spleen size), VISDT (visit date), 
VSPERF (vital signs), MRI_PAREXEL (MRI/CT Spleen Volume).

If subject was rolled over to the GS-US-352-1154 study: as the last date from previous 
datasets but prior to or on the Day 1 of GS-US-352-1154

If subject discontinued MMB treatment due to death, the date of death will be the last 
participation date in the study.
Note AE, CM (con meds), PR_TFSN (transfusion), LAB (local lab), LABHGB, LABHEM,
PK_EX_SERIAL and PK_SERIAL will not be included in the derivation.
3.7.2.
Analysis Windows
Subject visits might not occur on protocol-specified days. Therefore, for the purpose of analysis, 
observations will be assigned to analysis windows.
In general, the baseline value will be the last nonmissing value on or prior to the first dose date 
of MMB. If multiple measurements occur on the same day, the last nonmissing value prior to the 
time of first dose of MMB will be considered as the baseline value. If these multiple 
measurements occur at the same time or the time is not available, the average of these 
measurements (for continuous data) or the worst among these measurements (for categorical 
data) will be considered the baseline value.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 19
16 October 2017
3.7.2.1.
Analysis Windows for Efficacy Analyses
For efficacy analyses in MMB treatment, observations will be assigned to analysis windows for 
efficacy analyses of the endpoints MRI splenic response, TSS response rate, hepcidin, anemia 
related biomarkers, erythropoietin, MRI liver iron content, C-reactive protein, and 
pharmacodynamics biomarkers, as provided in Table 3-1 through Table 3-7.  
The 8-weeks period for RBC transfusion dependence status at baseline is defined as the period 
from Day -55 to Day 1.
Nominal Day referenced in the below Table 3-1 through Table 3-7 are the Study Day calculated 
from the date of first dose of MMB.
Table 3-1.
Analysis Windows for Efficacy Endpoints MRI Spleen Volume
Response Assessment and MRI Liver Iron Content
Nominal Visit
Nominal Day
Lower Limit
Upper Limit
Baseline for MRI Spleen 
Volume/Liver Iron Content
1
-30
1
Week 24a
169
141
197
a
Due to the challenge of scheduling the imaging scan, assessment after a subject rolls over to the GS-US-352-1154 study and 
satisfying the analysis window will:

be used for the corresponding nominal visit, if no assessment prior to or on the date of the first dose of MMB in the 
GS-US-352-1154 study is available in the analysis window;

not be used for the corresponding nominal visit, when there are assessments from the GS-US-352-1672 study, prior to 
or on the date of the first dose of MMB in the GS-US-352-1154 study, and satisfying the corresponding analysis 
window; instead assessments from GS-US-352-1672 will be used.
Table 3-2.
Analysis Windows for Efficacy Analyses of TSS Response Rate at 
Week 24
Nominal Visit
Nominal Day
Lower Limit
Upper Limit
Baseline for TSS
1
-7
-1 
Week 24a
169
28 days period with last 
day as Day 162. 
28 days period with last 
day as Day 176.
a
Last 28 consecutive days with ≥20 available daily TSS, with the last day of the 28 days period searched backward from the 
earliest date of “Upper limit” or the last participation date, through “Lower Limit”, on days with non-missing Daily TSS.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 20
16 October 2017
Table 3-3.
Analysis Windows for Hepcidin
Nominal Visit
Nominal Day
Lower Limit
Upper Limit
Baseline
-1
-30
-1
Enrollment
1
1
1
Week 2
15
8
21
Week 4
29
22
42
Week 8   
57
43
70
Week 12
85
71
98
Week 16
113
99
126
Week 20
141
127
154
Week 24
169
155
182
Table 3-4.
Analysis Windows for Anemia Related Biomarkersa
Nominal Visit
Nominal Day
Lower Limit
Upper Limit
Baseline
1
-30
1
Week 2
15
8
21
Week 4
29
22
42
Week 8
57
43
70
Week 12
85
71
98
Week 16
113
99
126
Week 20
141
127
154
Week 24
169
155
182
a
Anemia related biomarkers include iron related biomarkers (iron, iron binding capacity, ferritin, non-transferrin bound iron, 
transferrin saturation, soluble transferrin receptor) and hematology biomarkers (hemoglobin, hematocrit, platelets, WBC, 
differential, reticulocyte count, % blasts, erythropoietin). For erythropoietin, observations will be assigned to different 
analysis windows from the rest of anemia related biomarkers.
Table 3-5.
Analysis Windows for Erythropoietin
Nominal Visit
Nominal Day
Lower Limit
Upper Limit
Baseline
1
-30
1
Week 8
57
29
85
Week 20
141
113
169


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 21
16 October 2017
Table 3-6.
Analysis Windows for C-reactive Protein
Nominal Visit
Nominal Day
Lower Limit
Upper Limit
Baseline
1
-30
1
Week 2
15
8
43
Week 12
85
57
113
Week 24
169
141
197
Table 3-7.
Analysis Windows for Pharmacodynamics Biomarker pSTAT3
Nominal Visit
Nominal Day
Lower Limit
Upper Limit
Enrollment
1
1
1
Week 4
29
8
57
Week 24
169
141
197
3.7.3.
Selection of Data in the Event of Multiple Records in an Analysis Window
Depending on the statistical analysis method, single values may be required for each analysis 
window. For example, change from baseline by visit usually requires a single value, whereas a 
time-to-event analysis would not require 1 value per analysis window. 
If multiple non-missing numeric observations exist in an analysis window, records will be 
chosen based on the following rules if a single value is needed:

For baseline, the last available record on or prior to the date of the first dose of MMB will be 
selected. If there are multiple records with the same time or no time recorded on the same 
day, average (arithmetic or geometric mean, as appropriate) will be used for the baseline 
value. 

For post-baseline visits: 
The record closest to the nominal day for that visit will be selected. 
If there are 2 records that are equidistant from the nominal day, the later record will be 
selected.
If there is more than 1 record on the selected day, the average will be taken, unless 
otherwise specified.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 22
16 October 2017
If multiple valid non-missing categorical observations exist in a window, records will be selected
as follows:

For baseline, the last available record on or prior to the date of the first dose of MMB will be 
selected. If there are multiple records with the same time or no time recorded on the same 
day, the value with the lowest severity will be selected (eg, normal will be selected over 
abnormal for safety electrocardiogram [ECG] findings).

For post-baseline visits, if there are multiple records with the same time or no time recorded 
on the same day, the most conservative value within the window will be selected 
(eg, abnormal will be selected over normal for safety ECG findings).


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 23
16 October 2017
4.
SUBJECT DISPOSITION
4.1.
Subject Enrollment and Disposition
A summary of subject enrollment and disposition will be provided. This summary will present 
the number of subjects screened, the number of subjects rescreened, the number of subjects 
enrolled, and the number and percentage of subjects in each of the categories listed below. For 
the “Treated”, the denominator for the percentage calculation will be the total number of subjects 
enrolled for each column. For all other categories, the denominator for the percentage calculation 
will be the total number of subjects in the Safety Analysis Set for each column.

Screened

Treated (Safety Analysis Set)

Completed MMB

Did not complete MMB with reason for premature discontinuation of MMB

Completed the study

Did not complete the study with reason for discontinuation of study

Entered the roll over study of GS-US-352-1154

Biomarker analysis.

Pharmacokinetics analysis
In addition, the total number of subjects who were enrolled in the study and the number and 
percentage of subjects in each of the disposition categories listed above will be displayed in a 
flow chart.
The following by-subject listings will be provided by subject ID number in ascending order to 
support the above summary tables:

Reasons for discontinuation of MMB or study

Reasons for screen failure (will be provided by screening ID number in ascending order)

Lot number and kit ID
4.2.
Extent of Exposure 
Extent of exposure to MMB will be examined by assessing the total duration of exposure to 
MMB and the level of adherence to the MMB specified in the protocol. 


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 24
16 October 2017
4.2.1.
Duration of Exposure to MMB
Total duration of exposure to MMB will be defined as last dosing date minus first dosing date 
plus 1, regardless of any temporary interruptions in MMB administration, and will be expressed 
in weeks using up to 1 decimal place (eg, 4.5 weeks). 
When the stopping date of the study drug is missing or partial, the following rule will be used to 
impute the stopping date:

If subjects are continuing on study drug, use the earliest of the date of death or data cutoff 
date or date of rolling over to GS-US-352-1154 study for analysis to impute the last dosing 
date for the calculation of the duration of exposure to study drug.

If the stopping date is partial, then stopping date will be imputed with the earliest of the last 
date of the month (if month and year are available) or the last month of the year (if only year 
is available), the date of one day prior to the first dose in the rollover study, or the early study 
drug discontinuation date or date of death.
The total duration of exposure to MMB will be summarized using descriptive statistics (number 
of subjects [n], mean, StD, median, Q1, Q3, minimum, and maximum) and using the number 
(ie, cumulative counts) and percentage of subjects exposed through the following time periods:
Baseline (Day 1), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), 
Week 16 (Day 113), Week 20 (Day 141), and Week 24 (Day 169).
Summaries will be provided for the Safety Analysis Set. 
The number of subjects who have dose reduction or interruptions, and the reasons, will be 
summarized.
No inferential statistics will be provided.
4.2.2.
Adherence to MMB
The total number of tablets administered will be summarized using descriptive statistics (n, 
mean, StD, median, Q1, Q3, minimum, and maximum). 
The presumed total number of tablets administered to a subject will be determined by the data 
collected on the drug accountability CRF using the following formula:







ed
Administer
Not 
Tablets
of
No.
Dispensed
Tablets
of
No.
ed
Administer
Tablets
of
Number 
Total
where the number of tablets not administered is the sum of (a) the number of doses returned and 
(b) the number of (reported) missed tablets that were not returned.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 25
16 October 2017
If returned tablets were missing for the last dispensed bottle at the data cutoff date for subjects 
who were continuing on study drug, it will be assumed that these subjects had received the 
correct number of or tablets at the time of the data cutoff date.
The average daily dose (mg) will be calculated using the following formula:


Drug
Study 
on 
Days
of
Number 
Total
mg
in 
Dose
Daily 
(mg)
Dose
Daily 
Average


Total Number of Days on Study Drug = Last Dosing Date – First Dosing + 1
The level of adherence with the MMB regimen while subjects were on treatment (i.e., on-
treatment adherence) will be determined by the total amount of MMB administered relative to 
the total amount of MMB expected to be administered during subject’s actual on-treatment 
period based on the MMB regimen.
The level of on-treatment adherence will be expressed in percentage using the following 
formula:
100
Treatment 
on 
ed
Administer
Be
 to
Expected
MMB
  
ed
Administer
MMB
of
Amount 
Total
(%)
Adherence
Treatment 
-
On








Study drug expected to be administered on treatment (mg) is the dose (mg) prescribed, taking 
into account for dose reduction and interruption (ie, if dose reduced or interrupted for certain 
period, the dose expected to be administered should be the reduced dose level or 0mg if 
interrupted for that particular period) until the date of study drug withdrawn prematurely or 
completion. 
Descriptive statistics for the level of on-treatment adherence (n, mean, StD, median, Q1, Q3, 
minimum, and maximum) with the number and percentage of subjects belonging to adherence 
categories (eg, < 75%, ≥ 75 to < 90%, ≥ 90%) will be provided by treatment group for the Safety 
Analysis Set. 
No inferential statistics will be provided. 
A separate by-subject listing of MMB administration and MMB accountability will be provided 
by subject ID number (in ascending order) and visit (in chronological order).
4.3.
Protocol Deviations 
Subjects who did not meet the eligibility criteria for study entry will be summarized regardless of
whether they were exempted by the sponsor or not. The summary will present the number and 
percentage of subjects who did not meet at least 1 entry criterion and the number of subjects who 
violated specific entry criteria based on all enrolled subjects. A by-subject listing will be 
provided for those subjects who violated at least 1 inclusion or exclusion criterion. The listing 
will present the entry criterion (or criteria if more than 1 violation) that subjects did not meet and 
related comments, if collected.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 26
16 October 2017
Protocol deviations occurring after subjects entered the study are documented during routine 
monitoring. The number and percentage of subjects with important protocol deviations by 
deviation reason (eg, nonadherence to MMB, violation of inclusion/exclusion criteria) will be 
summarized for the all enrolled subjects. A by-subject listing will be provided for those subjects 
with any protocol deviation.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 27
16 October 2017
5.
BASELINE CHARACTERISTICS
5.1.
Demographics 
Subject demographic variables (ie, age, sex, race, and ethnicity) will be summarized using 
descriptive statistics (n, mean, StD, median, Q1, Q3, minimum, and maximum) for age, and 
using the numbers and percentages of subjects for gender, age (<65 yrs vs ≥65 yrs), race, and 
ethnicity. Age is calculated in years at the date of initial MMB administration. If a subject did 
not receive MMB after enrollment, the subject’s age will be calculated from the date that the 
subject signed the informed consent form. The summary of demographic data will be provided 
for the Safety Analysis Set. Partial date of birth will be imputed per Section 5.3.2.1.
A by-subject demographic listing, which includes the date the informed consent was signed, will 
be provided by subject ID number in ascending order.
5.2.
Other Baseline Characteristics
Other baseline characteristics include body weight (in kg), height (in cm), body mass index 
(BMI; in kg/m2), and disease and baseline characteristics will include type of MF (PMF, Post-PV 
MF, or post-ET MF), spleen volume(cm3), TSS, RBC units transfused within 8 weeks prior to 
enrollment, bone marrow fibrosis grade, cytogenetics findings, DIPSS risk level, hemoglobin 
level (continuous and categorical by <8 or 8 g/dL), WBC (x10^3/uL), ANC (x10^3/uL),
Platelet count (x10^3/uL), JAK2V617F mutation status (positive or negative) at baseline. These 
baseline characteristics will be summarized using descriptive statistics (n, mean, StD, median, 
Q1, Q3, minimum, and maximum) for continuous variables and using the numbers and 
percentages of subjects for categorical variables. The summary of baseline characteristics will be 
provided for the Safety Analysis Set.
A by-subject listing of other baseline characteristics will be provided by subject ID number in 
ascending order.
5.3.
Medical History
5.3.1.
General Medical History
General medical history (ie, conditions not specific to the disease being studied) data will be
collected at screening and listed only. A by-subject listing of general medical history will be 
provided by subject ID number in ascending order. 
5.3.2.
Myelofibrosis Disease History
Myelofibrosis disease history will be collected at screening for disease-specific conditions.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 28
16 October 2017
Time since disease diagnosis (years) will be calculated by (date of first dosing date of 
MMB - date of MF diagnosis + 1) / 365.25. Time since disease diagnosis will be summarized 
using summary statistics for a continuous variable. No inferential statistics will be generated.
Myelofibrosis disease type (PMF, post-PV MF, and post-ET MF) will be summarized by using 
number and percentage of subjects.  
A by-subject listing of disease-specific conditions will be provided by subject ID number in 
ascending order.
5.3.2.1.
Incomplete Dates
All partial dates of diagnosis and last regimen will be identified, and the partial dates will be 
imputed as follows:

If day and month are missing but year is available, then the imputed day and month will be 
01 Jan.

If day is missing but the month and year are available, then the imputed day will be the 
first day of the month.

Partial date will not be imputed if the year is missing.
5.4.
Myelofibrosis Disease-Specific Prior Therapy 
Myelofibrosis disease-specific prior medication, defined as any medication for the purpose of 
treating MF disease with a start date that is prior to the enrollment, will be summarized by 
preferred term (PT) (collected through concomitant medication eCRF page) using the number 
and percentage of subjects on the medication. A subject reporting the same medication more than 
once will be counted only once when calculating the number and percentage of subjects who 
received that medication. The summary will be ordered by descending overall frequency of PT 
term. For drugs with the same frequency, sorting will be done alphabetically. If a partial start 
date is entered, any medication with the month and year (if day is missing) or year (if day and 
month are missing) prior to or the same as the enrollment will be included in the prior 
medication summary. Medication with day, month and year all missing for start date will also be 
taken as MF disease-specific prior medication. All MF disease-specific prior medication will be 
provided in a by-subject listing sorted by subject ID number and administration date in 
chronological order.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 29
16 October 2017
6.
EFFICACY ANALYSES
6.1.
Primary Efficacy Endpoint
6.1.1.
Definition of the Primary Efficacy Endpoint
The primary efficacy endpoint of this study is transfusion independence (TI) response rate by 
Week 24 defined as becoming transfusion independent for ≥12 weeks at any time on study.
Twelve-week transfusion independent response by Week 24: ≥84 days transfusion 
independence response for subjects who are transfusion dependent at baseline, where transfusion 
dependent is defined as receiving at least 4 units of RBC transfusion in the 8 weeks prior to 
screening (or first dose of MMB). The subject will be considered as 12-week transfusion 
independent in post-baseline if at least 1 of the following 4 criteria is satisfied:
1) There is a time duration of at least 84 days between the first dose of MMB and the first RBC 
transfusion in post-baseline, where the duration will be calculated as follows:
Duration between the first dose of MMB to the first RBC transfusion in post-baseline (days) 
= Date of first RBC transfusion in post-baseline – Date of first dose of MMB + 1 
2) There is a time duration of at least 84 days between 2 consecutive RBC transfusions in 
post-baseline, where the duration will be calculated as follows:
Duration between the 2 consecutive RBC transfusions in post-baseline (days) = Date of the 
second RBC transfusion in the consecutive RBC transfusions in post-baseline – Date of the 
first RBC transfusion in the successive RBC transfusions in post-baseline + 1
3) There is a time duration of at least 84 days between the last RBC transfusion in post-baseline 
and the last visit date, where the duration will be calculated as follows:
Duration between the last RBC transfusion in post-baseline and the last available visit in 
post-baseline (days) = Date of the last available visit in post-baseline – Date of the last RBC 
transfusion in post-baseline + 1
4) No transfusion during the entire study in post-baseline and the length of the study is at least 
84 days, where the duration will be determined as follows:
Duration between the date of first dose of MMB and the last available visit in post-baseline 
(days) = Date of the last available visit in post-baseline – Date of the first dose of MMB + 1
Twelve-week transfusion independent response by Week 12: a subject is considered as 12-week 
transfusion indepdent by Week 12, if he did not have any transfusion in the first 84 days on 
study. 


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU
$Q\HQUROOHGVXEMHFW LQWKH6DIHW\$QDO\VLV6HWZKRGLGQRWPHHWDQ\RIWKHFULWHULDOLVWHGDERYH
ZLOOEHFRQVLGHUHGD ZHHNWUDQVIXVLRQLQGHSHQGHQWQRQUHVSRQGHU
&DOFXODWLRQRIZHHNWUDQVIXVLRQLQGHSHQGHQWUHVSRQVH UDWHE\:HHN DQG:HHN 
݌̂ଵଶି்ி 
ൈ
ே௨௠௕௘௥ ௢௙ ௣௔௧௜௘௡௧௦ ௪௜௧௛ ௧௪௘௟௩௘ି௪௘௘௞ ௧௥௔௡௦௙௨௦௜௢௡ ௜௡ௗ௘௣௘௡ௗ௘௡௧ ௥௘௦௣௢௡௦௘
்௢௧௔௟ ௡௨௠௕௘௥ ௢௙ ௘௡௥௢௟௟௘ௗ ௣௔௧௜௘௡௧௦ ௜௡ ௌ௔௙௘௧௬ ஺௡௔௟௬௦௜௦ ௌ௘௧ 
7KHGHQRPLQDWRUIRUFDOFXODWLRQRIWKHSHUFHQWDJHRIZHHNWUDQVIXVLRQLQGHSHQGHQWUDWHE\
:HHN DQG:HHN LQFOXGHGDOOHQUROOHGVXEMHFWVLQ6DIHW\ $QDO\VLV6HW

6WDWLVWLFDO+\SRWKHVLVIRUWKH3ULPDU\(IILFDF\(QGSRLQW
7KHUHLVQRIRUPDOK\SRWKHVLVWHVWLQJLQWKLVVWXG\GXHWRWKHH[SORUDWRU\QDWXUHRIWKHSULPDU\
HQGSRLQWV

$QDO\VLVRIWKH3ULPDU\(IILFDF\(QGSRLQW
7KHSXUSRVHRIWKHSULPDU\DQDO\VLVLVWRLQYHVWLJDWHWKHZHHNWUDQVIXVLRQLQGHSHQGHQFH
UHVSRQVHUDWHE\:HHNZLWKWKHWUHDWPHQWRI 00%,QRUGHUWRHYDOXDWHWKHSURSRUWLRQ
݌̂ଵଶି்ி DFRQYHQWLRQDOVLGHG100ሺ1 െߙሻH[DFWFRQILGHQFHOLPLWV EDVHGRQ&ORSSHU3HDUVRQ
PHWKRG ^&ORSSHU` IRUELQRPLQDOGLVWULEXWLRQ ZLOOEHFDOFXODWHGZKHUH ߙLVWKHFRQILGHQFH
OHYHO8QOHVVRWKHUZLVHLQGLFDWHGLWLVHTXDOWRLQWKLVVWXG\ 1XPEHUDQGSHUFHQWZLOOEH
SURYLGHGIRU VXEMHFWVZLWKRUZLWKRXW+JEJG/GXULQJZHHNWUDQVIXVLRQIUHHZLQGRZ

([SORUDWRU\$QDO\VLV
$QH[SORUDWRU\DQDO\VLVZLOOEHSHUIRUPHGWRLQYHVWLJDWHWKHSRWHQWLDOSURJQRVWLFIDFWRUV
LQIOXHQFLQJ WUDQVIXVLRQLQGHSHQGHQWUHVSRQVHUDWH XVLQJWKHORJLVWLFUHJUHVVLRQPRGHODSSURDFK
7KHYDULDEOHVZLWKSURJQRVWLFSRWHQWLDOZLOOEHLQFOXGHGLQWKHPRGHOWRLGHQWLI\SODXVLEOH
VLJQLILFDQWIDFWRUVRQ WUDQVIXVLRQLQGHSHQGHQWUHVSRQVHUDWH
•
$JH \HDUV DQG ≥\HDUV
•
*HQGHU PDOHDQGIHPDOH
•
5DFHZKLWHDQGDOORWKHUUDFHV
•
',366DVVHVVPHQW,QWHUPHGLDWHDQGKLJKULVN
•
7\SHRI0)30)3RVW390)DQG3RVW(70)
•
-$.9)PXWDWLRQVWDWXVDWEDVHOLQHSRVLWLYH DQGQHJDWLYH
•
+HPRJORELQOHYHODWEDVHOLQHJG/DQG൒JG/


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU
•
766DWEDVHOLQHPHGLDQDQG൒PHGLDQ
•
6SOHHQYROXPH DWEDVHOLQH PHGLDQDQG൒PHGLDQ
•
+HSFLGLQDWEDVHOLQHPRUQLQJWLPHSRLQWPHGLDQDQG൒PHGLDQ
•
/LYHULURQFRQWHQWDWEDVHOLQHPHGLDQDQG൒PHGLDQ
•
7UDQVIHUULQVDWXUDWLRQDWEDVHOLQHDQG൒
(DFKSURJQRVWLFIDFWRUZLOOEHSUHOLPLQDULO\HYDOXDWHGLQWKH ORJLVWLFUHJUHVVLRQ PRGHO2QO\WKH
YDULDEOHV ZLWK VLJQLILFDQFH OHYHOOHVVWKDQ ZLOOEHFRQVLGHUHGWREXLOGWKHPXOWLYDULDWHPRGHO
$ VWHSZLVH VHOHFWLRQSURFHVVZLWKVLJQLILFDQFHOHYHORI  IRUHQWHULQJYDULDEOHV DQGVLJQLILFDQFH
OHYHORIIRUNHHSLQJYDULDEOHV ZLOOEHDSSOLHGWRWKRVHFDQGLGDWHYDULDEOHVWRLGHQWLI\WKH
ILQDOVXEVHWRIUHOHYDQWFRYDULDWHVLQWKHORJLVWLFUHJUHVVLRQPRGHO

'XUDWLRQRI7,5HVSRQVH'257,
'XUDWLRQRI7,UHVSRQVHLVGHILQHGDV WKHLQWHUYDOIURPWKHILUVWRQVHWGDWHRI7,UHVSRQVHWRWKH
HDUOLHVWRQVHWGDWHRIORVVRI7,UHVSRQVH RUFHQVRULQJGDWH DPRQJVXEMHFWVZKRDFKLHYHG7,
UHVSRQVHLH GXUDWLRQRI7,UHVSRQVHZHHNV GDWHRIORVVRI7,UHVSRQVHRUFHQVRULQJ± GDWHRI
ILUVW7, UHVSRQVH7KHORVVRI7,UHVSRQVHLVGHILQHGDVWKHGDWHRIWKHILUVWWUDQVIXVLRQ
SRVWWKH7,UHVSRQVH 6XEMHFWVZKRUHPDLQ7,ZLOOEHFHQVRUHGDWWKHODVWSDUWLFLSDWLRQGDWH
'XUDWLRQRI7,UHVSRQVHZLOOEHVXPPDUL]HGXVLQJ.DSODQ0HLHUPHWKRG IRU7,UHVSRQVHE\
:HHNRQO\1XPEHURIVXEMHFWVZLWKHYHQWVDQGVXEMHFWVFHQVRUHGPHGLDQ44PLQDQG
PD[HVWLPDWHV ZLOOEHSUHVHQWHG

7LPHWR7, 5HVSRQVH 7W7,
7LPHWR7,UHVSRQVH7W7,DPRQJVXEMHFWV ZKRDFKLHYHG7,UHVSRQVHLVGHILQHGDVWKHLQWHUYDO
IURPWKHGDWHRIWKHILUVWGRVHRI00%DGPLQLVWUDWLRQ WRWKHILUVWRQVHWGDWHRI7, UHVSRQVH
LH WLPHWR7,ZHHNV WKHGDWHRIILUVW7,UHVSRQVHRQVHW ± GDWHRIWKHILUVWGRVHRI
00%    1RFHQVRULQJLVQHHGHG
7LPHWR7,UHVSRQVHZLOOEHVXPPDUL]HGRQO\IRU7,UHVSRQVHE\:HHNWKURXJKGHVFULSWLYH
VWDWLVWLFVQ PHDQ6W'PHGLDQ44PLQLPXP DQGPD[LPXP

6HFRQGDU\(IILFDF\(QGSRLQWV

'HILQLWLRQRI6HFRQGDU\(IILFDF\(QGSRLQWV
7KHIROORZLQJHQGSRLQWV RIWKLVVWXG\DUHGHVLJQDWHGDVVHFRQGDU\HQGSRLQWV


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU

7UDQVIXVLRQ5HVSRQVH5DWH IRU൒:HHNV
7UDQVIXVLRQUHVSRQVHIRU൒ZHHNVGHILQHGDVQR 5%&WUDQVIXVLRQV IRUDWOHDVWZHHNVDWDQ\
WLPHRQVWXG\ $ VXEMHFW ZLOOEHFRQVLGHUHGWRDFKLHYH WUDQVIXVLRQ UHVSRQVHIRU൒ZHHNV
SRVWEDVHOLQHLIDWOHDVWRQHRIWKHIROORZLQJ FULWHULDLVVDWLVILHG
 ,IWKHUHLVQRDQ\WUDQVIXVLRQHYHQW SRVWEDVHOLQH DQGWKHOHQJWKRIVWXG\LV൒GD\V
'XUDWLRQEHWZHHQGDWHVLQSRVWEDVHOLQH WKHODVW SDUWLFLSDQWGDWH± ILUVWGRVHGDWHRI00%
 ,IWKHUHLVDQ\WLPHLQWHUYDOEHWZHHQDQ\FRQVHFXWLYH WUDQVIXVLRQHYHQWVSRVWEDVHOLQHRU
WKHWLPHLQWHUYDOEHWZHHQWKHILUVWGRVHRI00%GDWHDQG WKHILUVWWUDQVIXVLRQGDWHSRVW
EDVHOLQHRUWKHODVWWUDQVIXVLRQGDWHDQGWKHWLPHLQWHUYDOEHWZHHQWKHODVWDYDLODEOHYLVLW
GDWH൒GD\V
'XUDWLRQEHWZHHQGDWHV LQSRVWEDVHOLQH  ODWHUGDWH± IRUPHUGDWH

6SOHQLF5HVSRQVH5DWHDW:HHN
6SOHQLFUHVSRQVHUDWHDW:HHN GHILQHGSURSRUWLRQRIVXEMHFWVZKRDFKLHYHD ൒UHGXFWLRQ
LQVSOHHQYROXPHDW:HHN 655IURPEDVHOLQHDVPHDVXUHGE\05,7KHVSOHHQYROXPH
ZLOOEHREWDLQHGWKURXJKWKHDVVHVVPHQWRI05,VFDQE\DFHQWUDOLPDJLQJODERUDWRU\ GHVFULEHG
LQWKH6HFWLRQ LQWKHSURWRFRO
7KHEDVHOLQHVSOHHQYROXPHLVGHILQHGDVWKHODVWVSOHHQYROXPHPHDVXUHGE\05,IURPWKH
EDVHOLQHSHULRGSULRUWRRURQWKHGDWHRIILUVWGRVHRI00%DGPLQLVWUDWLRQ'D\ WR'D\ 
'D\LVGHILQHGDVWKHGD\RIILUVWGRVHRI00%DGPLQLVWUDWLRQLQWKHVWXG\
7KH:HHNVSOHHQYROXPHLVGHILQHGDVWKHVSOHHQYROXPHPHDVXUHPHQWE\05,DW:HHN
'D\ WR:KHQPXOWLSOHUHFRUGVDUHH[LVWHQWEHWZHHQ'D\DQG'D\WKHUXOHV
VSHFLILHGLQ6HFWLRQ DUHDSSOLHG'XHWRWKHFKDOOHQJHRIVFKHGXOLQJWKHLPDJLQJVFDQ
DVVHVVPHQWDIWHUWKHILUVW 00%GRVH LQWKHUROORYHUVWXG\ DQGEHWZHHQ'D\WRIRU WKH
VXEMHFWVZKRZHUH UROOHGRYHUWR6WXG\*686ZLOO
•
%HXVHGIRU :HHNVSOHHQYROXPHLIQRDVVHVVPHQWSULRUWRRURQWKHGDWHRIWKH ILUVW
UROORYHUVWXG\00%GRVLQJ DQGEHWZHHQ'D\DQG'D\LVDYDLODEOH
•
1RWEHXVHG IRU:HHNVSOHHQYROXPHLIWKHUHDUHDVVHVVPHQWVLQ6WXG\*686
SULRUWRRURQWKHGDWHRIILUVW UROORYHUVWXG\ 00%GRVLQJDQGEHWZHHQ'D\DQG
'D\ LQVWHDGDVVHVVPHQWVLQ6WXG\*686 ZLOOEHVHOHFWHGSHUUXOHVVSHFLILHG
LQ6HFWLRQ


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU
7KH&KDQJHLQVSOHHQYROXPHIURPEDVHOLQHWR:HHNLVFDOFXODWHGE\
%݄ܿܽ݊݃݁ൌ 100 ൈܹ݁݁݇ 24 ܵ݌݈݁݁݊ ܸ݋݈ݑ݉݁െܤܽݏ݈݁݅݊݁ ܵ݌݈݁݁݊ ܸ݋݈ݑ݉݁
ܤܽݏ݈݁݅݊݁ ܵ݌݈݁݁݊ ܸ݋݈ݑ݉݁

5HVSRQVH5DWHRI 7RWDO6\PSWRP6FRUH766DW:HHN
7KHPRGLILHG0316$)766LVDQLWHPTXHVWLRQQDLUHGHYHORSHGWRDVVHVVV\PSWRPEXUGHQ
DQGTXDOLW\RIOLIHLQSDWLHQWVZLWKP\HORSUROLIHUDWLYHQHRSODVPV031V7KH766LVDVVHVVHG
RYHUWLPHWRHYDOXDWHFKDQJHVLQ031UHODWHGV\PSWRPV7KHPRGLILHG0316$)766LV
FRPSOHWHGGDLO\RQDQHOHFWURQLFGLDU\H'LDU\GHYLFH127(VFRUHVIRUWKHTXHVWLRQRI
LQDFWLYLW\LQWKHGLDU\ ZLOOQRWEHLQFOXGHGLQ766 DVVHVVPHQWV
7KHSURSRUWLRQRIVXEMHFWVZKRKDYHDFKLHYHG≥UHGXFWLRQIURPEDVHOLQHWR:HHN LQ766
EDVHGRQWKHPRGLILHG0316$)766ZLOOEHGHWHUPLQHGDVIROORZV
7KHGLDU\LVFRPSOHWHGDWWKHHQGRIHDFKGD\ZLWKDKRXUUHFDOOSHULRGDQGWKHGDLO\766LV
GHILQHGDVWKHVXPRILQGLYLGXDOV\PSWRPVFRUHVHDFKZLWKD WRSRLQWVFDOHFROOHFWHGRQ
WKHVDPHGD\7KHGDLO\766ZLOOEHPLVVLQJLIWKHUHDUHDQ\PLVVLQJLQGLYLGXDOVFRUHV ,I
PXOWLSOHUHFRUGVDUHDYDLODEOHRQWKHVDPHGD\WKHODVWUHFRUGZLOOEHXVHGDVDQDVVHVVPHQWIRU
WKDWGD\
7KHEDVHOLQH766LVGHILQHGDVWKHDYHUDJHRIWKHGDLO\766 IURPWKHGD\EDVHOLQHSHULRG
'D\ íWKURXJK'D\í 7KH EDVHOLQH766ZLOOEHPLVVLQJLIWKHUHDUHPRUHWKDQGD\VRI
PLVVLQJGDLO\766GXULQJWKHGD\EDVHOLQHSHULRG
7KH:HHN766LVGHILQHGDVWKHDYHUDJHRI WKH GDLO\766IURPDFRQVHFXWLYHGD\SHULRGDW
:HHN7KHFRQVHFXWLYHGD\SHULRGDW:HHN LVGHILQHGDVWKHODWHVW HOLJLEOHSHULRGRI
 FRQVHFXWLYHGD\VWKDWKDV DYDLODEOHGDLO\766 WKHODVWGD\RIWKDWGD\SHULRGPXVWEH
SULRUWRRURQWKHODVWSDUWLFLSDWLRQGDWHKDYHQRQPLVVLQJGDLO\766DQGIDOOEHWZHHQ'D\V
DQGLQFOXVLYH,IQRVXFKFRQVHFXWLYHGD\ SHULRGZLWK  DYDLODEOHGDLO\766LV
DYDLODEOHRUWKHODVWSDUWLFLSDWLRQGD\ZDVSULRUWR'D\ WKH:HHN766ZLOOEHFRQVLGHUHG
PLVVLQJ
7KHSHUFHQWDJH FKDQJHLQ766 IURPEDVHOLQHWR:HHNLVFDOFXODWHGDVIROORZV
&KDQJH × :HHN766± %DVHOLQH766%DVHOLQH766

&KDQJHLQ+HSFLGLQ
+HSFLGLQLVPHDVXUHGWZLFHDWHDFKVWXG\YLVLWRQHSUHGRVHLQWKHPRUQLQJDQG RQHKRXUV
SRVWGRVH +HSFLGLQLVPHDVXUHDWWKH%DVHOLQH9LVLWERWKPRUQLQJDQGKRXU VDPSOHVDUH
SUHGRVHDWWKH(QUROOPHQW9LVLWDQG:HHNVDQG &KDQJHDQGFKDQJHIURP
EDVHOLQHZLOOFDOFXODWHGIRUSUHGRVHDQGSRVWGRVHYDOXHVUHVSHFWLYHO\+HSFLGLQYDOXHLV
REWDLQHGWKURXJKWKHDVVHVVPHQWE\KHSFLGLQDQDO\VLV5DGERXQG


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU
7KHEDVHOLQHYLVLWIRUKHSFLGLQ LVGHILQHGDVWKHODVWYLVLW LQ WKHEDVHOLQHSHULRGSULRUWRWKHGDWH
RIILUVWGRVHRI00%DGPLQLVWUDWLRQ'D\ WR'D\ 'D\LVGHILQHGDVWKHGD\RIILUVWGRVH
RI00%DGPLQLVWUDWLRQLQWKHVWXG\ +HSFLGLQYDOXHDWSUHGRVHWLPHSRLQWLQWKHPRUQLQJDWWKH
EDVHOLQHYLVLWZLOOEHXVHGDVWKHEDVHOLQHYDOXHIRUSUHGRVHKHSFLGLQPHDVXUHPHQW+HSFLGLQ
YDOXHDWKRXUVSRVWGRVHDWWKHEDVHOLQHYLVLWZLOOEHXVHGDVWKHEDVHOLQHYDOXHIRUKRXUV
SRVWGRVH KHSFLGLQPHDVXUHPHQW
7KHSRVWEDVHOLQHYLVLWV IRUKHSFLGLQDUH GHILQHGXVLQJWKHDQDO\VLVZLQGRZVSHFLILHGLQ
6HFWLRQ 3UHGRVHYDOXHDQGKRXUVSRVWGRVHYDOXHDWHDFKSRVWEDVHOLQHYLVLWZLOOEHXVHG
WRFDOFXODWH WKHFKDQJHDQGFKDQJHIURPEDVHOLQHIRUKHSFLGLQPHDVXUHGDWSUHGRVHWLPHSRLQW
DQGKRXUVSRVWGRVH
'DLO\KHSFLGLQFKDQJHZLOODOVREHFDOFXODWHGDWHDFKVWXG\YLVLWXVLQJWKHIRUPXODEHORZ
ܦ݈ܽ݅ݕ ݄݁݌ܿ݅݀݅݊ ݄ܿܽ݊݃݁ൌ6 ݄݋ݑݎݏ ݌݋ݏݐ݀݋ݏ݁ ݄݁݌ܿ݅݀݅݊ ݒ݈ܽݑ݁െ݌ݎ݁݀݋ݏ݁ ݄݁݌ܿ݅݀݅݊ ݒ݈ܽݑ݁
'DLO\KHSFLGLQFKDQJHDWWKHEDVHOLQHYLVLWZLOOEHXVHGDVWKHEDVHOLQHYDOXHIRUGDLO\KHSFLGLQ
FKDQJH'DLO\KHSFLGLQFKDQJHDWSRVWEDVHOLQHYLVLWVLVGHILQHGE\WKHDQDO\VLVZLQGRZVSHFLILHG
LQ6HFWLRQ  &KDQJHDQGFKDQJHIURPEDVHOLQHRIGDLO\KHSFLGLQFKDQJHZLOOEH
FDOFXODWHG

%DVHOLQHDQG&KDQJHLQ$QHPLD5HODWHG%LRPDUNHUV
&KDQJHDQGFKDQJHIURPEDVHOLQHZLOOEHFDOFXODWHGIRUDQHPLDUHODWHGELRPDUNHUVLQFOXGLQJ
LURQUHODWHGELRPDUNHUV LURQLURQELQGLQJFDSDFLW\IHUULWLQQRQWUDQVIHUULQERXQGLURQ
WUDQVIHUULQVDWXUDWLRQDQGVROXEOHWUDQVIHUULQUHFHSWRU DQGKHPDWRORJ\ELRPDUNHUV KHPRJORELQ
KHPDWRFULWSODWHOHWV:%&5%&UHWLFXORF\WHFRXQWUHWLFXORF\WHHU\WKURF\WH EODVWVDQG
HU\WKURSRLHWLQ7KHYDOXHV RIWKHVHELRPDUNHUVDUHREWDLQHGIURP WKHFHQWUDOODERUDWRU\
DVVHVVPHQWDVGHVFULEHGLQ3URWRFRO6HFWLRQ
7KHEDVHOLQHELRPDUNHUYDOXH LVGHILQHGDVWKHODVWYDOXH IURPWKHEDVHOLQHSHULRGSULRUWRRURQ
WKHGDWHRIILUVWGRVHRI00%DGPLQLVWUDWLRQ'D\ WR'D\ 'D\LVGHILQHGDVWKHGD\RI
ILUVWGRVHRI00%DGPLQLVWUDWLRQLQWKHVWXG\
7KHSRVWEDVHOLQHELRPDUNHUYDOXHLVGHILQHGDVWKHYDOXHPHDVXUHGZLWKLQWKHDQDO\VLVZLQGRZV
RISRVWEDVHOLQHYLVLWVVSHFLILHGLQ6HFWLRQ:KHQPXOWLSOHUHFRUGVDUHLQWKHDQDO\VLV
ZLQGRZRIDSRVWEDVHOLQHYLVLWWKHUXOHVVSHFLILHGLQ6HFWLRQ DUHDSSOLHG

$QHPLD5HODWHG%LRPDUNHUIRU7,5HVSRQGHUV
)RU7,UHVSRQGHUVFKDQJHDQGFKDQJHIURPSUH7,UHVSRQVHZLOOEH FDOFXODWHGIRUDQHPLD
UHODWHGELRPDUNHUYDOXHVGXULQJWKHSHULRGRI7,UHVSRQVH$QHPLDUHODWHGELRPDUNHUIRUWKLV
DQDO\VLVLQFOXGHSUHGRVHKHSFLGLQKHSFLGLQKRXUSRVWGRVHKHSFLGLQGDLO\FKDQJHLURQLURQ
ELQGLQJFDSDFLW\IHUULWLQQRQWUDQVIHUULQERXQGLURQWUDQVIHUULQVDWXUDWLRQVROXEOHWUDQVIHUULQ
UHFHSWRUKHPRJORELQKHPDWRFULWSODWHOHWV:%&5%&UHWLFXORF\WHFRXQW
UHWLFXORF\WHHU\WKURF\WHEODVWVDQGHU\WKURSRLHWLQ


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 35
16 October 2017
The pre-TI response anemia biomarker value is defined as the last value prior to the start of the 
TI response window defined in Section 6.1.1. Anemia related biomarker values used for pre-TI 
response and during the period of TI response should be chosen from the baseline and 
post-baseline anemia related biomarker values defined above, and change and % change from 
pre-TI response will be calculated at 2 weeks, 4 weeks, 8 weeks, 12 weeks etc., after the pre-TI 
response anemia related biomarker value.  
6.2.1.6.
Change in Liver Iron Content
Change and % change from baseline will be calculated for liver iron content. The liver iron 
content is obtained from the central imaging laboratory MRI assessment described in Protocol 
Section 6.2.8.2.
The baseline liver iron content is defined as the last value from the baseline period prior to or on 
the date of first dose of MMB administration (Day -30 to Day 1, Day 1 is defined as the day of 
first dose of MMB administration in the study).
The Week 24 liver iron content is defined as the value measured within the analysis window of 
the Week 24 visit specified in Section 3.7.2. When multiple records are in the analysis window 
of a post-baseline visit, the rules specified in Section 3.7.3 are applied.
6.2.1.7.
Change in C-reactive Protein 
Change and % change from baseline will be calculated for C-reactive protein. The value of 
C-reactive protein is obtained from the central laboratory assessment described in Protocol 
Section 6.2.7.
The baseline C-reactive protein value is defined as the last value from the baseline period prior to 
or on the date of first dose of MMB administration (Day -30 to Day 1, Day 1 is defined as the 
day of first dose of MMB administration in the study).
The post-baseline C-reactive protein value is defined as the value measured within the analysis 
window of post-baseline visits specified in Section 3.7.2. When multiple records are in the 
analysis window of a post-baseline visit, the rules specified in Section 3.7.3 are applied.
6.2.1.8.
Change in Pharmacodynamics Biomarker pSTAT3
Change and % change from baseline will be calculated for the pharmacodynamics biomarker 
pSTAT3, including %pSTAT Stimulated CD3+/4+ T cell and ratio between %pSTAT 
Stimulated CD3+/4+ T cell and %tSTAT Stimulated CD3+/4+ T cell. Ratio between %pSTAT 
Stimulated CD3+/4+ T cell and %tSTAT Stimulated CD3+/4+ T cell is calculated as 
100%× (%pSTAT Stimulated CD3+/4+ T cell ÷ %tSTAT Stimulated CD3+/4+ T cell). pSTAT3 
is measured at time points of predose, 2, 4 and 6 hour postdose at Enrollment, Week 4 and 24. 
The value of pSTAT3 is obtained from the central laboratory assessment described in Protocol
Section 6.2.


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU
7KHEDVHOLQHS67$7YDOXHLVGHILQHGDVWKHODVWSUHGRVHYDOXHIURPWKHEDVHOLQHSHULRGSULRUWR
RURQWKHGDWHRIILUVWGRVHRI00%DGPLQLVWUDWLRQ'D\WR 'D\'D\LVGHILQHGDVWKH
GD\RIILUVWGRVHRI00%DGPLQLVWUDWLRQLQWKHVWXG\
7KH:HHNDQGS67$7YDOXHV DUH GHILQHGDVYDOXHV PHDVXUHGZLWKLQWKHDQDO\VLVZLQGRZV
RIWKH:HHNDQGYLVLWVVSHFLILHGLQ6HFWLRQ:KHQPXOWLSOHUHFRUGVDUHLQWKHDQDO\VLV
ZLQGRZRIDSRVWEDVHOLQHYLVLWWKHUXOHVVSHFLILHGLQ6HFWLRQ DUHDSSOLHG

$QDO\VLV0HWKRGVIRU6HFRQGDU\(IILFDF\(QGSRLQWV
6LPLODUZLWKWKHDQDO\VLVPHWKRGIRUWKHSULPDU\HIILFDF\HQGSRLQWWKHSULPDU\DQDO\VHVRIDOORI
WKHVHFRQGDU\HIILFDF\HQGSRLQWVZLOOEHFRQGXFWHGXVLQJWKH6DIHW\$QDO\VLV6HW

7UDQVIXVLRQ5HVSRQVH5DWH ൒ZHHNV
&DOFXODWLRQRI WKHWUDQVIXVLRQUHVSRQVH UDWHE\:HHN
݌଼̂ି்ி 100 ൈ
ܰݑܾ݉݁ݎ ݋݂ ܴ݁ݏ݌݋݊݀݁ݎݏ
ܶ݋ݐ݈ܽ ݊ݑܾ݉݁ݎ ݋݂ ݁݊ݎ݋݈݈݁݀ ݏݑܾ݆݁ܿݐݏ ݅݊ ݐ݄݁ ݂ܵܽ݁ݐݕ ܣ݈݊ܽݕݏ݅ݏ ܵ݁ݐ 
7KHGHQRPLQDWRUIRUFDOFXODWLRQRIWKHWUDQVIXVLRQ UHVSRQVH UDWHE\:HHNLQFOXGHV DOO
HQUROOHGVXEMHFWVLQ6DIHW\ $QDO\VLV6HW
7KHSURSRUWLRQ݌଼̂ି்ிZLWKDFRQYHQWLRQDOVLGHG100ሺ1 െߙሻH[DFWFRQILGHQFHOLPLWVEDVHG
RQ&ORSSHU3HDUVRQPHWKRG IRUELQRPLQDOGLVWULEXWLRQ ZLOOEHFDOFXODWHG

6SOHQLF5HVSRQVH5DWH DW:HHN
&DOFXODWLRQRI WKHVSOHQLFUHVSRQVHUDWHDW :HHN
݌̂௦௣௟௘௘௡ 
6HW
$QDO\VLV
6DIHW\
LQWKH
VXEMHFWV
HQUROOHG
RI
QXPEHU
7RWDO

DWZHHN
UHGXFWLRQ
XPH
VSOHHQYRO

ZLWK
VXEMHFWV
RI
1XPEHU

≥
×
7KH GHQRPLQDWRUIRUFDOFXODWLRQRIWKHVSOHQLFUHVSRQVHUDWHDW:HHNLQFOXGHV DOOHQUROOHG
VXEMHFWVLQ6DIHW\ $QDO\VLV6HW
,IVSOHHQYROXPH RIDVXEMHFW ZDVQRWDVVHVVHGE\05,VFDQEHWZHHQ6WXG\'D\ DQG'D\
LQFOXGLQJ'D\DQG'D\WKHVXEMHFWZLOOEHFRGHG DVDQRQUHVSRQGHURIVSOHQLF UHVSRQVH
6XEMHFWVZKRGLVFRQWLQXHIURPWKHWUHDWPHQWEHIRUH:HHNDQGPLVV WKH:HHNVSOHHQ
YROXPH PHDVXUHPHQWZLOODOVREHFRQVLGHUHGDVDQRQUHVSRQGHU
7KHSURSRUWLRQ ݌ෝ௦௣௟௘௘௡ZLWKDFRQYHQWLRQDOVLGHG100ሺ1 െߙሻH[DFWFRQILGHQFHOLPLWVEDVHG
RQ&ORSSHU3HDUVRQPHWKRG IRUELQRPLQDOGLVWULEXWLRQ ZLOOEHFDOFXODWHG


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU

5HVSRQVH5DWHLQ766
&DOFXODWLRQRI WKH766UHVSRQVHUDWHDW :HHN
݌்̂ௌௌ 
×

6HW
$QDO\VLV
6DIHW\
LQWKH
766
EDVHOLQH
PLVVLQJ

QRQ
ZLWK
VXEMHFWV
HQUROOHG
RI
QXPEHU
7RWDO

DWZHHN
UHGXFWLRQ
766

ZLWK
VXEMHFWV
RI
1XPEHU
≥
5HVSRQVHUDWHLQ766DW:HHNZLOOEHDQDO\]HGIRUVXEMHFWVZKRKDYHDEDVHOLQH766!RU
VXEMHFWVZKRKDYHDEDVHOLQH766 EXWQRQ]HURRUPLVVLQJ766DW:HHN 6XEMHFWVZLWK
PLVVLQJ:HHN766ZLOOEHFRQVLGHUHGDVQRQUHVSRQGHUV
7KHSURSRUWLRQ݌்̂ௌௌZLWKDFRQYHQWLRQDOVLGHG100ሺ1 െߙሻH[DFWFRQILGHQFHOLPLWVEDVHG
RQ&ORSSHU3HDUVRQPHWKRG IRUELQRPLQDOGLVWULEXWLRQ ZLOOEHFDOFXODWHG

&KDQJHLQ+HSFLGLQ
'HVFULSWLYHVXPPDU\VWDWLVWLFVZLOOEHSURYLGHGIRUDFWXDO YDOXHFKDQJH DQGFKDQJHIURP
EDVHOLQHIRUKHSFLGLQPHDVXUHGDWSUHGRVHDQGKRXUVSRVWGRVHRIHDFKVWXG\YLVLWE\7,
UHVSRQVH([SORUDWRU\SORWVVXFKDVPHGLDQ,45SORWRIKHSFLGLQYDOXH E\YLVLWDQG7,UHVSRQVH
PD\EHSURYLGHG
$OLQHDUPL[HGHIIHFWVPRGHOPD\ EHILWWHGWRFKDQJHIURPEDVHOLQHIRUKHSFLGLQZLWK YLVLWWLPH
SRLQW DQG7,UHVSRQVHDVWKHIL[HGHIIHFWVDQGVXEMHFWDVWKHUDQGRPHIIHFWV/HDVWVTXDUHPHDQ
HVWLPDWH DQGVLGHG 100ሺ1 െߙሻFRQILGHQFHLQWHUYDOV&,ZLOOEHFDOFXODWHG IRU FKDQJHIURP
EDVHOLQHRIKHSFLGLQDWWKHSUHGRVHDQGKRXUSRVWGRVHWLPHSRLQWDWHDFKSRVWEDVHOLQHVWXG\
YLVLW ,IQHFHVVDU\ORJWUDQVIRUPDWLRQPD\EHDSSOLHGWRKHSFLGLQYDOXH
'HVFULSWLYHVXPPDU\VWDWLVWLFVZLOOEHSURYLGHGIRUGDLO\KHSFLGLQFKDQJHFKDQJH DQGFKDQJH
IURPEDVHOLQHIRUGDLO\KHSFLGLQFKDQJHE\VWXG\YLVLWDQG 7,UHVSRQVH([SORUDWRU\SORWVVXFK
DVPHGLDQ,45SORWRI FKDQJHIURPEDVHOLQHRIGDLO\ KHSFLGLQ FKDQJHE\YLVLWDQG7,
UHVSRQVH PD\EHSURYLGHG
$OLQHDUPL[HGHIIHFWPRGHOPD\EHILWWHGWRFKDQJHIURPEDVHOLQHIRUGDLO\ KHSFLGLQFKDQJH
ZLWKYLVLW DQG7,UHVSRQVHDVWKHIL[HGHIIHFWVDQGVXEMHFWDVWKHUDQGRPHIIHFWV/HDVWVTXDUH
PHDQVDQGVLGHG100ሺ1 െߙሻFRQILGHQFHLQWHUYDOV&,ZLOOEHFDOFXODWHGIRUFKDQJHIURP
EDVHOLQHRIGDLO\ KHSFLGLQ FKDQJHDWHDFKSRVWEDVHOLQHVWXG\YLVLW ,IQHFHVVDU\ORJ
WUDQVIRUPDWLRQPD\EHDSSOLHGWRGDLO\KHSFLGLQFKDQJH

%DVHOLQHDQG&KDQJHLQ$QHPLD5HODWHG%LRPDUNHUV
'HVFULSWLYHVXPPDU\VWDWLVWLFVZLOOEHSURYLGHGIRUDFWXDOYDOXHFKDQJH DQGFKDQJHIURP
EDVHOLQHRIDQHPLDUHODWHGELRPDUNHUVE\YLVLW DQG7,UHVSRQVH([SORUDWRU\SORWVVXFKDV
PHGLDQ,45SORWRIFKDQJHIURPEDVHOLQHRIDQHPLDUHODWHGELRPDUNHUVE\ YLVLWDQG7,
UHVSRQVH PD\EHSURYLGHG


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 38
16 October 2017
6.2.2.6.
Change in Liver Iron Content
Descriptive summary statistics will be provided for actual value, change, and % change from 
baseline of liver iron content by visit and TI response. 
6.2.2.7.
Change in C-reactive Protein
Descriptive summary statistics will be provided for actual value, change, and % change from 
baseline of C-reactive protein by visit and TI response. Exploratory plots, such as median-IQR 
plot of % change from baseline of C-reactive protein by visit and TI response, may be provided. 
6.2.2.8.
Change in Pharmacodynamics Biomarker pSTAT3
Descriptive summary statistics will be provided for actual value, change, and % change from 
baseline of pSTAT3 at each time point and visit. Exploratory plots, such as median -IQR plot of 
% change from baseline of pSTAT3 by visit may be provided. 
6.3.
Exploratory Efficacy Endpoint
6.3.1.
Definition of Exploratory Efficacy Endpoints
6.3.1.1.
Duration of TI Response (DOR-TI) 
Duration of TI response is defined as the interval from the first onset date of TI response to the 
earliest onset date of loss of TI response or censoring date among subjects who achieved TI 
response, ie, duration of TI response (weeks) = (date of loss of TI response or censoring – date of 
first TI response + 1) / 7. The loss of TI response is defined as the date of the first transfusion 
post the TI response. Subjects who remain TI will be censored at the last participation date.
Duration of TI response will be summarized using Kaplan-Meier method. Number of subjects 
with events and subjects censored, median, Q1, Q3, and min and max estimates will be 
presented. 
6.3.1.2.
Time to TI Response (TtTI) 
Time to TI response (TtTI) among subjects who achieved TI response is defined as the interval 
from the date of the first dose of MMB administration to the first onset date of TI response, ie, 
time to TI (weeks) = (the date of first TI response onset – date of the first dose of MMB + 1) / 7.  
No censoring is needed
Time to TI response will be summarized through descriptive statistics (n, mean, StD, median,
Q1, Q3, minimum, and maximum).
6.3.1.3.
Leukemia-Free Survival
Leukemia-free survival (LFS) is defined as the interval first dose date to the date of first 
documented leukemic transformation or death from any cause, ie, LFS (weeks) = (date of 
censoring or date of earliest of leukemic transformation or death – first dose date + 1) / 7. 
Leukemic transformation was documented in long-term follow up and AE eCRF page. Leukemic 
transformation related AE PTs are listed in Appendix 6.   


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU

%RQH0DUURZ)LEURVLV6FRUH
%RQHPDUURZILEURVLVLPSURYHPHQWLVUHGXFWLRQLQERQHPDUURZILEURVLVVFRUHE\RQHRUPRUH
WKDQRQHJUDGH

$QDO\VLV0HWKRGVIRU([SORUDWRU\(IILFDF\(QGSRLQWV
7LPHWRHYHQW HQGSRLQWVZLOOEHVXPPDUL]HGXVLQJ.DSODQ0HLHUPHWKRGZLWKH[FHSWLRQWKDW
7W7,ZLOOEHVXPPDUL]HGWKURXJKGHVFULSWLYHVWDWLVWLFVQPHDQ6W'PHGLDQ44PLQLPXP
DQGPD[LPXP1XPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWKHYHQWVDQGFHQVRUHGVXEMHFWVPHGLDQV
DQGUDQJHVRIVXUYLYDOWLPHZLOOEHSUHVHQWHG $SORWRIWKH.DSODQ0HLHUFXUYHVZLOOEH
SURYLGHG&HQVRULQJIRUHDFKWLPHWRHYHQWHQGSRLQWVZDVVSHFLILHGLQ6HFWLRQ 
)RUERQHPDUURZILEURVLVVFRUHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFKJUDGHZLOOEH
SURYLGHG1XPEHUDQGSHUFHQWDJHRIVXEMHFWVZKRVHERQHPDUURZILEURVLVLPSURYHGWRJUDGH
IURPEDVHOLQHERQHPDUURZILEURVLVJUHDWHUWKDQJUDGHZLOODOVREHSURYLGHG,PSURYLQJUDWH
GHILQHGDVSURSRUWLRQ RIVXEMHFWVZLWKERQHPDUURZILEURVLVLPSURYHPHQW DPRQJVXEMHFWVZLWK
QRQPLVVLQJEDVHOLQHERQHPDUURZILEURVLVVFRUH ZLOOEHFDOFXODWHG DFRQYHQWLRQDOVLGHG
100ሺ1 െߙሻH[DFWFRQILGHQFHOLPLWVEDVHGRQ&ORSSHU3HDUVRQPHWKRG IRUELQRPLQDO
GLVWULEXWLRQ ZLOOEHFDOFXODWHGZKHUH ߙLVWKHFRQILGHQFHOHYHO
&RUUHVSRQGLQJOLVWLQJVZLOOEHSURYLGHG

&KDQJHV)URP3URWRFRO6SHFLILHG(IILFDF\$QDO\VHV
3KDUPDFRNLQHWLFVSDUDPHWHUV&PD[&ODVW&WDXDQG$8&ODVWLIDYDLODEOHIRU00%PHQWLRQHGLQ
3URWRFRO6HFWLRQKDYHEHHQUHPRYHGDVDQDQDO\VLVHQGSRLQWLQWKH6$3 GXHWRWKHVSDUVH
3.VDPSOHVFROOHFWLRQ
&KDQJHLQFLUFXODWLQJF\WRNLQHDQGLQIODPPDWRU\PDUNHUVHJ,/ ,/,)1JDPPD
71)DOSKD KDYHEHHQUHPRYHGDVDQDQDO\VLVHQGSRLQWLQWKH6$3
7KHIROORZLQJH[SORUDWRU\HQGSRLQWV KDYHEHHQUHPRYHGDVDQDO\VLVHQGSRLQWVLQWKH 6$3
•
%DVHOLQHDQGFKDQJHLQPDUNHUVRIRUWKRJRQDORUSDUDOOHOVLJQDOLQJSDWKZD\V
HJ 5$60$3.3,.$.7
•
%DVHOLQHDQGFKDQJHLQJHQHH[SUHVVLRQSURILOHVLQZKROHEORRGDQGVRPDWLFPXWDWLRQVLQ
ZKROHEORRGLIDSSOLFDEOH
•
%DVHOLQHDQGFKDQJHLQLPPXQHVXEVHWVLQZKROHEORRG
•
&KDQJHLQH[SORUDWRU\SKDUPDFRG\QDPLFVPDUNHUVRIVLJQDOLQJPHGLDWHGE\-$.DQGRU
-$.HJS67$7S67$7DQGS67$7


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 40
16 October 2017
7.
SAFETY ANALYSES
7.1.
Adverse Events and Deaths
7.1.1.
Adverse Event Dictionary
Clinical and laboratory adverse events (AEs) will be coded using the current version of 
MedDRA. System organ class (SOC), preferred term (PT) will be provided in the AE dataset.
7.1.2.
Adverse Event Severity
Adverse events are graded by the investigator as Grade 1 (mild), 2 (moderate), 3 (severe), 
4 (life-threatening), or 5 (fatal) according to the Common Terminology Criteria for Adverse 
Events [CTCAE] Version 4.03. The severity grade of events for which the investigator did not 
record severity will be categorized as “missing” for tabular summaries and data listings. The
missing category will be listed last in summary presentation.
7.1.3.
Relationship of Adverse Events to MMB
Related AEs are those for which the investigator selected “Related” on the AE case report form 
(CRF) to the question of “Related to Study Treatment.” Relatedness will always default to the 
investigator’s choice, not that of the medical monitor. Events for which the investigator did not 
record relationships to MMB will be considered related to MMB for summary purposes. 
However, by-subject data listings will show the relationship as missing from that captured on the 
CRF.
7.1.4.
Serious Adverse Events
Serious adverse events (SAEs) will be identified and captured as SAEs if AEs met the definition 
of an SAE specified in the study protocol. Serious adverse events captured and stored in the 
clinical database will be reconciled with the SAE database from the Gilead Drug Safety and 
Public Health Department before database finalization.
7.1.5.
Treatment-Emergent Adverse Events
7.1.5.1.
Definition of Treatment Emergent
Treatment-emergent adverse events (TEAEs) are defined as 1 or both of the following:

Any AEs with an onset date on or after the MMB start date and no later than 30 days after 
permanent discontinuation of MMB.

Any AEs leading to premature discontinuation of MMB.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 41
16 October 2017
7.1.5.2.
Incomplete Dates
If the onset date of the AE is incomplete and AE stop date is not prior to the first dosing date of 
MMB, the month and year (or year alone if month is missing too) of onset determine whether an 
AE is treatment emergent. The AE is considered treatment emergent if both of the following 
2 criteria are met:

The AE onset is the same as or after the month and year (or year) of the first dosing date of 
MMB, and

The AE onset date is the same as or before the month and year (or year) of the date 
corresponding to 30 days after the date of the last dose of MMB.
An AE with completely missing onset and stop dates, or with the onset date missing and a stop 
date later than the first dosing date of MMB, will be considered to be treatment emergent.
7.1.6.
Summaries of Adverse Events and Deaths
A brief high-level summary of TEAEs will be provided by the number and percentage of 
subjects who had the following: any AE; any AE of Grade 3 or above; any treatment-related AE;
any treatment-related AE of Grade 3 or above; any SAE; any treatment-related SAE; any AE that 
led to premature discontinuation of MMB; and any AE that led to premature discontinuation of 
study; and any AE of interest. All deaths (including those that are treatment emergent and those 
that are not treatment emergent) observed will also be summarized and included in this table.
Adverse event summaries will provide the number and percentage of subjects with TEAEs by 
SOC, PT and Severity, using the Safety Analysis Set as follows:

All AEs (by SOC, PT and Severity)

All AEs of Grade 3 or above

All treatment-related AEs

All treatment-related AEs of Grade 3 or above

All SAEs

All treatment-related SAEs 

All AEs leading to premature discontinuation of MMB

All AEs leading to a temporary interruption of MMB

All AEs leading to a dose reduction of MMB


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 42
16 October 2017

All AEs leading to death (i.e., outcome of death)

All AEs of interest 
Peripheral Neuropathy SMQ (narrow terms only)
Cataract 
First Dose Effect AE (defined as AE with PT of Dizziness, Flushing, Hot Flush, Headache, 
Hypotension, or Nausea, which occurred on the day of the first dosing date and resolved by the 
next day)In addition, all AEs recorded between screening and first dose of study drug will also 
be summarized for the Safety Analysis Set.
Multiple events will be counted only once per subject in each summary. The AEs will be 
summarized and listed first by SOC in descending order of incidence and then by PT, also in 
descending order of incidence, within each SOC of the investigational MMB group. For 
summaries by severity, the most severe grade will be used for those AEs that occurred in a given 
subject more than once during the study. 
In addition to the presentation by SOC and PT, summaries will also be presented by PT only, 
ordered by decreasing total frequency for TEAEs that occurred in at least 5% of subjects within 
any treatment group, treatment-related TEAEs leading to discontinuation of IPs; TEAEs leading 
to dose modification or interruption of IP; treatment-emergent SAEs; and TEAEs of Grade >= 3 
or above.
Summary of all TEAEs will also be presented by SOC, and PT for the following subgroups: 
gender (Male or Female), age group (<65 or >=65 years) and race (White or Non-White).
In addition to the summaries described above, data listings will be provided for the following:

All AEs (with a variable indicating whether the event is treatment emergent)

All AEs of Grade 3 or above

SAEs

Deaths

All SAEs leading to death

AEs leading to premature discontinuation of study drug

AEs leading to premature discontinuation of study

AEs leading to Dose interruption or modification of study drug


0RPHORWLQLE
*686
6WDWLVWLFDO$QDO\VLV3ODQ± )LQDO$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH
2FWREHU
•
$(UHODWHGWRVWXG\GUXJ
•
$(V RILQWHUHVW
⎯3HULSKHUDO1HXURSDWK\604 QDUURZ WHUPV RQO\
⎯&DWDUDFW
⎯)LUVW'RVH(IIHFW

$GGLWLRQDO$QDO\VLVRI$GYHUVH(YHQWV

([SRVXUH$GMXVWHG7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV5DWH
7KHH[SRVXUHDGMXVWHG7($(UDWHLVGHILQHGDVWKHQXPEHU RIVXEMHFWVZLWKDVSHFLILFHYHQW
GLYLGHGE\WKHWRWDOH[SRVXUHWLPHDPRQJWKHVXEMHFWVLQWKHWUHDWPHQWJURXSDQGDWULVNRIDQ
LQLWLDORFFXUUHQFHRIWKHHYHQW6SHFLILFDOO\
ZKHUHQLVWKHQXPEHU RIVXEMHFWVZLWKHYHQWVݐ௜LVWKHLQWHUYDO\HDUVIURPILUVWGRVLQJGDWHRI
VWXG\GUXJWRWKHRQVHWRIILUVWHYHQWIRUVXEMHFWVZLWKHYHQWVRUZLOOEHFHQVRUHGDWWKHWLPHRI
WKHODVWSDUWLFLSDWLRQGDWHRUGHDWKGDWHRUGDWDFXWRIIGDWH ZKLFKHYHULVHDUOLHVW IRUVXEMHFWV
ZLWKRXWHYHQWV
7KHH[SRVXUHDGMXVWHG7($(UDWHZLOOEHVXPPDUL]HG IRUDOO7($(V6$(V *UDGH$(V

7LPHWR2QVHWRI$(RI,QWHUHVW3HULSKHUDO1HXURSDWK\7($(V
7LPHWRRQVHWRI$(RILQWHUHVWLVGHILQHGDVWKHLQWHUYDOIURPWKHILUVWGRVHRIVWXG\GUXJWRWKH
RQVHWGDWHRIWKHILUVWHYHQWRIWKH$(RILQWHUHVWLHFDOFXODWHGDVWKHRQVHWGDWHRIWKHILUVW
HYHQWRIWKH$(RILQWHUHVWRUFHQVRULQJGDWH± GDWHRIWKHILUVWGRVHRIVWXG\GUXJ,QWKH
DEVHQFHRIWKHRFFXUUHQFHRIWKH$(RILQWHUHVWWKHFHQVRULQJGDWHLVWKHODVWSDUWLFLSDWLRQGDWH
RUGHDWKGDWHRUGDWDFXWRIIGDWH ZKLFKHYHULVHDUOLHVW IRUVXEMHFWVZLWKRXWHYHQWV
6XPPDU\DQG.DSODQ0HLHUSORWZLOOEHSURYLGHGIRUSHULSKHUDOQHXURSDWK\7($(VQDUURZ
WHUPRQO\

7LPHWR5HVROXWLRQRI$(RI,QWHUHVW3HULSKHUDO1HXURSDWK\7($(V
7LPHWRUHVROXWLRQRI$(RILQWHUHVWLVGHILQHGDVWKHLQWHUYDOIURPWKHRQVHWGDWHRIWKH
ILUVW HYHQWRIWKH$(RILQWHUHVWWRWKHWLPHWKDWWKHODVWHYHQWRIWKH$(RILQWHUHVWLVUHVROYHG
LH FDOFXODWHGDVWKHUHVROXWLRQGDWHRIWKHODVWHYHQWRIWKH$(RILQWHUHVWRUFHQVRULQJGDWH± WKH
RQVHWGDWHRIWKHILUVWHYHQWRIWKH$(RILQWHUHVW,QWKHDEVHQFHRIWKHUHVROXWLRQRIWKH$(
RILQWHUHVWWKHFHQVRULQJGDWHLVWKHODVWSDUWLFLSDWLRQGDWHRUGHDWKGDWHRUGDWDFXWRIIGDWH
ZKLFKHYHULVHDUOLHVW


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 44
16 October 2017
Summary and Kaplan-Meier plot will be provided for peripheral neuropathy TEAEs (narrow 
term only). 
7.2.
Laboratory Evaluations
Laboratory data collected during the study will be analyzed and summarized using both 
quantitative and qualitative methods. Summaries of laboratory data will be provided for the 
Safety Analysis Set. The analysis will be based on values reported in conventional units. When 
values are below the limit of quantitation, they will be listed as such, and the closest imputed 
value will be used for the purpose of calculating summary statistics. Hemolyzed test results will 
not be included in the analysis, but they will be listed in by-subject laboratory listings.
A by-subject listing for laboratory test results will be provided by subject ID number and visit in 
chronological order for hematology, serum chemistry, urinalysis and thiamine separately. Values 
falling outside of the relevant reference range and/or having a severity grade of 1 or higher on 
the CTCAE severity grade will be flagged in the data listings, as appropriate.
No inferential statistics will be generated.
7.2.1.
Graded Laboratory Values
CTCAE Version 4.03 will be used for assigning toxicity grades (0 to 4) to laboratory results for 
analysis except for anemia (hemoglobin, Hgb) which will be graded using the CTCAE Version 
3.0 as defined in Table 7-1. Grade 0 includes all values that do not meet the criteria for an 
abnormality of at least Grade 1. Some laboratory tests have criteria for both increased and 
decreased levels; analyses for each direction (i.e., increased, decreased) will be presented 
separately. 
Table 7-1.
Grading of Hemoglobin Severity
Grade (CTCAE 3.0)
1
2
3
4
5
<LLN – 10.0 g/dL
<LLN – 6.2 mmol/L
<LLN – 100 g/L
<10.0 – 8.0 g/dL
<6.2 – 4.9 mmol/L
<100 – 80 g/L
<8.0 – 6.5 g/dL
<4.9 – 4.0 mmol/L 
<80 – 65 g/L 
<6.5 g/dL
<4.0 mmol/L
<65 g/L 
Death
7.2.1.1.
Treatment-Emergent (TE) Laboratory Abnormalities
Treatment-emergent laboratory abnormalities are defined as values that increase at least 
1 toxicity grade from baseline at any post-baseline time point, up to and including the date of last 
dose of MMB plus 30 days for subjects who permanently discontinued MMB. If the relevant 
baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the 
time frame specified above will be considered treatment emergent.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 45
16 October 2017
7.2.1.2.
Treatment-Emergent Marked Laboratory Abnormalities
Treatment-emergent marked laboratory abnormalities are defined as values that increase from 
baseline by at least 3 toxicity grades at any post-baseline time point, up to and including the date 
of the last dose of MMB plus 30 days for subjects who permanently discontinued MMB. If the 
relevant baseline laboratory value is missing, any Grade 3 or 4 values observed within the 
timeframe specified above will be considered treatment-emergent marked abnormalities.
7.2.1.3.
Summaries of Laboratory Abnormalities
The following summaries (number and percentage of subjects) for treatment-emergent laboratory 
abnormalities will be provided by lab test; subjects will be categorized according to the most 
severe post-baseline abnormality grade for a given lab test:

All laboratory abnormalities

Grade 3 or 4 laboratory abnormalities

Marked laboratory abnormalities
For all summaries of laboratory abnormalities, the denominator is the number of subjects with 
nonmissing post-baseline values.
A by-subject listing of treatment-emergent Grade 3 or 4 laboratory abnormalities or marked 
laboratory abnormalities, if abnormalities were not graded will be provided by subject ID 
number and visit in chronological order. This listing will include all test results that were 
collected throughout the study for the lab test of interest, with all applicable severity grades or 
abnormal flags displayed.
7.2.2.
Shifts Relative to the Baseline Value
Shift tables will be presented by showing change in CTCAE severity grade from baseline to the 
worst grade post-baseline grade. For lab tests for which a severity scale does not exist, shift 
tables will be presented showing change in results from baseline value (low, normal and high) to 
the worst post-baseline value (low, normal, high and “high & low”, where “high & low” is for 
lab tests with both high and low values at post-baseline visits).
7.3.
Body Weight
Descriptive statistics (n, mean, StD, median, Q1, Q3, minimum, and maximum) will be provided 
for body weight as follows:

Baseline value

Values at each post-baseline time point 

Change from baseline at each post-baseline time point 


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 46
16 October 2017

Post-baseline maximum value

Change from baseline to post-baseline maximum value

Post-baseline minimum value

Change from baseline to post-baseline minimum value
A baseline value will be defined as the last available value collected on or prior to the date/time 
of first dose of MMB. Change from baseline to a post-baseline visit will be defined as the post-
baseline value minus the baseline value. Body weight measured at unscheduled visits will be 
included for the baseline and post-baseline maximum and minimum value selection.
In the case of multiple values in an analysis window, data will be selected for analysis as 
described in Section 3.7.3. No inferential statistics will be generated.
Body weight will be summarized by grade, where grade is defined as follows: 
The maximum grade of post-baseline weight gain and weight loss will be calculated and 
summarized based on the below table per CTCAE 4.03: 
Post-baseline Maximum Grade of 
Weight Gain or Weight Loss
Grade
Criteria for Grade
Weight Gain
0
maximum % change from baseline < 5%
1
5% ≤  maximum % change from baseline < 10%
2
10% ≤  maximum % change from baseline < 20%
3
maximum % change from baseline  ≥ 20%
Weight Loss
0
-5% < minimum % change from baseline
1
-10% < minimum % change from baseline ≤ -5%
2
-20% <  minimum % change from baseline ≤ -10%
3
minimum  % change from baseline   ≤  -20%
7.4.
Prior and Concomitant Medications
Medications collected at screening and during the study will be coded using the current version
of the World Health Organization (WHO) Drug dictionary. The medications will be categorized 
as prior, concomitant, or both using the following definitions:

Prior medications: any medications taken and stopped prior to or on the initial MMB dosing
date based on the Prior and Concomitant Medication eCRF page

Concomitant medications: any medications taken after the initial MMB dosing date and up to 
the last dosing date of MMB


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 47
16 October 2017
7.4.1.
Prior Medications and Concomitant Medications
Prior medications and concomitant medications will be summarized by Anatomical Therapeutic 
Chemical (ATC) drug class Level 2, Level 4 and preferred name using the number and 
percentage of subjects for each treatment group and overall. A subject reporting the same 
medication more than once will be counted only once when calculating the number and 
percentage of subjects who received that medication. The summary will be ordered by 
descending overall frequency of ATC drug classes and then by preferred names within an ATC 
drug class of the MMB treatment. For drugs with the same frequency, sorting will be done 
alphabetically.
Summaries will be based on the Safety Analysis Set. No inferential statistics will be generated. 
For purposes of analysis, any medication with a stop date that is prior to or on the initial MMB
dosing date will be included in the prior medication summary. If a partial stop date is entered, 
any medication with the month and year (if day is missing) or year (if day and month are 
missing) prior to the initial MMB dosing date will be included in the prior medication summary.
All prior and concomitant medications (other than per-protocol study drugs) will be provided in a 
by-subject listing sorted by subject ID number and administration date in chronological order. 
7.5.
Electrocardiogram Results
Electrocardiogram (ECG) data will not be presented in the CSR since ECGs were not assessed in 
this study other than as part of the screening process for potential new subjects.
7.6.
Other Safety Measures
7.6.1.
Overall Survival (OS)
OS, for subjects who died while on study, is defined as the interval from the date of the first dose 
of study drug to the date of the death from any cause, ie, the date of death– the first dose date +1.
Data from surviving subjects (ie. subjects who do not die while on study) will be censored at the 
last date that subject was known to be alive, ie, the last study participation date. 
Overall survival will be summarized using the Kaplan-Meier method. A plot of the 
Kaplan-Meier curves will be provided. Number and percentage of subjects with events and 
censored subjects, medians and ranges of survival time will be presented.
A listing of overall survival will also be provided.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 48
16 October 2017
8.
PHARMACOKINETIC ANALYSES
The concentration data of MMB and major metabolite GS-644603 , will be listed and 
summarized by nominal sampling time using descriptive statistics by study visit if applicable. 
Summary statistics (n, mean, StD, coefficient of variation [%CV], median, min, max, Q1, and 
Q3) will be presented.  
Individual concentration data listings and summaries will include all subjects with concentration 
data. The sample size for each time point will be based on the number of subjects with 
nonmissing concentration data at that time point. The number of subjects with concentration 
BLQ will be presented for each time point. 
The following tables will be provided for each analyte:

Individual subject concentration data and summary statistics
The following figures may be provided for each analyte by visit:

Mean (± StD) concentration data versus time (on linear and semilogarithmic scales)

Median (Q1, Q3) concentration data versus time (on linear and semilogarithmic scales)

Individual, mean, and median postdose concentration values that are ≤ LLOQ will not be
displayed in the figures and remaining points connected.
The following listings will be provided:

PK sampling details by subject including deviations in scheduled and actual draw times and
procedures


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 49
16 October 2017
9.
REFERENCES
Clopper CJ, Pearson ES. The Use of Confidence or Fiducial Limits Illustrated in the Case of the 
Binomial. Dec. Biometrika 1934;26 (4):pp. 404-13.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 50
16 October 2017
10.
SOFTWARE
SAS® Software Version 9.2. SAS Institute Inc., Cary, NC, USA.
nQuery Advisor(R) Version X.0. Statistical Solutions, Cork, Ireland.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 51
16 October 2017
11.
SAP REVISION
Revision Date
(DD MMM YYYY)
Section
Summary of Revision
Reason for Revision


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 52
16 October 2017
12.
APPENDICES
Appendix 1.
Table of Contents for Statistical Tables, Figures, and Listings
Appendix 2.
Study Procedures Table
Appendix 3.
Peripheral Neuropathy SMQ AEs
Appendix 4.
Cataract MST AEs
Appendix 5.
Leukemic Transformation MST AEs
Appendix 6.
Validation document of hepcidin testing from Radboud University
Appendix 7.
Validation document of pSTAT testing from Covance


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 53
16 October 2017
Appendix 1.
Table of Contents for Statistical Tables, Figures, and Listings
TFL Number
Title1
Title2
Title3
15.8.1.1
Enrollment by Country, Region and Investigator
Safety Analysis Set
15.8.1.2
Subject Disposition
Safety Analysis Set
15.8.2.1
Eligibility Criteria Deviations
Safety Analysis Set
15.8.2.2
Important Protocol Deviations
Safety Analysis Set
15.8.3.1
Demographics
Safety Analysis Set
15.8.3.2
Baseline Characteristics
Safety Analysis Set
15.8.3.3
Prior Myelofibrosis Therapy
Safety Analysis Set
15.8.3.4
Myelofibrosis Disease History
Safety Analysis Set
15.8.4
Adherence to Study Drug Regimen
Safety Analysis Set
15.8.5
Analysis Sets
Safety Analysis Set
15.10.1
Summary of Plasma Concentration of MMB and 
GS-644603
Pharmacokinetic 
Analysis Set
15.11.1
Extent of Exposure to Study Drug 
Safety Analysis Set
15.11.2.1.1
TEAEs: Overall Summary
Safety Analysis Set
15.11.2.1.2
Exposure-Adjusted TEAEs: Overall Summary
Safety Analysis Set
15.11.2.1.3.1
TEAEs by PT Occurred in >=5% of Subjects
Safety Analysis Set
15.11.2.1.3.2
Exposure-Adjusted TEAEs by PT
Safety Analysis Set
15.11.2.1.4.1
TEAEs by SOC, PT, and Severity by Gender
Safety Analysis Set
15.11.2.1.4.2
TEAEs by SOC, PT, and Severity by Age Group
Safety Analysis Set
15.11.2.1.4.3
TEAEs by SOC, PT, and Severity by Race
Safety Analysis Set
15.11.2.2.1
TEAEs by SOC, PT, and Severity
Safety Analysis Set
15.11.2.2.2.1
TEAEs with Severity of Grade 3 or 4 by PT
Safety Analysis Set
15.11.2.2.2.2
TEAEs with Severity of Grade 3 or 4 by SOC, PT, 
and Severity
Safety Analysis Set
15.11.2.2.2.3
Exposure-Adjusted TEAEs with Severity of Grade 
3 or Above by PT
Safety Analysis Set
15.11.2.3
Treatment-Related TEAEs with Severity of Grade 3 
or Above by PT
Safety Analysis Set
15.11.2.4.1
TEAE Leading to Dose Reduction or Temporary 
Interruption of Study Drug (MMB) by SOC, PT, 
and Severity
Safety Analysis Set
15.11.2.4.2.1
TEAE of Peripheral Neuropathy SMQ (Narrow 
Terms only) by SOC, PT, and Severity
Safety Analysis Set
15.11.2.4.2.2
TEAE of Cataract MST by SOC, PT, and Severity
Safety Analysis Set


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 54
16 October 2017
TFL Number
Title1
Title2
Title3
15.11.2.4.3.1
Time to Onset of First Peripheral Neuropathy SMQ 
(Narrow Term Only) 
Safety Analysis Set
15.11.2.4.3.2
Time to Resolution of Peripheral Neuropathy SMQ 
(Narrow Term Only) 
Safety Analysis Set
15.11.2.4.4
TEAEs for First Dose Effect by PT
Safety Analysis Set
15.11.3
TEAEs Leading to Death by SOC,PT and Severity
Safety Analysis Set
15.11.4.1.1
Serious TEAEs by SOC, PT, and Severity
Safety Analysis Set
15.11.4.1.2
Serious TEAEs by PT
Safety Analysis Set
15.11.4.1.3
Exposure-Adjusted Serious TEAEs by PT
Safety Analysis Set
15.11.4.2
Treatment-Related Serious TEAEs by PT
Safety Analysis Set
15.11.4.3
Serious TEAEs for First Dose Effect by PT
Safety Analysis Set
15.11.5.1.1
TEAE Leading to Premature Discontinuation of 
Study Drug (MMB) by SOC, PT, and Severity
Safety Analysis Set
15.11.5.1.2
TEAE of Peripheral Neuropathy SMQ (Narrow 
Term Only) Leading to Study Drug (MMB) 
Discontinuation by SOC, PT, and Severity
Safety Analysis Set
15.11.6.1
Hematology: Shift from Baseline for Gradable 
Tests
Safety Analysis Set
15.11.6.2
Chemistry: Shift from Baseline for Gradable Tests
Safety Analysis Set
15.11.6.3
Urinalysis: Shift from Baseline for Gradable Tests
Safety Analysis Set
15.11.6.4.1
Treatment-Emergent Laboratory Abnormalities
Safety Analysis Set
15.11.6.4.2
Treatment-Emergent Grade 3 or 4 Laboratory 
Abnormalities
Safety Analysis Set
15.11.6.4.3
Treatment-Emergent Marked Laboratory 
Abnormalities
Safety Analysis Set
15.11.6.4.4
Exposure-Adjusted Treatment-Emergent 
Laboratory Abnormalities
Safety Analysis Set
15.11.6.4.5
Exposure-Adjusted Treatment-Emergent Marked 
Laboratory Abnormalities
Safety Analysis Set
15.11.7.1
Body Weight (kg) Change and % Change from 
Baseline
Safety Analysis Set
15.11.7.2
Summary of Change of Body Weight (kg) from 
Baseline by Grade
Safety Analysis Set
15.11.8.1
Prior Medications by Drug Class and Preferred 
Drug Name
Safety Analysis Set
15.11.8.2
Concomitant Medications by Drug Class and 
Preferred Drug Name
Safety Analysis Set


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 55
16 October 2017
TFL Number
Title1
Title2
Title3
15.12.1.1
Analysis of Transfusion Independent Response 
Rate by Week 24 and Week 12
Safety Analysis Set
15.12.1.2
Exploratory Analysis of Transfusion Independent 
Response Rate by Week 24 and Week 12 with 
Prognostic Factors
Safety Analysis Set
15.12.2
Analysis of Transfusion Response Rate by Week 24
Safety Analysis Set
15.12.3
Analysis of Splenic Response Rate at Week 24 
Safety Analysis Set
15.12.4
Analysis of Response Rate in TSS at Week 24
Safety Analysis Set
15.12.5.1
Analysis of Hepcidin Change from Baseline by TI 
Response
Biomarker 
Analysis Set
15.12.5.2
Analysis of Change from Baseline of Hepcidin 
Daily Change by TI Response
Biomarker 
Analysis Set
15.12.6.1
Anemia Markers: Change and % Change from 
Baseline by TI Response
Biomarker 
Analysis Set
15.12.6.2
Anemia Markers: Change after TI Response from 
before TI Response in TI Responders 
Biomarker 
Analysis Set
TI Responders 
15.12.6.3
Correlation of Anemia Markers in TI Responders 
Biomarker 
Analysis Set
TI Responders 
15.12.6.4
Anemia Markers: Change and % Change from 
Baseline by TI Response through Week 4
Biomarker 
Analysis Set
Subjects with No 
Transfusion 
through Week 4
15.12.7
Liver Iron Content Change and % Change from 
Baseline by TI Response
Biomarker 
Analysis Set
15.12.8
C-reactive Protein Change and % Change from 
Baseline by TI Response
Biomarker 
Analysis Set
15.12.9
Pharmacodynamics Biomarker pSTAT3 Change 
and % Change from Baseline
Biomarker 
Analysis Set
15.12.10.1
Analysis of Duration of Transfusion Independent 
Response
Safety Analysis Set
15.12.10.2
Analysis of Time to Transfusion Independent (TI)
Safety Analysis Set
15.12.10.3
Analysis of Overall Survival
Safety Analysis Set
15.12.10.4
Analysis of Leukemia-Free Survival 
Safety Analysis Set
15.12.10.5
Analysis of Bone Marrow Fibrosis Score
Safety Analysis Set
15.12.10.6
Efficacy Profile (Spleen, TSS, Transfusion 
Independent Response Status) by Week 24
Safety Analysis Set
15.8
Disposition of Study Subjects
Safety Analysis Set
15.12.3
Waterfall Plots for % Change from Baseline in 
Spleen Volume at Week 24 
Safety Analysis Set


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 56
16 October 2017
TFL Number
Title1
Title2
Title3
15.12.4
Waterfall Plots for Change and  % Change in 
Average of TSS by Treatment at Week 24
Safety Analysis Set
15.12.5.1
Median (Q1, Q3) plot of Hepcidin by Visit
Biomarker 
Analysis Set
15.12.5.2
Median (Q1, Q3) plot of % Change of Hepcidin by 
Visit
Biomarker 
Analysis Set
15.12.5.3
Median (Q1, Q3) plot of Hepcidin by Visit and TI 
Response
Biomarker 
Analysis Set
15.12.5.4
Median (Q1, Q3) plot of % Change of Hepcidin by 
Visit and TI Response
Biomarker 
Analysis Set
15.12.5.5
Median (Q1, Q3) plot of Daily Hepcidin Change by 
Visit
Biomarker 
Analysis Set
15.12.5.6
Median (Q1, Q3) plot of % Change of Daily 
Hepcidin Change by Visit
Biomarker 
Analysis Set
15.12.5.7
Median (Q1, Q3) plot of Daily Hepcidin Change by 
Visit and TI Response
Biomarker 
Analysis Set
15.12.5.8
Median (Q1, Q3) plot of % Change of Daily 
Hepcidin Change by Visit and TI Response
Biomarker 
Analysis Set
15.12.6.1
Median (Q1, Q3) plot of Anemia Biomarkers by 
Visit
Biomarker 
Analysis Set
15.12.6.2
Median (Q1, Q3) plot of % Change from Baseline 
of Anemia Biomarkers by Visit
Biomarker 
Analysis Set
15.12.6.3
Median (Q1, Q3) plot  of Anemia Biomarkers by 
Visit and TI Response
Biomarker 
Analysis Set
15.12.6.4
Median (Q1, Q3) plot of % Change from Baseline 
of Anemia Biomarkers by Visit and TI Response
Biomarker 
Analysis Set
15.12.6.5
Median (Q1, Q3) plot of Anemia Biomarkers by 
Time for TI Responders
Biomarker 
Analysis Set
TI Responders 
15.12.6.6
Median (Q1, Q3) plot of % Change from Pre-TI 
Response of Anemia Biomarkers by Time for TI 
Responders
Biomarker 
Analysis Set
TI Responders 
15.12.6.7
Median (Q1, Q3) plot of Anemia Biomarkers by 
Visit through Week 4
Biomarker 
Analysis Set
Subjects with No 
Transfusion 
through Week 4
15.12.6.8
Median (Q1, Q3) plot of % Change from Baseline 
of Anemia Biomarkers by Visit through Week 4
Biomarker 
Analysis Set
Subjects with No 
Transfusion 
through Week 4
15.12.6.9
Median (Q1, Q3) plot of Anemia Biomarkers by 
Visit and TI Response through Week 4
Biomarker 
Analysis Set
Subjects with No 
Transfusion 
through Week 4


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 57
16 October 2017
TFL Number
Title1
Title2
Title3
15.12.6.10
Median (Q1, Q3) plot of % Change from Baseline 
of Anemia Biomarkers by Visit and TI Response 
through Week 4
Biomarker 
Analysis Set
Subjects with No 
Transfusion 
through Week 4
15.12.6.11
Forest Plot of Anemia Biomarker Difference at 
Baseline between TI Responders and Non-
responders
Biomarker 
Analysis Set
15.12.6.12
Forest Plot of Anemia Biomarker % Change from 
Pre-TI Response for TI Responders
Biomarker 
Analysis Set
TI Responders 
15.12.8
Median (Q1, Q3) plot of % Change from Baseline 
of C-reactive Protein by Visit
Biomarker 
Analysis Set
15.12.9
Median (Q1, Q3) plot of % Change from Baseline 
of pSTAT3 by Visit
Biomarker 
Analysis Set
15.12.10.1
Venn Diagram of Spleen Response, TSS Response 
and TI response at Week 24
Safety Analysis Set
15.12.10.2
Kaplan-Meier Plot for Overall Survival
Safety Analysis Set
15.12.10.3
Kaplan-Meier Plot for Leukemia-Free Survival 
(LFS)
Safety Analysis Set
15.13.2
Median (Q1, Q3) Plot Plasma Concentration of 
MMB and GS-644603 (Linear Scale and 
Semilogarithmic Scale)
Pharmacokinetic 
Analysis Set
16.1.6
Subjects Who Received Study Drug(s) from 
Specific Batches
Safety Analysis Set
16.2.1.1
Subject Profiles
Safety Analysis Set
16.2.1.2
Enrollment
Safety Analysis Set
16.2.1.3
Subject Disposition
Safety Analysis Set
16.2.1.4
Reasons for Screen Failure
Subjects Screened 
But Not Enrolled
16.2.2.1
Eligibility Criteria Deviations
Safety Analysis Set
16.2.2.2
Important Protocol Deviations
Safety Analysis Set
16.2.3
Subjects Excluded From Any Analysis Set
Safety Analysis Set
16.2.4.1
Demographics
Safety Analysis Set
16.2.4.2.1
Baseline Characteristics Part I
Safety Analysis Set
16.2.4.2.2
Baseline Characteristics Part II
Safety Analysis Set
16.2.4.2.3
Baseline Characteristics Part III
Safety Analysis Set
16.2.4.3
Medical History
Safety Analysis Set
16.2.4.4
Myelofibrosis Medical History
Safety Analysis Set
16.2.4.5
Prior Medications
Safety Analysis Set
16.2.4.6
Concomitant Medications
Safety Analysis Set


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 58
16 October 2017
TFL Number
Title1
Title2
Title3
16.2.4.7
Prior Myelofibrosis Therapy
Safety Analysis Set
16.2.5.1
Study Drug Administration
Safety Analysis Set
16.2.5.2
Subjects Who Prematurely Discontinued Study 
Drug
Safety Analysis Set
16.2.5.3
Study Drug Accountability
Safety Analysis Set
16.2.5.4
Plasma Pharmacokinetic Sampling Details and 
Concentrations
Safety Analysis Set
16.2.7.1.1
Adverse Events
Safety Analysis Set
16.2.7.1.2
Adverse Events for Peripheral Neuropathy SMQ
Safety Analysis Set
16.2.7.1.3
Adverse Events for Cataract MST
Safety Analysis Set
16.2.7.1.4
Adverse Events for First Dose Effect
Safety Analysis Set
16.2.7.2.1
Deaths
All Screened 
Subjects
16.2.7.2.2
Adverse Events Leading to Death
Safety Analysis Set
16.2.7.3
Serious Adverse Events
Safety Analysis Set
16.2.7.4
Adverse Events with Severity of Grade 3 or Above
Safety Analysis Set
16.2.7.5.1
Adverse Events Leading to Premature 
Discontinuation of Study Drug
Safety Analysis Set
16.2.7.5.2
Adverse Events Leading to Dose Reduction or 
Temporary Interruption of Study Drug
Safety Analysis Set
16.2.8.1.1.1
Hematology Results Part 1
Safety Analysis Set
16.2.8.1.1.2
Hematology Results Part 2
Safety Analysis Set
16.2.8.1.1.3
Hematology Results Part 3
Safety Analysis Set
16.2.8.1.1.4
Hematology Results Part 4
Safety Analysis Set
16.2.8.1.1.5
Hematology Results Part 5
Safety Analysis Set
16.2.8.1.1.6
Hematology Results Part 6
Safety Analysis Set
16.2.8.1.2.1
Serum Chemistry Results Part 1
Safety Analysis Set
16.2.8.1.2.2
Serum Chemistry Results Part 2
Safety Analysis Set
16.2.8.1.2.3
Serum Chemistry Results Part 3
Safety Analysis Set
16.2.8.1.2.4
Serum Chemistry Results Part 4
Safety Analysis Set
16.2.8.1.2.5
Serum Chemistry Results Part 5
Safety Analysis Set
16.2.8.1.3.1
Urinalysis Results Part 1
Safety Analysis Set
16.2.8.1.3.2
Urinalysis Results Part 2
Safety Analysis Set
16.2.8.1.3.3
Urinalysis Results Part 3
Safety Analysis Set
16.2.8.1.3.4
Urinalysis Results Part 4
Safety Analysis Set


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 59
16 October 2017
TFL Number
Title1
Title2
Title3
16.2.8.1.4
Iron Test Results
Safety Analysis Set
16.2.8.1.5
Treatment-Emergent Marked Laboratory 
Abnormalities
Safety Analysis Set
16.2.8.1.6
Treatment-Emergent Grade 3 or Above Laboratory 
Abnormalities
Safety Analysis Set
16.2.8.2.1
Vital Signs
Safety Analysis Set
16.2.8.2.2
Body Weight and Height
Safety Analysis Set
16.2.8.3
Pregnancy Report
Safety Analysis Set
16.3.1
Spleen Volume Measurement
Safety Analysis Set
16.3.2.1
Response of TSS
Safety Analysis Set
16.3.2.2
TSS Measurement
Safety Analysis Set
16.3.2.3
Individual Score of MPN-SAF 2.0 by Every 4 
Weeks
Safety Analysis Set
16.3.3.1
RBC Transfusion 
Safety Analysis Set
16.3.3.2
Transfusion Independent/Dependent by Week 24
Safety Analysis Set
16.3.3.3
Duration of Transfusion Independent for Subjects 
Safety Analysis Set
16.3.4.1
Hepcidin
Biomarker 
Analysis Set
16.3.4.2.1
Anemia Biomarkers Part 1
Biomarker 
Analysis Set
16.3.4.2.2
Anemia Biomarkers Part 2
Biomarker 
Analysis Set
16.3.4.2.3
Anemia Biomarkers for TI Responder Part 1
Biomarker 
Analysis Set
16.3.4.2.4
Anemia Biomarkers for TI Responder Part 2
Biomarker 
Analysis Set
16.3.4.3
Liver iron content
Biomarker 
Analysis Set
16.3.4.4
C-reactive Protein
Biomarker 
Analysis Set
16.3.4.5
Phosphorylated STAT3
Biomarker 
Analysis Set
16.3.4.6
Overall Survival
Safety Analysis Set
16.3.4.7
Leukemia-Free Survival
Safety Analysis Set
16.3.5
Patient Global Improvement of Change (PGIC)
Safety Analysis Set


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 60
16 October 2017
Appendix 2.
Study Procedures Table
Assessment
Screening
(-28 to -21 
days)
Baseline
(-7 +/- 2 
days)
Enrollment
Week 
2
(+/- 3 
days)
Week 
4
(+/- 3 
days)
Week 
8
(+/- 3 
days)
Week 
12 
(+/- 3 
days)
Week 
16 
(+/- 3 
days)
Week 
20 
(+/- 3 
days)
Week 
24
(+/- 3 
days)
Early Study 
Drug 
Discontinuation
30 Day 
Follow-
Up
Informed consent
X
Medication and medical 
history
X
Transfusion recoding
X
X
X
X
X
X
X
X
X
X
X
X
Physical exam and 
myelofibrosis 
symptoms assessment
X
X
X
X
X
X
X
X
X
X
X
X
DIPSS assessment
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
AEs, concomitant 
medications
X
X
X
X
X
X
X
X
X
X
X
Ophthalmic 
examination
X
X
X
MMB accountability
and dispensingg
X
X
X
X
X
X
X
X
MMB Dosing at site
X
X
X
X
X
X
X
X
Patient reporting outcomes
Modified MPN-SAF 
TSS
-------------------------------------------------------Daily--------------------------------------------------
X
PGIC
X
X


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 61
16 October 2017
Assessment
Screening
(-28 to -21 
days)
Baseline
(-7 +/- 2 
days)
Enrollment
Week 
2
(+/- 3 
days)
Week 
4
(+/- 3 
days)
Week 
8
(+/- 3 
days)
Week 
12 
(+/- 3 
days)
Week 
16 
(+/- 3 
days)
Week 
20 
(+/- 3 
days)
Week 
24
(+/- 3 
days)
Early Study 
Drug 
Discontinuation
30 Day 
Follow-
Up
Laboratory Assessments
Viral hepatitis B and C
X
Chemistry
X
X
X
X
X
CBC with differential, 
reticulocyte count
X
X
X
X
X
X
X
X
X
X
X
Thiamine status
X
X
X
Erythropoietin
X
X
X
C-reactive protein
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
X
X
X
X
Serum pregnancy testa
X
Urine pregnancy test
X
X
X
X
X
X
X
X
Biomarker Samples
Bone marrow biopsy & 
aspirate
X
X
Buccal swab
X
Spleen & LIC MRI
X
X
X
Iron studies
X
X
X
X
X
X
X
X
X
Hepcidin
X
X
X
X
X
X
X
X
X
JAK2V617F allele 
burden and other 
mutation tests
X
X
X
Pharmacodynamicsc,d
Xd
X
X
Pharmacokineticse
X
X
X


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 62
16 October 2017
Assessment
Screening
(-28 to -21 
days)
Baseline
(-7 +/- 2 
days)
Enrollment
Week 
2
(+/- 3 
days)
Week 
4
(+/- 3 
days)
Week 
8
(+/- 3 
days)
Week 
12 
(+/- 3 
days)
Week 
16 
(+/- 3 
days)
Week 
20 
(+/- 3 
days)
Week 
24
(+/- 3 
days)
Early Study 
Drug 
Discontinuation
30 Day 
Follow-
Up
Cytokines/chemokines
X
Xf
X
X
X
X
X
X
Exploratory signaling 
(mass cytometry)
X
X
X
X
CD34+ cell count
X
X
X
X
Gene expression
X
X
X
X
Immunophenotype     
(flow cytometry)
X
X
X
X
a
For female subject post-menopausal for less than two years, if FSH < 40 mIU/mL a serum pregnancy test will be required
b
Hepcidin sample collection will occur at the following times?: baseline visit, between 8am-10am, 6 hours later; enrollment, Weeks 4, 8, 12, 16, 20 and 24  predose (between 
8am and 10am) and 6 hours postdose
c
Pharmacodynamics biomarker sample collection will occur at the following times: predose, 2,4 and 6 hours postdose at enrollment, then Week 4 and 24.
d
Additional exploratory pharmacodynamics sample collection will occur at the following tines: predose, and 2 hours postdose at enrollment only.
e
PK sample collection at the following times: predose, 6 hours postdose. All other time points: predose only.
f
Cytokine sample collection times at enrollment: predose, 6 hours postdose. All other time points: predose only.
g
MMB accountability ONLY at Week 24 and ESDD visits.


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 63
16 October 2017
Appendix 3.
Peripheral Neuropathy SMQ AEs
Name
Code
Level
Scope
Acute painful neuropathy of rapid glycaemic control
10072909
PT
Narrow
Acute polyneuropathy
10066699
PT
Narrow
Amyotrophy
10002027
PT
Narrow
Autoimmune neuropathy
10070439
PT
Narrow
Axonal neuropathy
10003882
PT
Narrow
Biopsy peripheral nerve abnormal
10004846
PT
Narrow
Decreased vibratory sense
10067502
PT
Narrow
Demyelinating polyneuropathy
10061811
PT
Narrow
Guillain-Barre syndrome
10018767
PT
Narrow
Ischaemic neuropathy
10051307
PT
Narrow
Loss of proprioception
10057332
PT
Narrow
Miller Fisher syndrome
10049567
PT
Narrow
Multifocal motor neuropathy
10065579
PT
Narrow
Myelopathy
10028570
PT
Narrow
Nerve conduction studies abnormal
10029175
PT
Narrow
Neuralgia
10029223
PT
Narrow
Neuritis
10029240
PT
Narrow
Neuronal neuropathy
10071579
PT
Narrow
Neuropathic muscular atrophy
10075469
PT
Narrow
Neuropathy peripheral
10029331
PT
Narrow
Notalgia paraesthetica
10072643
PT
Narrow
Peripheral motor neuropathy
10034580
PT
Narrow
Acute painful neuropathy of rapid glycaemic control
10072909
PT
Narrow
Acute polyneuropathy
10066699
PT
Narrow
Amyotrophy
10002027
PT
Narrow
Angiopathic neuropathy
10079036
PT
Narrow
Anti-myelin-associated glycoprotein associated polyneuropathy
10078324
PT
Narrow
Autoimmune neuropathy
10070439
PT
Narrow
Axonal neuropathy
10003882
PT
Narrow
Biopsy peripheral nerve abnormal
10004846
PT
Narrow
Decreased vibratory sense
10067502
PT
Narrow
Demyelinating polyneuropathy
10061811
PT
Narrow


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 64
16 October 2017
Name
Code
Level
Scope
Guillain-Barre syndrome
10018767
PT
Narrow
Ischaemic neuropathy
10051307
PT
Narrow
Loss of proprioception
10057332
PT
Narrow
Miller Fisher syndrome
10049567
PT
Narrow
Multifocal motor neuropathy
10065579
PT
Narrow
Myelopathy
10028570
PT
Narrow
Nerve conduction studies abnormal
10029175
PT
Narrow
Neuralgia
10029223
PT
Narrow
Neuritis
10029240
PT
Narrow
Neuronal neuropathy
10071579
PT
Narrow
Neuropathic muscular atrophy
10075469
PT
Narrow
Neuropathy peripheral
10029331
PT
Narrow
Notalgia paraesthetica
10072643
PT
Narrow
Peripheral motor neuropathy
10034580
PT
Narrow
Peripheral nervous system function test abnormal
10034591
PT
Narrow
Peripheral sensorimotor neuropathy
10056673
PT
Narrow
Peripheral sensory neuropathy
10034620
PT
Narrow
Polyneuropathy
10036105
PT
Narrow
Polyneuropathy chronic
10064135
PT
Narrow
Polyneuropathy idiopathic progressive
10036111
PT
Narrow
Radiation neuropathy
10068886
PT
Narrow
Sensorimotor disorder
10062162
PT
Narrow
Sensory disturbance
10040026
PT
Narrow
Sensory loss
10040030
PT
Narrow
Small fibre neuropathy
10073928
PT
Narrow
Tick paralysis
10077336
PT
Narrow
Toxic neuropathy
10067722
PT
Narrow


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 65
16 October 2017
Appendix 4.
Cataract MST AEs
MEDDRA Term Name
MEDDRA Code
MEDDRA Level
Atopic cataract
10069649
PT
Cataract
10007739
PT
Cataract congenital
10007747
PT
Cataract cortical
10007748
PT
Cataract diabetic
10007749
PT
Cataract nuclear
10007759
PT
Cataract operation
10063797
PT
Cataract subcapsular
10007764
PT
Cataract traumatic
10007766
PT
Lens discolouration
10070549
PT
Lenticular opacities
10024214
PT
Radiation cataract
10037756
PT
Toxic cataract
10044135
PT
Bioptic eye surgery
10078599
PT
Eye opacity
10078394
PT
Cornea verticillata
10077604
PT


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 66
16 October 2017
Appendix 5.
Leukemic Transformation MST AEs
MEDDRA Term Name
MEDDRA Code
MEDDRA Level
Acute megakaryocytic leukaemia
10000860
PT
Acute megakaryocytic leukaemia (in remission)
10057194
PT
Acute monocytic leukaemia
10000871
PT
Acute monocytic leukaemia (in remission)
10000872
PT
Acute myeloid leukaemia
10000880
PT
Acute myeloid leukaemia (in remission)
10000881
PT
Acute myeloid leukaemia recurrent
10059034
PT
Acute myelomonocytic leukaemia
10000890
PT
Acute promyelocytic leukaemia
10001019
PT
Erythraemic myelosis (in remission)
10015246
PT
Erythroleukaemia
10015281
PT
Acute biphenotypic leukaemia
10067399
PT
Acute leukaemia
10000830
PT
Acute leukaemia in remission
10060930
PT
Acute undifferentiated leukaemia
10073479
PT
Blast cell crisis
10053747
PT
Blast crisis in myelogenous leukaemia
10050282
PT
Chloroma
10008583
PT
Chloroma (in remission)
10008584
PT
Eosinophilic leukaemia
10014958
PT
Leukaemia basophilic
10024293
PT
Leukaemia granulocytic
10024299
PT
Leukaemia monocytic
10024305
PT
Monocytic leukaemia in remission
10061295
PT
Myeloid leukaemia
10028549
PT
Myeloid leukaemia in remission
10061301
PT
Aleukaemic leukaemia
10001660
PT
Central nervous system leukaemia
10066231
PT
Leukaemia
10024288
PT
Leukaemia cutis
10053180
PT
Leukaemia in remission
10061220
PT
Leukaemia recurrent
10062489
PT


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 67
16 October 2017
MEDDRA Term Name
MEDDRA Code
MEDDRA Level
Leukaemic cardiac infiltration
10077563
PT
Leukaemic infiltration
10069360
PT
Leukaemic infiltration extramedullary
10067117
PT
Leukaemic infiltration gingiva
10067431
PT
Leukaemic infiltration hepatic
10058671
PT
Leukaemic infiltration ovary
10075853
PT
Leukaemic infiltration pulmonary
10052368
PT
Leukaemic infiltration renal
10069359
PT
Leukaemic retinopathy
10059239
PT
Mastocytic leukaemia
10056450
PT
Neonatal leukaemia
10028958
PT


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 68
16 October 2017
Appendix 6.
Validation document of hepcidin testing from Radboud University


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 1 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
 
 
 
 
 
 
 
 
 
 
 
  
Method name 
Hepcidine in serum/plasma met WCX-TOF-massaspectrometrie methode 
Work Unit 
Iron metabolism 
Method Sop no. 
036977 
In production   
May  2012 
Equipment  
Microflex LT. 
Equipment Sop nr. 
032496 
Authors 
Name  
sign 
Date 
Research technicians 
Coby Laarakkers BSc. 
 
Erwin Wiegerinck BSc. 
Qportal 
digital 
Supervisor 
Prof. Dr. Dorine Swinkels, 
MD/PhD 
Qdoc 
digital 
ID   
042010  v 3 
Datum print 
 
Paraaf KAM-adviseur 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 2 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
Index 
1. 
Generally. 
3 
1.1 
Purpose. 
3 
1.2 
Background. 
3 
1.3 
Responsibilities. 
3 
1.4 
Evaluation period. 
3 
2. 
Equipment/ method/ assay. 
3 
3. 
Definition and Terminology. 
3 
3.1 
Abbreviations. 
3 
3.2 
Units and decimals. 
4 
4. 
Procedure. 
4 
4.1 
Internal standard heavy hepcidin-25 
4 
4.2  
Calibration hepcidin mass. 
4 
4.3 
Internal Quality Control and Precision. 
5 
4.4 
Linearity curve synthetic Hepcidin-25. 
9 
4.5 
Intra run. 
10 
4.6 
Inter run. 
11 
4.6.1  Linearity of  native hepcidin-25 in serum/plasma (1). 
12 
4.6.2 Linearity of  native hepcidin-25 in serum/plasma  (2). 
15 
4.7 
Detection limit 
16 
4.8 
Reference values. 
16 
5. 
Clinical validation. 
20 
6  
Archivating 
20 
7. 
References. 
21 
Bijlage meetonnauwkeurigheden. 
23 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 3 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
1. 
Generally. 
1.1 Purpose. 
Purpose is to validate the Weak Cation Exchange -Time Of  Flight – Mass Spectrometry (WCX-TOF-MS) 
method for hepcidin-25 in serum/plasma 
1.2 Background. 
 
Hepcidin is an iron regulating peptide hormone and mainly produced in the liver. There are 3 isoforms 
hepcidin-20 (20 amino-acids [aa]), hepcidin-22 (22 aa) and hepcidin-24(24 aa) hep24 has recently discovered in 
samples from kidney patients. Only hepcidin-25(25 aa) has been shown to participate in the regulation of iron 
metabolism. It is thought to be the major regulator of dietary iron absorption and cellular iron release. It exerts its 
regulatory function by counteracting the function of ferroportin, the major cellular iron exporter in the membrane of 
macrophages, hepatocytes and the basolateral site of enterocytes. Hepcidin-25 induces the internalization and 
degradation of ferroportin, resulting in increased intracellular iron stores, decreased dietary iron absorption and 
decreased circulating iron concentrations. Several physiologic and pathologic processes regulate the synthesis of 
hepcidin. Iron deficiency, hypoxia, anemia and HFE-related hemochromatosis lead to a decrease in hepcidin synthesis 
and subsequent increased iron absorption from the intestine. Infection and inflammation lead to an increase in 
circulating hepcidin levels and subsequent decrease of  iron absorption from the intestine and iron entrapment in the 
reticulo-endothelial macrophages, which may result in anemia of chronic disease. See for more information: 
www.hepcidinanalysis.com and (1, 2,8).  
Since 2005 we measure hepcidin in our  laboratory which resulted in numerous publications in peer reviewed 
journals. 
In the clinic this assay is currently used as a diagnostic or monitoring tool for unexplained i) iron overload  or ii) iron 
deficiency anemia. Moreover, the assay is exploited for clinical studies aiming for a better understanding of the 
pathophysiology of iron disorders and clinical trials in the monitoring or treatment with newly developed hepcidin 
modulating agents (11).  
1.3 Responsibilities. 
 
Performance: 
 
 
Coby Laarakkers, BSc. 
 
  
 
 
 
Erwin Wiegerinck BSc. 
 
Supervision: 
 
 
Prof. Dr. Dorine Swinkels, MD/ PhD. 
 
End responsibility           
Prof. Dr. Dorine Swinkels, MD/ PhD. 
 
1.4 Evaluation period. 
 
Start date: 
 
October 2011. 
 
Scheduled end date: 
 Mai 2012 
 
2. 
Equipment/ method/ assay. 
 
Equipment: 
 
Microflex LT. 
 
Method:  
 
WCX-TOF-MS. 
 
Assay: 
 
 
Hepcidin-25 in serum. 
 
3. 
Definition and Terminology. 
3.1 Abbreviations. 
 
WCX 
-Weak Cation Exchange. 
 
TOF 
-Time Of Flight. 
 
MS 
-Mass Spectrometry. 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 4 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
3.2 Units and decimals. 
Assay 
Unit 
Significant figures 
Hepcidin-25 
nM 
3 
 
4. 
Procedure. 
4.1 Internal standard heavy hepcidin-25 
Procedure. 
For this assay we have a custom made heavy hepcidin-25 internal standard (mass 2829.4 Da); DTHF 
(13C9,15N)P(13C5,15N)I(13C6,15N)CI(13C6,15N)F(13C9,15N)CCG(15N)CCHRSKCGMCCKT disulfide bridged (Peptide 
International, AF-179, Lot No221-006221)(9). 
10 vials, freeze dried heavy hepcidin-25 are solved in H2O in accordance with the manual. Solved  heavy 
hepcidin25+40 of all the 10 vials were put together and mixed. Heavy hepcidin-25 with a concentration of 0.1 mM is 
aliquoted á 12 µL in PCR tubes á 200 µL and stored at -80ºC  in  deep freezer “Iron metabolism” room 4.07 
M325.04.264. 
This internal standard is controlled by 10 x measurement of HiQC and LoQC. 
The average of these 10 measurements should not differ more than  0.2 nM of the nominal values of the controls. 
Data:  H\microflex\2 controle IS hep25+41. 
HiQC 2014: 10.12 ± 0.2 nM 
LoQC 2014: 2.34 ± 0.1 nM 
4.2  Calibration hepcidin mass. 
Procedure. 
Calibration of the Microflex LT will be performed after ion source cleaning and services. 
The calibrator contains hepcidin-20, hepcidin-22, hepcidin-24 (Peptides International, custom made, PCS-37242-PI, 
synthetic) and hepcidin-25 (Peptides International, PLP-4392-s, synthetic).  Hepcidin-20 and 22 are a special gift from 
Tom Ganz  and are isolated from urine (3). The mass values of the hepcidins can be found at UniProtKB 
(Proteinknowledgebase).  
 
Peptide 
m/z 
Hepcidin-20 
2191.77 
Hepcidin-22 
2436.06 
Hepcidin-24 
2673.90 
Hepcidin-25 
2789.40 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 5 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
4.3 Internal Quality Control and Precision. 
 
Procedure. 
Precision is calculated by using MedLabQC (version:Philippe Marquis 3.24) 
Control charts show the internal quality control. Hepcidin-25 results for the QC controls for the subsequent 
measurement runs. 
 
Material. 
HiQC 2014: heparin plasma pool is made by pooling samples from intensive care patients and plasma from an iron 
depleted HFE-hemochromatosis patient.  
LoQC 2014: heparin plasma pool is made by pooling samples from 3 iron depleted hemochromatosis patients and 
plasma from intensive care patients. 
The controls are aliquoted in polypropylene tubes (2 mL) á 250 ul sample. In deep freezer (-80 ˚C)  “Iron metabolism” 
room 4.07 M325.04.264. number. For both QC’s there are about 500 samples in the freezer. 
 
 
4.3.1 Results MedLabQC 
 
HiQC and LoQC 2014 
Hepcidin-25 measurements March  2015 
 
 
 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 6 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
HiQC 2014 
Hepcidin-20 measurements March  2015 
 
 
 
HiQC 2014 
Hepcidin-22 measurements March  2015 
 
 
 
 
 
 
HiQC 2014 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 7 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
Hepcidin-24 measurements March  2015 
 
 
 
 
 
 
HiQC 2014 
LoQC 2014 
 
Hep25 
n 
20 
20 
average 
10.12 nM 
2.34 nM 
SD 
0.557 nM 
0.157 nM 
3x SD 
1.67 nM 
0.47 nM 
CV 
5.5 % 
6.7 % 
 
 
HiQC 2014 
 
Hep20 
Hep22 
Hep24 
n 
20 
20 
20 
average 
1.85 nM 
1.12 nM 
1.78 nM 
SD 
0.224 nM 
0.148 nM 
0.219 nM 
3x SD 
0.67 nM 
0.44 nM 
0.66 nM 
CV 
12.1 % 
13.2 % 
12.3% 
 
 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 8 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
4.3.2 Control charts HiQC and LoQC  hepcidin-25  
 
 
 
Hepcidin-25 measurements March –April 2015.  
 
 
 
Hepcidin-25 measurements March –April 2015 
 
 
 
Control charts: H\LKN\ijzermetabolisme\Microflex\1-controle kaarten 
 
 
 
7,0
7,5
8,0
8,5
9,0
9,5
10,0
10,5
11,0
11,5
12,0
12,5
13,0
13,5
0
10
20
30
40
50
60
70
80
90
100
110
120
Hepcidin-25 (nM) 
Run No 
control chart HiQC 2014 hepcidin-25 
3sd+
mea
n
3sd-
1,5
1,7
1,9
2,1
2,3
2,5
2,7
2,9
3,1
0
10
20
30
40
50
60
70
80
90
100
110
120
Hepcidin-25  (nM)  
Run No 
control chart LoQC 2014 hepcidin-25 
3SD+
mean
3SD-


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 9 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
4.4 Linearity curve synthetic Hepcidin-25. 
Procedure. 
For this curve we used zero hepcidin serum coming from patient with juvenile haemochromatosis  due to a 
homozygous mutation in the hemojuvelin gene (4). Different concentrations synthetic hepcidine-25 are  added to this 
serum. 
. 
 
A. Linearity curve range (0-40 nM): concentrations synthetic hepcidine-25 added: 0, 0.5,1, 2, 3, 5, 7.5, 10, 15, 20 en 
40 nM. 
 
 
 
 
Linearity curve (0- 40.0 nM) synthetic hepcidin-25 in zero serum with heavy hep25 as internal standard. 
 
Conclusion. 
The curve is linear to at least 40 nM. 
y = 0,9642x + 0,0701 
R² = 0,9995 
0,0
5,0
10,0
15,0
20,0
25,0
30,0
35,0
40,0
45,0
0,0
10,0
20,0
30,0
40,0
50,0
measured hep25 in nM 
nominal hep25 in nM 
linearity synthetic hep25 in serum 
IS Hhep25+41


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 10 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
4.5 Intra run. 
Procedure. 
4 patient plasma samples were measured 8 times in one run with WCX-TOF-ms. method with the Microflex LT. 
 
Results (hepcidin-25 in nM).  
n=8 
1 
2 
3 
4 
average  
10.34 
2.59 
3.52 
7.40 
STD 
0.22 
0.15 
0.12 
0.26 
CV (%)  
2.14 
2.67 
3.31 
3.53 
 
3 of these 4 samples contained isoforms of hepcidin-25 ( > 1 nM) 
 
Results (hepcidin-20 in nM). 
n=8 
1 
3 
4 
average  
2.34 
5.75 
4.90 
STD 
0.18 
0.35 
0.21 
CV (%)  
7.61 
6.04 
4.20 
 
Results (hepcidin-22 in nM) 
n=8 
1 
4 
average  
1.36 
1.71 
STD 
0.12 
0.13 
CV (%)  
8.62 
7.87 
 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 11 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
Results (hepcidin-24 in nM) 
n=8 
1 
3 
4 
average  
2.25 
1.38 
2.37 
STD 
0.09 
0.11 
0.07 
CV (%)  
4.01 
8.22 
2.89 
 
 
Conclusie. 
Intra run CV for hepcidin-25: < 3.6%. 
Intra run CV’s for the hepcidin isoforms are higher (between 2.9 and 8.6 %). 
4.6 Inter run. 
Procedure. 
Two plasma samples are measured on 8 different days (in 8 different runs) with the WCX-TOF-ms method for 
hepcidin-25 on Microflex LT. 
 
Results (hepcidin-25 in nM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=8 
5 
6 
average  
10.47 
2.58 
STD 
0.49 
0.21 
CV (%)  
4.63 
8.26 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 12 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
 Results (hepcidin-20, 22, 24 in nM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusie. 
 
Interrun hepcidin-25: CV< 8.3 % 
Interrun hepcidin-isoforms: CV: 11.6-16.8 % 
 
4.6.1 Linearity of  native hepcidin-25 in serum/plasma (1). 
 
Material. 
4 serum samples of healthy volunteers are selected for this test. Two samples have a hepcidin-25 concentration above 
10 nM and 2 samples a concentration below 3 nM.  
 
Procedure. 
We tested  linearity (1) in duplicate and used there for 4 serum samples, 2 with a high hepcidin concentration and 2 
with a low hepcidin concentration. 1 High and 1 low sample is measured in duplicate in different mixture ratio on 
Microflex LT. You can find in table below the used mixture ratios. Based on the known values of the undiluted 
samples we calculated the rate value of the mixtures. The test should be linear for the evaluated range and the 
measured values should be equal to the calculated values. 
 
Table: Mixture ratios. 
 
Sample  A (low) 
Sample B (high) 
Calculated value 
1 
1 volume 
50 µL 
nvt 
0 μL 
= sample A 
2 
3 volumes 
37.5 μL 
1 volume 
12.5 μL 
= (3 x A + 1x B) / 4 
3 
2 volumes 
25 μL 
2 volumes 
25 μL 
= (2 x A + 2 x B) / 4 
4 
1 volume 
12.5 μL 
3 volumes 
37.5 μL 
= (1 x A + 3 x B) / 4 
5 
na 
0 μL 
1 volume 
50 µL 
= sample B 
 
 
 
 
 
n=8 
Sample 5 
Hep20 
Sample 5 
Hep22 
Sample 5 
Hep24 
average  
2.50 
1.38 
2.31 
STD 
0.34 
0.16 
0.39 
CV (%)  
13.7 
11.6 
16.8 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 13 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
Results (Hepcidin-25 in nM). 
 
Samples 
A1 and B1 
Measured value 
(avg duplicate) 
Calculated 
value 
Difference between measured 
and calculated value  
1 
16.1 
16.1 
0.0 
2 
11.6 
12.8 
1.2 
3 
8.2 
9.5 
1.3 
4 
6.0 
6.1 
0.1 
5 
2.8 
2.8 
0.0 
  
Samples 
A2 and B2 
Measured value 
(avg duplicate) 
Calculated 
value 
Difference between measured 
and calculated value  
1 
10.1 
10.1 
0.0 
2 
8.1 
8.2 
0.1 
3 
5.9 
6.3 
0.4 
4 
4.5 
4.5 
0.0 
5 
2.6 
2.6 
0.0 
 
   
 
 
 
y = 1,015x + 0,3878 
R² = 0,9856 
0,0
2,0
4,0
6,0
8,0
10,0
12,0
14,0
16,0
18,0
20,0
0,0
5,0
10,0
15,0
20,0
calculated hep25 in nM 
measured hep25 in nM 
linearity (1) [A1 and B1] 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 14 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
 
 
 
Conclusion: the method is linear to at least 16 nM .  
 
 
 
 
 
 
 
 
 
 
 
y = 1,0052x + 0,0658 
R² = 0,9965 
0,0
2,0
4,0
6,0
8,0
10,0
12,0
0,0
2,0
4,0
6,0
8,0
10,0
12,0
calculated hep25 in nM 
measured hep25 in nM 
linearity (1) [A2 and B2]  


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 15 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
4.6.2 Linearity of  native hepcidin-25 in serum/plasma  (2). 
Procedure. 
To test linearity (2) we used 2 samples. These samples were measured in 5 different dilutions see table below and 
measured in duplicate on Microflex LT.  
 
Table: Dilutions. 
 
sample 
1 
undiluted 
 
2 
1.25x  
 
3 
1.66x 
 
4 
2x 
 
5 
5x 
 
6 
10x 
 
 
 
Material. 
We selected 1 serum sample from a healthy volunteer (CH2) with a hepcidin concentration above 10 nM and 1 plasma 
sample from a kidney patient (KF218) with a high hepcidin value. See for dilutions table above. 
 
 
Results (hepcidin-25 in nM). 
 
 
KF218 
CH2 
 
Hep25 in nM 
undiluted 
15.9 
11.0 
1.25x 
12.0 
8.1 
1.66x 
9.1 
6.3 
2.5x 
5.8 
4.3 
5x 
3.1 
2.0 
Measured hepcidin. 
 
Dil.factor 
KF218 
CH2 
Hep25 in nM 
1 
15.9 
11.0 
1,25 
15.0 
10.2 
1,66 
15.1 
10.5 
2,5 
14.4 
10.7 
5 
15.4 
10.2 
avg 
15.15 
10.51 
sd 
0.507 
0.302 
VC 
3.35% 
2.87% 
Calculated hepcidin levels using the measured value and the dilution factor. 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 16 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
 
Measured hepcidin-25 values: stars = HF218; dots = CH2 
 
Conclusion. 
Hepcidin measurement in these samples is linear for at least to 15 nM. 
 
 
4.7 Detection limit 
The detection limit is determined at 0.5 nM. The signal/noise ratio was >2 for a zero serum added with 0.5 nM 
synthetic hepcidin-25  (5). 
 
4.8 Reference values. 
Procedure. 
 
The reference range of serum hepcidin-25 is <0.5 nM-14.7 nM (median 4.5 nM) for men, <0.5 -12.3 nM (median 2.0 
nM) for premenopausal women, and <0.5-15.6 nM (median 4.9 nM) for postmenopausal women. We have also 
assessed i) references ranges per 5-year age group for men and women; ii) for hepcidin/ferritin ratio and transferrin 
saturation/hepcidin ratio. These reference levels for the WCX-TOF MS method are derived from those of our ELISA 
method[6,7], based on the regression line between the ELISA and WCX-TOF MS results obtained for the same 
samples from patients without hepcidin isoforms[1,7].  
We also assessed: 
 references ranges for serum hepcidin-25  and hepcidin/ferritin ratio in children (6 months to 3 years old) in the 
normative population (N=292) as measured by weak cation exchange time-of-flight mass spectrometry 
(WCX-TOF MS) [9]. 
 Reference ranges for serum hepcidin-25 during pregnancy [12].  
 
 
More details on the WCX-TOF MS reference values for hepcidin can be found on  our website 
www.hepcidinanalysis.com and in the references. 
 
4.9  measurement uncertainty  
The measurement uncertainty is 14.1%, calculated by CV total variation analyse   
This  is lower than ½CVbiological variation 
Calculation see supplement 1 
0,0
5,0
10,0
15,0
20,0
25,0
30,0
0
1
2
3
4
5
6
hepcidin-25 in nM 
dilution factor 
linearity (2) 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 17 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
Results:  
 
MS-method_ hepcidin-25 (nM) 
 
Reference ranges for serum hepcidin (nM) per 5-year age group for adult men and women in the reference 
population. 
 
 
 
Men (N=1,066) 
 
Women (N=882) 
 
 
 
 
95% reference range 
 
 
 
95% reference range 
Age, years 
 
N     (%) 
Median 
P2.5 
P97.5 
 
N      (%) 
Median 
P2.5 
P97.5 
18-24 
 
10      (1) 
5.3 
0.8 
11.0 
 
21      (2) 
1.1 
< 0.5 
6.3 
 
 
 
 
 
 
 
 
 
 
 
25-29 
 
16      (2) 
4.9 
< 0.5 
15.3 
 
28      (3) 
1.4 
< 0.5 
6.6 
 
 
 
 
 
 
 
 
 
 
 
30-34 
 
18      (2) 
4.2 
< 0.5 
15.8 
 
24      (3) 
1.9 
< 0.5 
13.1 
 
 
 
 
 
 
 
 
 
 
 
35-39 
 
22      (2) 
3.6 
< 0.5 
12.1 
 
36      (4) 
1.5 
< 0.5 
9.9 
 
 
 
 
 
 
 
 
 
 
 
40-44 
 
19      (2) 
6.1 
< 0.5 
11.0 
 
65      (7) 
2.5 
< 0.5 
15.2 
 
 
 
 
 
 
 
 
 
 
 
45-49 
 
76      (7) 
3.4 
< 0.5 
13.2 
 
110    (12) 
1.6 
< 0.5 
8.9 
 
 
 
 
 
 
 
 
 
 
 
50-54 
 
106    (10) 
4.0 
< 0.5 
13.8 
 
140    (16) 
2.9 
< 0.5 
14.3 
 
 
 
 
 
 
 
 
 
 
 
55-59 
 
173    (16) 
4.4 
< 0.5 
15.7 
 
129    (15) 
4.9 
< 0.5 
13.6 
 
 
 
 
 
 
 
 
 
 
 
60-64 
 
179    (17) 
4.5 
< 0.5 
14.3 
 
137    (16) 
4.7 
< 0.5 
17.3 
 
 
 
 
 
 
 
 
 
 
 
65-69 
 
186    (17) 
5.3 
< 0.5 
13.9 
 
95    (11) 
4.9 
< 0.5 
14.2 
 
 
 
 
 
 
 
 
 
 
 
70-74 
 
133    (12) 
4.9 
< 0.5 
17.0 
 
62      (7) 
5.1 
< 0.5 
24.2 
 
 
 
 
 
 
 
 
 
 
 
75-79 
 
99      (9) 
3.8 
< 0.5 
16.1 
 
16      (2) 
5.4 
0.8 
18.4 
 
 
 
 
 
 
 
 
 
 
 
80-84 
 
22      (2) 
3.8 
1.6 
12.6 
 
10      (1) 
7.2 
< 0.5 
12.0 
 
 
 
 
 
 
 
 
 
 
 
≥85 
 
7      (1) 
6.8 
1.6 
12.8 
 
9      (1) 
3.7 
< 0.5 
15.4 
 
 
 
 
 
 
 
 
 
 
 
All 
 
1,066 (100) 
4.5 
< 0.5 
14.7 
 
882  (100) 
3.6 
< 0.5 
14.6 
 
 
Premenopausal women (<55 year): (N=424) 
- 
Median = 2.0 nM 
- 
P2.5 =  0.1 nM (<0.5 nM)  
- 
P97.5 = 12.3 nM 
 
Postmenopausal women (>=55 year): (N=458) 
- 
Median = 4.9 nM 
- 
P2.5 = 0.2 nM (<0.5 nM) 
- 
P97.5 = 15.6 nM 
 
 
 
 
 
 
 
 
 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 18 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
Reference ranges for serum hepcidin (nM) in  children aged 6 months to 3 years. 
 
 
 
 
 
 
 
Hepcidin 
 
95% CI 
N 
Median 
P2.5 
P97.5 
292 
3.6 
0.94 
12.2 
Hepcidin 
 
 
 
95% CI 
Age (months) 
N 
(%) 
Median 
P2.5 
P97.5 
3-12 
111 
(38) 
4.1 
1.1 
12.8 
13-18 
62 
(21) 
3.8 
0.8 
12.0 
19-24 
43 
(15) 
2.5 
0.9 
11.8 
25-30 
38 
(13) 
3.4 
0.8 
21.7 
31-36 
38 
(13) 
3.9 
0.3 
14.6 
Hepcidin 
 
 
95% CI 
Gender 
N 
Median 
P2.5 
P97.5 
Male 
207 
3.6 
0.9 
11.9 
Female 
85 
4.0 
0.8 
14.0 
Hepcidin 
 
 
95% CI 
Time of sample 
collection 
N 
Median 
P2.5 
P97.5 
<12.00 pm 
170 
3.0 
0.9 
11.4 
12.00-17.00 pm 
122 
4.5 
1.1 
14.0 
 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 19 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
Reference range for serum hepcidin in specified time periods during pregnancy 
 
 
 
 
Gestation                                               95 % reference range 
weeks 
N 
Median P2.5 
P97.5 
7-15 
22 
 
1.9 
 
< 0.5 
 
8.6 
19-25 
21 
< 0.5 
< 0.5 
6.8 
29-35 
16 
< 0.5 
< 0.5 
2.4 
 
 
 
Hepcidin-25/ferritin (pmol/µg) 
 
Reference ranges for hepcidin/ferritin per 5-year age group for adult men and women in the reference 
population. 
 
 
Men: (N=1064) 
- 
Median = 26.7 pmol/µg 
- 
P2.5 = 2.9 pmol/µg 
- 
P97.5 = 87.9 pmol/µg 
 
Premenopausal women (<55 year): (N=424) 
- 
Median = 35.7 pmol/µg 
- 
P2.5 = 3.0 pmol/µg 
- 
P97.5 = 167.3 pmol/µg 
 
Postmenopausal women (>=55 year): (N=458) 
- 
Median = 40.5 pmol/µg 
- 
P2.5 = 9.1 pmol/µg 
- 
P97.5 = 143.1 pmol/µg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference ranges for hepcidin/ferritin in  children  aged 6 months to 3 years. 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 20 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
 
 
 
 
 
MS-method_ TSAT/hepcidin-25 (%/nM) 
 
Men: (N=1059) 
- 
Median = 7.3 %/nM 
- 
P2.5 = 1.7 %/nM 
- 
P97.5 = 256.3 %/nM 
 
Premenopausal women (<55 year): (N=422) 
- 
Median = 13.9 %/nM 
- 
P2.5 = 2.0 %/nM 
- 
P97.5 = 330.0 %/nM 
 
Postmenopausal women (>=55 year): (N=457) 
- 
Median = 5.7 %/nM 
- 
P2.5 = 1.5 %/nM 
- 
P97.5 = 73.4 %/nM 
 
 
 
5. 
Clinical validation. 
Zie www.hepcidinanalysis.com/expertise/ (1). 
 
6  
Archivating 
Word-document: H-LKN\ijzermetabolisme\microflex\kwaliteit\validatie rapport hep25 
Laboratory notebook: 485 
 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 21 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
7. 
References. 
 
1. http://www.hepcidinanalysis.com/ 
 
2. Bergmans JP, Kemna EH, Janssen MC, Jacobs EM, Stalenhoef AF, Marx JJ, Swinkels DW.  [Hereditary 
haemochromatosis: novel genes, novel diseases and hepcidin] Ned Tijdschr Geneeskd. 200;151(20):1105-8. 
 
3. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J 
Biol Chem 2001;276:7806–10. 
 
4. van Dijk BA, Kemna EH, Tjalsma H, Klaver SM, Wiegerinck ET, Goossens JP, Slee PH, Breuning MH, 
Swinkels DW. Effect of the new HJV-L165X mutation on penetrance of HFE. Blood. 2007;109(12):5525-6. 
 
5. Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, Swinkels DW. (Pre)analytical 
imprecision, between-subject variability, and daily variations in serum and  urine hepcidin: Implications for 
clinical studies. Anal Biochem 2009 ;389(2):124-9.   
 
6. Kroot JJC. Laarakkers CM. Geurts-Moespot AJ. Grebenchtchikov N. Pickkers P. van Ede AE  et al. 
Immunochemical and Mass-Spectrometry-Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clin 
Chem 2010;56:1570-9. 
 
7. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienhoven D, Wetzels JF, 
Kiemeney LA, Sweep FC, de Heijer M, Swinkels DW. Serum hepcidin: reference ranges and biochemical 
correlates in the general population. Blood, 2011; 117(25)  
 
8. Kroot JJC, Tjalsma H, Fleming R and Swinkels DW . Hepcidin in human iron disorders: diagnostic implications. 
Clinical Chemistry 2011; 57:12, 1650-1669  
 
9. Laarakkers C , Wiegerinck E, Klaver S, Kolodziejcyk M, Gille H, Hohlbaum M, Tjalsma H, Swinkels D. 
Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin 
isoform.. PLoS  One,  2013; 8(10). 
 
10. Uijterschout L, Swinkels DW, Domellöf M, Lagerqvist C, Hudig C, Tjalsma H, Vos R, van Goudoever JB, 
Brus F. Serum hepcidin measured by immunochemical and mass-spectrometric methods and their correlation 
with iron status indicators in healthy children aged 0.5-3 y. Pediatric Research 2014; 76;409-414 
 
11. van Eijk LT, John AS, Schwoebel F, Summo L, Vauléon S, Zöllner S, Laarakkers CM, Kox M, van der 
Hoeven JG, Swinkels DW, Riecke K, Pickkers P. Effect of the antihepcidin Spiegelmer lexaptepid on 
inflammation-induced decrease in serum iron in humans. Blood. 2014;124(17): 2643-6. 
 
12. van Santen S, Kroot JJ, Zijderveld G, Wiegerinck ET, Spaanderman ME, Swinkels DW. The iron regulatory 
hormone hepcidin is decreased in pregnancy: a prospective longitudinal study. Clin Chem Lab Med 2012; 14: 
1-7. 
 
 
 
 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 22 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
 
 
Invoer referentiewaardes 
HELIX / GLIMS* 
Naam invoerder 
Nvt (geen wijzigingen) 
Datum 
 
Handtekening 
 
*  = Doorhalen wat niet van toepassing is 
 
 


FH 009815 Validatie/verificatie rapport  
KAM-systeem TML 
 
 
 
 
ID  013118 v 7 
Pagina 23 van 23 
 Afd. Laboratoriumgeneeskunde, TML 830 Radboudumc  
Supplement 1 
 
Bijlage meetonnauwkeurigheden. 
Biologische variatietussen dag humaan hepcidin is 48.8% (Murphy et al1) 
CVtotale variatie (pre)-analyse < ½ CVbiologische variatie 
Berekening: 
CVtotale variatie (pre)-analyse = √(CVanalyse)2 + (CV pre-analyse 24h)2 
CVtotale variatie (pre)-analyse = √(10)2 + (10)2 
CVtotale variatie (pre)-analyse = √200 
 
CVtotale variatie (pre)-analyse = 14.1% 
 
CVtotale variatie (pre)-analyse < ½ CVbiologische variatie 
 
14.1%  <  ½ x 48.8%  pass 
 
Serum en plasma samples mogen een dag bij KT blijven staan. 
Afspraak is samples dezelfde dag nog in de vriezer. 
 
1. Murphy et al, Quantitation of hepcidin from human and mouse serum using liquid 
chromatography tandem mass spectrometry, Blood, Vol 110, 3. 
2. The Hitch-hiker’s Guide to Measurement Uncertainty (MU) in Clinical LaboratoriesApril 2012 
3 Graham White, SA Pathology, Flinders Medical Centre, Bedford Park, Adelaide, SA 5042, Australia 
 
4 Clin Chem 2011 Sep 57(9): 1334-6. Gross overestimation of total allowable error based on biological variation. 
Oosterhuis WP 
 


Momelotinib
GS-US-352-1672
Statistical Analysis Plan – Final Analysis
Version 1.0
CONFIDENTIAL
Page 69
16 October 2017
Appendix 7.
Validation document of pSTAT testing from Covance